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SUMMARY 
As the vast majority of bilateral nasal polyps (NP) are associated with a prominent 
eosinophilic inflammation and as eosinophils are well recognised in eliciting tissue damage 
and subsequent re-modelling, we aimed to investigate the role of eosinophils in the 
pathogenesis of NP. Especially the regulation of interleukin-5 (IL-5) and the interleukin-5 
receptor α (Rα) isoforms were studied with emphasis on future therapeutic strategies in NP.  
Characterisation of NP suggests a central deposition of plasma proteins (albumin), regulated 
by the subepithelial, mainly eosinophilic inflammation, as pathogenetic principle of polyp 
formation and growth. The accumulation and activation of eosinophils is favoured by the low 
concentrations of TGF- β1 and overproduction of IL-5 and eotaxin in NP tissue. Although 
elevated IgE levels are found in NP, total IgE and IgE antibodies in NP tissue was unrelated 
to skin prick tests, but correlated with the degree of eosinophilia. In addition, we 
demonstrated the organisation of secondary lymphoid tissue in NP tissue and a polyclonal 
hyper-immunoglobulinemia E associated with the presence of IgE specific to S. aureus 
enterotoxins (SAEs), colonization with S. aureus, and increased eosinophilic inflammation in 
a relevant subgroup of NP patients.  
The ultimate way to test the role of IL-5 and eosinophils in the pathogenesis of nasal 
polyposis, is by antagonizing IL-5 in an interventional study in NP patients. However, 
eosinophils show varying IL-5 sensitivity due to a different expression of the IL-5Rα 
isoforms according to activation state, maturation and localization in the body. At the local 
tissue level, the membrane-anchored (TM) IL-5Rα isoform is down-regulated whereas the 
secreted (SOL) IL-5Rα variant is up-regulated in nasal polyp tissue, but eosinophils are still 
activated. Therefore, strategies to antagonize IL-5 may have to face unexpected difficulties. 
We demonstrated shrinkage of nasal polyps in half of the verum-treated patients for up to four 
weeks after intravenous injection of a single dose of an anti-human IL-5 monoclonal 
antibody. When carefully analysing responders and non-responders, only those nasal polyps 
with elevated baseline levels of IL-5 in nasal secretions seemed to benefit from anti-IL-5 
treatment. Remarkably, the degree of eosinophilia at baseline was not different between 
responders and non-responders. Our data show that at least in 50% of the nasal polyps, IL-5 
and eosinophils play a key role (IL-5-dependent) in sustaining polyp size, whereas in the other 
group, eosinophilia may be more dependent on other factors (IL-5-independent).  
Finally, these insights in the regulation of IL-5 and eosinophilia in NP, (re-)open therapeutic 
perspectives in nasal polyposis based on eosinophil-selective targets. 
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SAMENVATTING 
Aangezien de meeste bilaterale neuspoliepen (NP) gekenmerkt zijn door een prominente 
eosinofiele ontsteking en omdat deze granulocyten kunnen bijdragen tot weefselschade en 
bijgevolg remodellering, wensten we de rol van eosinofielen te onderzoeken in de 
pathogenese van neuspoliepen. Meer bepaald de functie en regulatie van interleukine-5 (IL-5) 
en interleukine-5 receptor α  (IL-5 Rα) zullen onderzocht worden voornamelijk in het kader 
van toekomstige therapeutische strategieën  in NP. 
Immunochemische karakterisering  van NP toont een centrale depositie van plasma proteïnen 
(albumine), mogelijk geregeld door een eosinofiele ontsteking als pathogenetisch principe van 
poliepvorming en groei. De accumulatie en activering van eosinofielen wordt begunstigd door 
lage TGF- β1 concentraties en een overmaat aan IL-5 en eotaxine in NP weefsel. Alhoewel we 
hoge IgE spiegels vonden in NP, was er geen relatie tussen huidallergietesten en totaal en 
specifiek IgE in NP weefsel.  Daarentegen was lokaal IgE gecorreleerd aan de graad van 
eosinofilie in NP. Eveneens, toonden we een organisatie van secundair lymfoid weefsel in NP 
weefsel en een polyclonale hyper-immunoglobulinemie E die geassocieerd is met de 
aanwezigheid van specifiek IgE tegen  S. aureus enterotoxines (SAEs), kolonisatie met  S. 
aureus en een sterke eosinofiele ontsteking in een belangrijke subgroep van patiënten met NP.  
De ultieme manier om de rol van IL-5 en eosinofielen in de pathogenese van NP te testen, is 
door de IL-5 functie te antagoniseren in een interventionele studie bij patiënten met NP. 
Eosinofielen tonen echter een wisselende sensitiviteit t.o.v. IL-5 door een verschillende 
expressie van de IL-5Rα isovormen naargelang de staat van activering, maturatie en 
lokalisatie in het lichaam. In het lokale weefsel compartiment vonden we een lage expressie 
van de membraangebonden (TM) IL-5Rα isovorm en een hoge expressie van de 
gesecreteerde (SOL) IL-5Rα variant in NP weefsel, ondanks het feit dat eosinofielen 
geactiveerd zijn. Het is daarom mogelijk dat strategieën, die de IL-5 functie antagoniseren, te 
kampen krijgen met onverwachte moeilijkheden.   
Bij de helft van de behandelde patiënten vonden we kleinere NP tot vier weken na 
intraveneuze injectie van één enkele dosis van een anti-humaan IL-5 monoclonaal 
antilichaam. Bij zorgvuldige analyse van gevoelige en niet-gevoelige NP patiënten voor anti-
IL-5 behandeling, bleek dat enkel NP met gestegen IL-5 in de neussecreties voordeel haalden 
uit deze behandeling. Opmerkelijk is dat de graad van eosinofilie in NP weefsel niet 
verschillend was tussen  gevoelige en niet-gevoelige NP patiënten bij aanvang van de studie. 
Summary - Samenvatting - Resumé 
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Onze data toonden dat IL-5 en eosinofielen een sleutelrol spelen in minstens 50% van de NP 
(IL-5 afhankelijk) in het onderhouden van de poliepgrootte, terwijl de eosinofiele ontsteking 
in de andere NP patiënten meer afhankelijk is van andere factoren (IL-5 onafhankelijk).  
Uiteindelijk (her)-openen deze inzichten in de regulatie van IL-5 en eosinofilie in 
neuspoliepen, nieuwe therapeutische perspectieven gebaseerd op eosinofiel-selectieve 
behandelingen in neuspoliepen. 
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RESUME 
Compte-tenu que la grande majorité des polypes naso-sinusiens bilatéraux (PNS) sont 
associés à une inflammation à prédominance éosinophilique et que les éosinophiles sont 
reconnus comme acteurs dans la dégradation tissulaire et le remodelage tissulaire conséquent, 
nous souhaitions investiguer le rôle joué par les éosinophiles dans la physiopathologie de la 
polypose naso-sinusienne. En particulier, la régulation de l’interleukine-5 (IL-5) et des 
isoformes du récepteur alpha de l’interleukine 5 (IL-5Rα) a été étudiée afin de traçer de 
nouvelles perspectives pour la stratégie thérapeutique des PNS.  
La caractérisation des PNS repose sur une déposition de protéines plasmatiques (albumine), 
régulé par une inflammation subépithéliale, principalement éosinophilique, soutendant les 
principes physiopathologiques de formation et de croissance polypeuse. L’accumulation et 
l‘activation éosinophilique sont favorisés par des concentrations basses en TGF-β1 et une 
surproduction d’IL-5 et d’éotaxine dans le tissu polypeux. Malgré des taux élevés d’IgE 
trouvés au sein du tissu polypeux, les concentrations en anticorps IgE locaux n’étaient pas 
corrélées aux résultats des tests allergiques cutanés, mais bien au degré d’éosinophilie. De 
plus, nous avons mis en évidence une organisation du tissu lymphoïde secondaire au sein du 
tissu polypeux, une hyper-immunoglobulinémie E polyclonale associée à la présence d’IgE 
spécifique contre les entérotoxines de Staphylococcus aureus (SAEs), une colonisation par S. 
aureus, et une inflammation éosinophilique augmentée dans ces groupes.  
La solution ultime pour tester le rôle de l’IL-5 et des eosinophils dans la pathogenèse de la 
polypose naso-sinusienne est l’antagonisme de l’IL-5 dans une étude interventionnelle chez 
des patients polypeux. Cependant, les éosinophiles montrent une sensibilité à l’IL-5 variable 
due à une expression différentes des isoformes IL-5Ra selon l’état d’activation, maturation et 
localisation dans le corps. Au niveau tissulaire local, l’isoforme transmembranaire (TM) de 
l’IL-5Rα est sous-régulé tandis que la variante soluble (SOL) de l’IL-5Rα est hyper-régulée 
mais les éosinophiles restent malgré tout activés. Ceci démontre que les stratégies 
d’antagonisation de l’IL-5 vont être confrontées à des difficultés inattendues.  
Nous avons démontré une réduction de volume des polypes chez la moitié des patients 
jusqu’à 4 semaines après injection intra-veineuse d’une dose simple d’un anticorps 
monoclonal anti-IL-5 humain. Nous avons particulièrement analysé les répondeurs et les non-
répondeurs: seuls les patients présentant des taux élevés d’IL-5 dans les sécrétions nasales 
avant injection semblent être les plus grands bénéficiaires du traitement anti-IL-5.  
Summary - Samenvatting - Resumé 
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D’une manière remarquable, le degré d’éosinophilie avant injection n’était pas différent entre 
les groupes de répondeurs et non-répondeurs. Nos résultats ont démontré qu’au moins dans 50 
% des PNS, l’IL-5 et les éosinophiles jouent un rôle (IL-5-dépendant) dans la formation 
polypeuses, alors que dans l’autre groupe, l’eosinophilie semble plus dépendante d’autres 
facteurs (IL-5-indépendant).  
Enfin, ces données sur la régulation de l’IL-5 et de l’éosinophilie dans la polypose naso-
sinusienne, (re-)ouvrent des perspectives thérapeutiques sélectives basées sur un ciblage 
éosinophilique dans la polypose naso-sinusienne. 
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NASAL POLYPOSIS:  
AN EOSINOPHIL-MEDIATED DISEASE? 
 
CLINICAL ASPECTS OF NASAL POLYPOSIS 
Nasal polyps represent edematous semitranslucent masses in the nasal and paranasal cavities, 
mostly originating from the mucosal linings of the sinuses and prolapsing into the nasal 
cavities. The preferred site of origination of nasal polyps was found to be the mucosa of the 
outlets of the sinuses: frontal recess, ethmoidal cell cleft and sinus ostia 1;2. Sometimes, the 
proper diagnosis can only be made during surgery, when polyps are present in the sinuses 
only. Nasal polyps cause long-term symptoms, in particular nasal obstruction and reduced 
sense of smell, the latter being indicative for polyps but not specific3. The typical history is a 
common cold like symptomatolgy that persists over month and years, leading to nasal 
obstruction and discharge as the most prominent symptoms4. Over time, hyposmia or anosmia 
develop, and additional complaint such as the sensation of a “full head” are present 5;6. 
Interestingly, whereas chronic sinusitis is sometimes associated with a kind of headache and 
facial pain, nasal polyposis itself rarely causes pain despite the fact that most of the sinuses 
including the frontal sinus are opacified.  
 
 
Figure 1: Massive nasal polyps in left nostril 
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Diagnosis 
Anterior rhinoscopy only is not considered to be sufficient to diagnose or exclude polyps, and 
especially for the differential diagnosis, an endoscopic investigation of the nose after topical 
decongestion is necessary. To investigate the extent of disease within the sinuses, a computer 
tomography (CT scan) is performed. A diagnosis based exclusively on the case history is not 
reliable. The prevalence figures of NP depend upon the methods chosen: questionnaire, 
endoscopy, CT-scan imaging. With the introduction of rigid or flexible endoscopes into daily 
practice, nasal polyps are discovered earlier today than 15 years ago.  
 
Staging 
To determine the extension of disease within the nose and the sinuses, endoscopy and CT- 
scan based staging systems have been proposed and partially validated 7. These systems may 
proof useful for medical communication and for the evaluation of therapeutic response. The 
endoscopic staging system is mainly based on the assumption that polyp growth starts from 
the middle nasal meatus and then extends in a two-dimensional way towards the floor of the 
nose. However, the fact that the nasal cavity is three-dimensional may sometimes have a 
negative impact on the repeatability of this technique by different investigators. In this 
dissertation we used an endoscopic staging system adapted from the Davos score (Table1)8. 
The radiologic staging system includes all sinuses and the ostiomeatal complex bilaterally 
(table 2).  
 
Table 1: Adapted endoscopic staging system 
Polyp Score Polyp Size 
0 No polyps. 
1 Small polyps in the middle meatus not reaching below the inferior 
border of the middle concha. 
2 Polyps reaching below the lower border of the middle turbinate. 
3 Large polyps reaching the lower border of the inferior turbinate or 
polyps medial to the middle concha. 
4 Large polyps causing complete congestion/obstruction of the inferior 
meatus. 
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Table 2: The radiologic staging system modified after Lund and Mackay7 
0: no abnormalities; 1: partial opacification; 2: total opacification;  
* Ostiomeatal complex: 0: not occluded; 2: occluded 
 Right Left 
Maxillar sinus (0,1,2)   
Anterior Ethmoid (0,1,2)   
Posterior Ethmoid (0,1,2)   
Sphenoid (0,1,2)   
Frontal sinus (0,1,2)   
Ostiomeatal Complex (0,2) *   
Total   
 
Classification 
Nasal polyposis is not a consistent disease; on clinical grounds and based on etiology, 
histopathology 9 and recently also mediator content 10, it may currently be subdivided into 
different groups, with impact on prognosis and treatment. In this dissertation, only bilateral 
nasal polyps were studied.   
 
Table 3: Classification of nasal polyps 4 
1) The antro-choanal polyp, mostly arising from the maxillary sinus and prolapsing into the 
choana, a commonly large isolated unilateral cyst-like non-eosinophilic formation  
2) Idiopathic unilateral or bilateral, mostly eosinophilic polyps without involvement of the 
lower airways 
3) Bilateral eosinophilic polyposis with concomitant asthma and/or aspirin sensitivity   
4) Polyposis with underlying systemic disease such as cystic fibrosis, primary ciliary 
dyskinesia, Churg-Strauss-syndrome, Kartagener-syndrome etc.  
 
EPIDEMIOLOGY AND NATURAL HISTORY 
The exact prevalence of nasal polyposis in the general population is not known, because there 
are few epidemiological studies and their results depend upon the selection of the study 
population and the diagnostic methods used. A postal questionnaire survey of a population-
based random sample of 4300 adult women and men aged 18-65 years was recently 
performed in southern Finland 4;11. The prevalence of nasal polyposis was 4.3%, and nasal 
polyposis and aspirin sensitivity were associated with an increased risk of asthma. The 
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prevalence of doctor-diagnosed aspirin sensitivity was 5.7%. The incidence is higher in men 
than in women and significantly increases after the age of 40 years 12;13. Nasal polyps occur 
more frequently in subgroups of patients such as asthmatics, aspirin sensitive and cystic 
fibrosis patients 14. When polyps occur in children and adolescents, cystic fibrosis should 
always be considered 14;15. Other conditions associated with nasal polyps are Churg-Strauss 
Syndrome and Kartagener’s syndrome.  
 
Table 4: Prevalence of nasal polyposis in population subgroups (adapted from Settipane)16 
Aspirin hypersensitivity  36-72%
Adult asthma  
IgE-mediated 
Non- IgE-mediated 
7%
5%
13%
Chronic sinusitis 
IgE-mediated 
Non- IgE-mediated 
2%
1%
5%
Childhood asthma/sinusitis 0,1%
Cystic fibrosis 
Children 
Adults 
10%
50%
Allergic fungal sinusitis 66-100%
   
 
Nasal polyps and allergy  
At the beginning of the last century, an allergic aetiology of nasal polyps has been presumed, 
but never firmly demonstrated. The major features pointing to an allergic cause of nasal polyps 
include clinical symptoms similar to allergic rhinitis, the association with late-onset asthma 
and an elevated local IgE in polyp fluid as well as a pronounced tissue eosinophilia. However, 
polyps were found in only 0.5% of 3000 consecutive atopic patients examined by Caplin et al 
17. Until today, an increased risk for allergic subjects to develop nasal polyps could not be 
demonstrated. In contrast, in a retrospective study by Settipane and Chafee 18, polyps were 
present in 2.8% of atopic patients, but in 5.2% of non-atopic subjects. In another study, there 
was a positive association between the blood eosinophil count and the presence of asthma with 
the number of polypectomies, but not with positive skin tests for different allergens 19. 
Seasonal allergen exposure in patients with nasal polyps also did not enhance symptoms or 
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markers of eosinophilic inflammation such as eosinophil percentage or eosinophil cationic 
protein concentration in nasal secretions 20. Although elevated total IgE was found in polyp 
fluid, there was no difference between polyps from allergic and non-allergic subjects 5. 
However, it was noted that total IgE was higher in polyp fluid than the corresponding serum in 
both allergic and non-allergic polyp subjects. Local specific IgE production could also be 
demonstrated in nasal polyps associated with negative skin tests and serum RAST 21.  
 
Nasal polyps and asthma 
Nasal polyposis is frequently found in association with lower respiratory tract disorders, such 
as asthma and non-specific bronchial hyperreactivity 22. In studies involving large series of 
patients with nasal polyposis, asthma was found in 20% to 70% 23. Furthermore, non-allergic 
asthma is significantly more frequently linked to polyps compared to allergic asthma 3;16. A 
long-term follow-up study confirmed that the incidence of subsequent clinically significant 
bronchial asthma in patients with NP was much higher than in the general population 3;16. 
Interestingly, patients with nasal polyposis and asymptomatic bronchial hyperreactivity have 
an eosinophilic bronchial inflammation similar to that observed in asthmatic patients with 
nasal polyposis, whereas patients with nasal polyposis without bronchial hyperreactivity do 
not feature eosinophilic lower airway inflammation22.  
 
Aspirin sensitivity 
About 15% of polyp patients have aspirin sensitivity whereas about 40 to 80% of patients 
with aspirin sensitivity suffer from polyposis. In 1922, Widal described a symptom triad 
consisting of aspirin sensitivity, steroid-dependent asthma and nasal polyposis 
(rhinosinusitis), which was made known by Samter and Beers later 24. Out of 500 patients 
registered at the European Network on Aspirin-Induced Asthma (AIANE), almost 80% 
complained of nasal blockage accompanied by rhinorrhea 25. Asthma and rhinitis attacks are 
caused by ingestion of aspirin and other non-steroidal anti-inflammatory drugs that share the 
possibility to inhibit cyclooxygenase enzymes. About 15% of patients with aspirin-inducible 
asthma and rhinitis are unaware of aspirin sensitivity, indicating that aspirin challenge is 
necessary to fully diagnose the disease. About 50% of patients need systemic steroid 
treatment on top of inhaled corticosteroids, emphasizing the severity of the disease in the 
upper and lower respiratory tract. Interestingly, the course of disease is independent from 
aspirin intake, indicating that the disease is driven by a so far unknown agent and with few 
exceptions, aspirin sensitivity remains life-long4.  
Nasal polyposis: an eosinophil mediated disease? 
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The full clinical picture of aspirin-sensitive rhinosinusitis (ASRS) is characterized by raised 
blood eosinophil counts, increased eosinophils in the nasal and bronchial mucosa, and 
elevated cys-leucotriene concentrations in the tissue and urine, which further raise due to 
aspirin exposure 4;25;26. Although ASRS often is associated with allergy and highly elevated 
local IgE levels 4, an IgE-mediated mechanism could not be demonstrated, and atopy does not 
seem to influence the risk to develop aspirin sensitivity 25.  
 
Cystic fibrosis  
Sinus disease is common in cystic fibrosis with 90 per cent of patients having radiological 
evidence of sinus disease. The association between nasal polyposis and CF is well 
documented. Hadield et al. studied 211 adults with CF and found nasal polyps in 37 per cent 
14 and other studies report nasal polyps in between 10 and 32 per cent of CF patients15. Fifty 
percent of the children between 4 and 16 years of age presenting with nasal polyps have CF 
15.  
 
Fungal disease 
The syndrome of nasal polyposis combined with positive Aspergillus cultures from the 
paranasal sinuses was recognized by Safirstein in 1976 27. Further clinical reports supported 
this finding and noted its similarities with allergic bronchopulmonary aspergillosis. After the 
recognition that species other than Aspergillus were associated with the disease the term 
‘allergic fungal sinusitis’ (AFS) was introduced. The sinus mucosa shows a characteristic 
eosinophilic inflammation, with allergic mucin filling the sinuses 28;29. AFS is found unilateral 
in more than 50% of the cases, but may involve several sinuses bilaterally, and bone erosion 
and extra-sinus extension have been reported. It was recently suggested that almost all chronic 
sinusitis cases would be due to fungus involvement 30. Fungal cultures of nasal secretions 
were positive in 96% of 210 consecutive chronic rhinosinusitis patients, without an IgE-
mediated hypersensitivity to fungal allergens in the majority of subjects30. However, fungus 
may be cultured from healthy subjects in the same magnitude using the same technique, and 
no pathophysiologic pathway was demonstrated to relate fungal presence to nasal disease. 
The presence of fungi alone is insufficient to implicate it as the pathogen in chronic sinusitis, 
as fungal DNA was found in 42% of control subjects and 40% of patients with chronic 
sinusitis by PCR analysis 31, while standard cultures were positive in 7% and 0% in this study. 
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HISTOPATHOLOGY OF NASAL POLYPS 
Histomorphological characterisation of polyp tissue reveals frequent epithelial damage, a 
thickened basement membrane, and an oedematous to sometimes fibrotic stromal tissue, with 
a reduced number of vessels and glands, but virtually no neural structure 3;32.  
Most of the polyp surface is covered by a ciliated pseudostratified epithelium, but a 
transitional and squamous epithelium is also found, especially in anterior polyps, influenced 
by the inhaled air currents 3;33. Epithelial defects have apparently also been described in NP 34, 
but when polyps are removed carefully and gentle methods are used for fixation, dehydration 
and cutting, the polyp epithelium appears well preserved without defects on scanning electron 
microscopy 35. 
The sensory nerves and the autonomic vasomotor and secretory nerves invariably found in 
normal and abnormal nasal mucosa cannot be identified within the stroma of NP, either in the 
vicinity of the epithelial basement membrane or within the walls of blood vessels or glands. A 
few nerve fibres can be seen in the stalk of some NP 36;37. It is therefore assumed that 
denervation of NP causes a decrease in secretory activity of the glands and induces an 
abnormal vascular permeability, leading to an irreversible tissue oedema. NP develop in areas 
where the lining of the nasal cavity joins that of the sinuses, and these marginal zones contain 
thin nerve fascicles36;37 which may be more sensitive to damage from, for example, eosinophil 
derived proteins3.  
The vascularity of NP is sparse compared with normal nasal mucosa 36, and neither venous 
sinusoids nor arteriovenous anastomoses are encountered. The venules of the NP show 
unusual organisation with respect to their endothelial cell junctions and the basement 
membrane. Many cell junctions have the appearance of a web of villous processes and are 
incompletely sealed, while others are wide open 3;37. The release of ECP, histamine and other 
inflammatory mediators (see below) may be an important factor in causing microvascular 
plasma exudation, which is highly characteristic NP. The vascular exudation of plasma 
suggests that the lamina propria, the basement membrane, the airway epithelium, and the 
mucosal surface are furnished with potent plasma derived peptides and proteins, and that the 
mucosal macromolecular milieu in nasal polyposis is therefore dramatically different from 
that of the normal nasal mucosa 3;38. It is of particular interest that the process of 
microvascular exudation of plasma may participate in the chronic generation of oedema fluid 
in NP. The stroma of bilateral NP is mainly characterised by its oedematous nature and 
consists of supporting fibroblasts and infiltrating inflammatory cells, localized around 
“empty” pseudocyst formations. Amongst the inflammatory cells, EG2 (activated) eosinophils 
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are a prominent and characteristic feature in about 80% of polyps 39;40, whereas lymphocytes 
and neutrophils as predominant cells occur in cystic fibrosis and in primary ciliary 
dyskinesia14;15. Eosinophils are localised around the vessels, glands, and directly beneath the 
mucosal epithelium 32. The neutrophilic inflammation predominates in 7% of all cases. The 
latter is often found in cases associated with CF, primary ciliary dyskinesia syndrome, or 
Young's syndrome 9. Mast cells, with most being degranulated, are found in increased 
numbers within the stroma of nasal polyps 5;26. Increased numbers of plasma cells and 
lymphocytes, have been found at the cellular level 5;25. Fokkens et al reported that more 
lymphocytes occurred in the lamina propria than in the epithelium, and that T lymphocytes 
were more numerous than B lymphocytes 41. The majority of the lymphocytes occurred as 
single cells, whereas small aggregates were seen relatively often and large aggregates rarely41. 
Furthermore, more CD8+ cells (suppressor/cytotoxic T cells) than CD4+ cells (helper/inducer 
T cells) were found in the polyps 39;41.  
To summarize, the stroma of NP is cell-poor, and no marked characteristics other than tissue 
eosinophilia can be found. The abundance of eosinophils in NP is the first key question to 
address in order to understand this disease. It may be explained in two different ways: first, by 
an increased migration of eosinophils into the tissue; second, by a prolonged survival of these 
cells, or - most likely - by a combination of both. The second key question concerns the 
precise pathomechanism by which eosinophils may contribute to the tissue damage, 
inflammation and polyp formation. 
 
CYTOKINES, CHEMOKINES AND ADHESION MOLECULES IN NASAL POLYPS 
Early studies by Denburg et al 42demonstrated that conditioned medium derived from cultured 
nasal polyp epithelial cells contained potent eosinophil colony-stimulating activities, as well 
as an interleukin-3-like activity. The authors suggested that accumulation of eosinophils in 
polyps may partly be a result of differentiation of progenitor cells stimulated by soluble 
hemopoietic factors derived from mucosal cell populations. An increased synthesis of GM-
CSF by epithelial cells, fibroblasts, monocytes, and eosinophils was suggested later 42-44. 
According to Hamilos et al 45, polyp tissue samples from patients with or without allergy 
contained different cytokine profiles. They found by in situ hybridization studies that patients 
with “allergic” polyps had higher tissue densities of GM-CSF, IL-3, IL-4, and IL-5 transcripts 
than controls, whereas patients with non-allergic polyps had higher tissue densities of GM-
CSF, IL-3, and IFN-gamma transcripts. From these results, distinct pathomechanisms for 
allergic versus non-allergic polyps were suggested45. However, other studies involving protein 
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measurements in tissue homogenates could not support these findings 10;46. In contrast, IL-3 
and GM-CSF protein concentration were found in only a small number of polyp and control 
turbinate samples. However, IL-5 was found to be significantly increased in nasal polyps, 
compared to healthy controls, and the concentration of IL-5 was independent of the atopic 
status of the patient. Actually, the highest concentrations of IL-5 were found in subjects with 
non-allergic asthma and aspirin sensitivity10;46. Furthermore, eosinophils were positively 
stained for IL-5, suggesting a possible autocrine role for this cytokine in the activation of 
eosinophils. A strong correlation between concentrations of IL-5 protein and eosinophilic 
cationic protein (ECP) was demonstrated later 4. The key role of IL-5 was supported by the 
finding that treatment of eosinophil-infiltrated polyp tissue with neutralizing anti-IL-5 
monoclonal antibody (mAB), but not anti-IL-3 or anti-GM-CSF mAbs in vitro, resulted in 
eosinophil apoptosis and decreased tissue eosinophilia 47. Collectively, these studies suggest 
that increased production of IL-5 is likely to influence the predominance and activation of 
eosinophils in nasal polyps independent from atopy. The lack of difference in the amounts of 
cytokines detected in polyps from allergic and non-allergic patients was meanwhile supported 
by several studies 48;49.  
The eosinophilic inflammation in polyps is orchestrated by T-cells, which have been 
characterized as activated 50. They represent a mixed population, consisting of CD4+ and 
CD8+ cells, and show a mixed Th1/Th2 profile. However, also inflammatory cells such as 
eosinophils, macrophages or mast cells may contribute to the release of cytokines, as was 
especially shown for eosinophils, contributing IL-4 and IL-5 in an autocrine manner.  
Recent studies have shown that NP also express high levels of RANTES and eotaxin, the 
predominantly recognised eosinophil chemoattractants. Bartels and colleagues 51 
demonstrated that expression of eotaxin- and RANTES mRNA, but not MCP-3 mRNA, was 
elevated in non-atopic and atopic NP, when compared to normal nasal mucosa. Similarly, 
Jahnsen et al. 52 demonstrated an increased mRNA expression for eotaxin, eotaxin-2, and 
MCP-4. The expression of eotaxin-2, a novel CCR3-specific chemokine, was found to be the 
most prominent of the three chemokines investigated. This is in accordance with the findings 
of a recent extensive study of about 950 non-allergic or allergic polyp patients, which has also 
suggested that NP eosinophilic infiltration and activation may correlate mainly with increased 
eotaxin gene expression, rather than with RANTES expression 53. 
Studies of cell adhesion molecules are relatively scarce. Early studies by Symon et al. 54 
demonstrated that ICAM-1, E-selectin and P-selectin were well expressed by NP 
endothelium, whereas VCAM-1 expression was weak or absent. In a study by Jahnsen et al 55, 
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employing three-colour immunofluorescence staining, has however demonstrated that both 
the number of eosinophils and the proportion of vessels positive for VCAM-1 were 
significantly increased in NP compared with the turbinate mucosa of the same patients. 
Moreover, treatment with topical glucocorticosteroids decreases the eosinophils density and 
the expression of VCAM-1 in NP 56. The interaction between VLA-4 on eosinophils and 
VCAM-1 on endothelial cells may be of importance in priming eosinophils by modifying the 
activation and effector functions 57. 
Consistent with the current knowledge on the pathophysiology of nasal polyposis, new 
therapeutic approaches could focus on eosinophilic inflammation, eosinophil recruitment, the 
T-cell as orchestrating cell, IgE antibodies, as well as on tissue destruction and remodeling 
processes.  
 
MANAGEMENT OF NASAL POLYPOSIS 
The management of patients with nasal polyps is one of the major problems 
otorhinolaryngologists have to face in daily practice. Especially since little evidence based or 
satisfying treatment approaches are available to help these patients. The primary goal of 
treatment is the relief of symptoms, the primary symptoms being nasal blockage, congestion, 
hypo- or anosmia and secretion. Other symptoms include post-nasal drainage, facial pain, 
headache, sleep disturbance and diminished quality of life 4. Secondary goals of treatment 
include a decrease in the frequency of infections and disease recurrences, an improvement in 
associated lower airway symptoms, and the prevention of complications such as mucoceles 
and orbital involvement 4.  
Hippocrates removed polyps with a snare and this remained the only treatment available until 
recently3. However, there have been two remarkable therapeutic innovations in the last two 
decades: first, the introduction of topically active corticosteroids, and second, endoscopic 
sinus surgery 58.  
 
Endoscopic polypectomy and sinus surgery 
The acronym “FESS” (Functional endoscopic sinus surgery) is frequently applied to any sinus 
surgery undertaken with endoscopic control, but it is clear that the removal of polyps is rarely 
functional in the sense in which the term was originally conceived. The extent of surgery 
varies according to the extent of disease, surgeon‘s individual practice and ranges from 
removal of polyps within the middle meatus, perhaps combined with uncinectomy, middle 
meatal antrostomy and opening of the bulla to a complete “nasalization” of all sinuses with 
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exenteration of all sinus mucosa. Nasal polyp tissue for research purposes was obtained 
within the middle meatus and was immediately processed.  
Extensive postoperative care and follow-up is required to preserve the postoperative results 
and prevent re-growth of polyps. Nevertheless, nasal polyposis is a chronic disease with a 
high rate of recurrences even after careful medical and surgical treatment. In a 20-year follow-
up study of 41 patients with nasal polyps, 85% of patients still suffered from the disease with 
anosmia present in 61% 59; 8 subjects, including 7 with aspirin sensitivity, had undergone 11 
or more surgical operations during the 20-year period. This study, as well as others showing 
the high recurrence rate in nasal polyps, clearly indicate the chronicity of the disease 
especially in this subgroup of patients and suggest a conservative surgical approach. Instead, a 
combined strategy involving surgical and medical treatment is recommended for long-term 
control of the disease 60;61.  
The medical or surgical treatment of nasal polyposis may have impact on the control of 
asthma. A study involving 205 patients with asthma and aspirin sensitivity indicated that 
surgery improves asthma for relatively long periods of time 62. However, there are no data 
concerning the evolution of asymptomatic bronchial hyperreactivity in patients with nasal 
polyposis, and individual patients may develop asthma symptoms after surgery. This 
development may represent the natural course of the disease rather than a true shift from 
upper to lower airway disease.    
 
Topical and systemic glucocorticosteroids (GCS) 
As nasal polyposis represents an eosinophilic inflammation with consecutive tissue changes, 
topical and systemic corticosteroids are the first choice treatment approaches4.  Systemic 
application affects all polyp tissue within the nose and sinuses, but has the disadvantage of 
systemic side effects, when used for long-term treatment. Topical application of 
corticosteroids significantly reduces side effects, but does not impact polyps within the 
sinuses.  In fact, the distribution of the drug within the nasal cavity, partially or completely 
obstructed by polyp tissue, already presents a notable problem to treatment success4.  
Glucocorticosteroids can suppress many phases of the inflammatory process 63;64, which may 
explain their strong effect on inflammation. T-cells are highly sensitive to treatment with 
GCS, reducing the number of T-cells in a dose dependent way, and the expression of mRNA 
and protein for IL-3, IL-4, IL-5 and IL-13 and their receptors 65. The secretion of numerous 
other cytokines and chemokines is also reduced, among them IL-1β, IL-2, IL-4, IL-6, IL-8, 
TNF-α, IFN-γ, GM-CSF, RANTES, and eotaxin 66. This affects recruitment, localization, 
Nasal polyposis: an eosinophil mediated disease? 
28
Chapter 1   
activation, protein synthesis and survival of inflammatory cells such as eosinophils. The 
recruitment of inflammatory cells is also diminished by the inhibition of expression of 
adhesion molecules such as ICAM-1 and VCAM-1, which affects the influx of basophils and 
mast cells in the epithelial layers of the nasal mucosa. GCS may also reduce the release of 
preformed and newly-generated mediators, such as histamine, prostanoids and 
leukotrienes4;65. However, this action may be partly due to the reduction of inflammatory cells 
in the mucosa. Finally, GCS can also act on IgE production 67 and may affect plasma protein 
retention. However, macrophages and neutrophils do not seem to be influenced 68, which 
might explain why local GCS do not have a negative effect on the immunity to bacterial in-
fections.  
The symptomatic efficacy of intranasal corticosteroids in patients with nasal polyps is well 
documented 69. Symptoms such as nasal blockage, rhinorrhea and occasionally hyposmia are 
reduced during the period of treatment, especially in obstructive polyposis 70;71. However, 
recurrence of symptoms or polyp growth, monitored by symptoms, endoscopy or 
rhinomanometry, occurs within weeks to months 72. After surgery, topical corticosteroids may 
also reduce the incidence of polyp recurrences or prolong the symptom-free time interval 73;74. 
Nevertheless, topical corticosteroids may be insufficient in severe bilateral polyps 4;58;75, and 
polyp growth may be observed despite treatment in these patients.  
Systemic oral GCS are indicated to start off or enforce conservative local treatment. So far, to 
our knowledge, not a single placebo-controlled, randomized trial with oral GCS has been 
published. However, oral GCS treatment has been studied in an uncontrolled study, showing a 
significant effect for some months with an improvement of symptoms in 72 % of the patients 
and a reduction of polyp size and of sinus opacification in the CT-scan in 52 % 76. In those 
subjects responding, recurrences mostly occurred within 5 months. Thus, oral GCS may be 
indicated to delay surgery or to facilitate surgery. However, there is no evidence so far that 
the natural course of the disease might be influenced by short- or long-term low-dose 
treatment regimes.   
The use of topical corticosteroids, taken on a daily basis for several months to years, is 
considered first line therapy in small to medium sized nasal polyps to reduce symptoms, and 
to avoid surgery and relapse 4. Topical treatment may be enforced by oral application of GCS, 
for which controlled studies are clearly needed, or combined with other treatment approaches. 
However, surgery needs to be considered in case of failure, side effects or unwillingness of 
the patient to comply with drug treatment, as well as in case of complications 4.  
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Antileukotrienes 
Changes in the arachidonic acid metabolism have been suggested to be involved in the 
pathomechanism of nasal polyposis especially in aspirin sensitive subjects. Theoretically, the 
use of antileukotrienes especially in aspirin sensitive nasal polyp patients could be appropriate 
77. However, large-scale controlled trials in clearly characterized patients – with or without 
aspirin sensitivity - are lacking so far.  
Parnes treated 40 patients diagnosed with sinonasal polyposis and sinusitis with either 
zileuton or zafirlukast on top of the classical treatment. Outcome measures included 
subjective interviews and questionnaire responses, as well as office endoscopic examinations 
and chart reviews78;79. Overall, 26 patients (72%) experienced subjective improvement of 
symptoms after starting the medication, and four patients (11%) discontinued the medication 
because of side effects 78;79.  
Montelukast, a leukotriene D4 receptor antagonist, was studied as an add-on therapy to 
topical and inhaled corticosteroids in patients with or without aspirin sensitivity, both with 
nasal polyposis and asthma 80. Clinical subjective improvement in nasal polyposis occurred in 
64% aspirin tolerant and 50% of sensitive patients, asthma improvement in 87% and 61% 
respectively. However, acoustic rhinometry, nasal inspiratory peak flow and nitric oxide 
levels did not change significantly in any group, and improvement on montelukast therapy 
was not associated with aspirin sensitivity 80. The findings are consistent with a subgroup of 
nasal polyps/asthma patients in whom leukotriene receptor antagonists may be effective, 
however unrelated to aspirin sensitivity 4.  
 
Antihistamines 
Antihistamines may be indicated in subjects with nasal polyposis and allergic rhinitis 
complaints; however, their use in patients with polyps only has not been extensively studied. 
Furthermore, even subjects with ragweed positive skin tests did not show enhanced symptoms 
or an increase in markers of eosinophilic inflammation (eosinophil percentage or ECP 
concentrations in nasal secretions) due to seasonal exposure 20. In a clinical study including 
45 patients with residual or recurrent nasal polyposis after ethmoidectomy, treatment with 
either cetirizine at twice the daily dose recommended (20 mg) or placebo for three months 
was performed 81. Although the number and size of polyps remained unchanged during the 
study period, the active treatment reduced sneezing and rhinorrhoea effectively, and also had 
a late effect on nasal obstruction 81.  
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Anti-IgE 
Considering the marked local production of IgE-antibodies in nasal polyps and its relation to 
severity of disease, it appears that local IgE is functional and involved in the regulation of 
chronic inflammation. Additionally, some studies have shown that anti-IgE therapy reduces 
circulating eosinophil numbers, but this is unlikely to be due to a direct effect because 
eosinophils have little, if any, IgE and FcεRI on their surface 82. Thus, strategies to antagonize 
IgE antibodies could be of relevance. Treatment of allergic asthma and rhinitis with 
omalizumab, a humanized monoclonal anti-IgE antibody, causes a marked reduction in 
circulating free IgE levels 83-89. Treatment has been shown to reduce symptoms and 
exacerbations and decrease the need for other medication in patients with these allergic 
diseases. No studies in NP have been performed yet to answer the question, whether high 
concentrations of IgE-antibodies within the NP tissue can be targeted with success.  
 
Anti-CCR3, anti-eotaxin 
CC-chemokine receptor 3 (CCR3)-stimulating chemokines are likely to have an important in 
vivo role in the regulation of eosinophil, basophil, and potentially T helper type 2 and mast 
cell recruitment. Several CC chemokines including eotaxin and RANTES are potent 
eosinophil chemotactic and activating peptides acting through CCR3. As eosinophils have 
also been implicated in the pathogenesis of nasal polyposis, and RANTES and eotaxin have 
been identified as eosinophil chemoattractants in polyp tissue, antagonism of CCR3 could 
have a therapeutic role in this disease. The development of small non-peptide molecule CCR3 
antagonists currently offers advantages over anti-chemokine (i.e. eotaxin) antibodies in terms 
of a broader approach, affecting several chemokines and effector cells, and a favorable 
pharmacokinetic, targeting the receptors on peripheral blood cell surfaces and being 
independent from tissue penetration. 
Recently anti-eotaxin antibodies were administered intranasally in grass pollen sensitive 
subjects. After nasal challenge pretreatment with anti-eotaxin reduces nasal obstruction, 
eosinophil influx and mast cells compared to placebo pretreatment 90. Studies in nasal polyps 
have not been reported yet.   
  
Conclusion 
The treatment of nasal polyps with systemic and topical corticoids and with surgery is 
common clinical use. However no medical or surgical treatment guarantees cure. 
Management of patients with severe nasal polyposis is still unsatisfactory and recurrences 
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remain a problem with a general rate of recurrence of more than 40% after 5 years. Future 
progress in therapy seems to be closely linked to a better understanding of the mechanisms 
underlying the migration, activation and maintenance of eosinophils in nasal polyp tissue. In 
chapter 2 we focus on the role of IL-5 and IL-5 receptor in eosinophilic inflammation, with 
emphasis on strategies to interfere with IL-5 function especially in nasal polyposis. 
 
REFERENCES 
 1.  Larsen PL, Tos M. Origin of nasal polyps. Laryngoscope 1991; 101(3):305-312. 
 2.  Larsen PL, Tos M. Site of origin of nasal polyps. Transcranially removed naso-
ethmoidal blocks as a screening method for nasal polyps in autopsy material. 
Rhinology 1995; 33(4):185-188. 
 3.  Mygind N, Lildholdt T. Nasal Polyposis: an inflammatory disease and its treatment. 
Copenhagen: Munksgaard, 1997. 
 4.  Bachert C, van Cauwenberge P. Nasal Polyps and Sinusitis. Allergy: principles and 
practice. Mosby, 2003. 
 5.  Drake-Lee AB, McLaughlan P. Clinical symptoms, free histamine and IgE in patients 
with nasal polyposis. Int Arch Allergy Appl Immunol 1982; 69(3):268-271. 
 6.  Drake-Lee AB, Lowe D, Swanston A, Grace A. Clinical profile and recurrence of 
nasal polyps. J Laryngol Otol 1984; 98(8):783-793. 
 7.  Lund VJ, Kennedy DW. Quantification for staging sinusitis. The Staging and Therapy 
Group. Ann Otol Rhinol Laryngol Suppl 1995; 167:17-21. 
 8.  Lund VJ. Management of nasal polyps: is objective assessment possible? Acta 
Otorhinolaryngol Belg 1995; 49(3):219-224. 
 9.  Stammberger H. Surgical treatment of nasal polyps: past, present, and future. Allergy 
1999; 54 Suppl 53:7-11. 
 10.  Bachert C, Wagenmann M, Rudack C, Hopken K, Hillebrandt M, Wang D et al. The 
role of cytokines in infectious sinusitis and nasal polyposis. Allergy 1998; 53(1):2-13. 
 11.  Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin 
intolerance, nasal polyposis and chronic obstructive pulmonary disease in a 
population-based study. Int J Epidemiol 1999; 28(4):717-722. 
 12.  Moloney JR. Nasal polyps, nasal polypectomy, asthma, and aspirin sensitivity. Their 
association in 445 cases of nasal polyps. J Laryngol Otol 1977; 91(10):837-846. 
 13.  Moloney JR, Collins J. Nasal polyps and bronchial asthma. Br J Dis Chest 1977; 
71(1):1-6. 
Nasal polyposis: an eosinophil mediated disease? 
32
Chapter 1   
 14.  Hadfield PJ, Rowe-Jones JM, Mackay IS. The prevalence of nasal polyps in adults 
with cystic fibrosis. Clin Otolaryngol 2000; 25(1):19-22. 
 15.  Schramm VL, Jr., Effron MZ. Nasal polyps in children. Laryngoscope 1980; 
90(9):1488-1495. 
 16.  Settipane GA. Epidemiology of nasal polyps. Allergy Asthma Proc 1996; 17(5):231-
236. 
 17.  Caplin I, Haynes JT, Spahn J. Are nasal polyps an allergic phenomenon? Ann Allergy 
1971; 29(12):631-634. 
 18.  Settipane GA, Chafee FH. Nasal polyps in asthma and rhinitis. A review of 6,037 
patients. J Allergy Clin Immunol 1977; 59(1):17-21. 
 19.  Kawabori S, Denburg JA, Schwartz LB, Irani AA, Wong D, Jordana G et al. 
Histochemical and immunohistochemical characteristics of mast cells in nasal polyps. 
Am J Respir Cell Mol Biol 1992; 6(1):37-43. 
 20.  Keith PK, Conway M, Evans S, Wong DA, Jordana G, Pengelly D et al. Nasal polyps: 
effects of seasonal allergen exposure. J Allergy Clin Immunol 1994; 93(3):567-574. 
 21.  Small P, Barrett D, Frenkiel S, Rochon L, Cohen C, Black M. Local specific IgE 
production in nasal polyps associated with negative skin tests and serum RAST. Ann 
Allergy 1985; 55(5):736-739. 
 22.  Lamblin C, Tillie-Leblond I, Darras J, Dubrulle F, Chevalier D, Cardot E et al. 
Sequential evaluation of pulmonary function and bronchial hyperresponsiveness in 
patients with nasal polyposis: a prospective study. Am J Respir Crit Care Med 1997; 
155(1):99-103. 
 23.  Settipane GA. Asthma, aspirin intolerance and nasal polyps. N Engl Reg Allergy Proc 
1986; 7(1):32-37. 
 24.  Samter M, Beers RF, Jr. Intolerance to aspirin. Clinical studies and consideration of its 
pathogenesis. Ann Intern Med 1968; 68(5):975-983. 
 25.  Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. 
AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 
2000; 16(3):432-436. 
 26.  Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced 
asthma. Thorax 2000; 55 Suppl 2:S42-S44. 
 27.  Safirstein BH. Allergic bronchopulmonary aspergillosis with obstruction of the upper 
respiratory tract. Chest 1976; 70(6):788-790. 
 28.  Katzenstein AL, Sale SR, Greenberger PA. Allergic Aspergillus sinusitis: a newly 
recognized form of sinusitis. J Allergy Clin Immunol 1983; 72(1):89-93. 
 29.  Katzenstein AL, Sale SR, Greenberger PA. Pathologic findings in allergic aspergillus 
sinusitis. A newly recognized form of sinusitis. Am J Surg Pathol 1983; 7(5):439-443. 
Nasal polyposis: an eosinophil mediated disease? 
33
Chapter 1   
 30.  Ponikau JU, Sherris DA, Kern EB, Homburger HA, Frigas E, Gaffey TA et al. The 
diagnosis and incidence of allergic fungal sinusitis. Mayo Clin Proc 1999; 74(9):877-
884. 
 31.  Catten MD, Murr AH, Goldstein JA, Mhatre AN, Lalwani AK. Detection of fungi in 
the nasal mucosa using polymerase chain reaction. Laryngoscope 2001; 111(3):399-
403. 
 32.  Kakoi H, Hiraide F. A histological study of formation and growth of nasal polyps. 
Acta Otolaryngol 1987; 103(1-2):137-144. 
 33.  Tos M, Larsen PL, Moller K. Goblet cell density in nasal polyps. Ann Otol Rhinol 
Laryngol 1990; 99(4 Pt 1):310-315. 
 34.  Larsen PL, Tos M. Nasal polyps: epithelium and goblet cell density. Laryngoscope 
1989; 99(12):1274-1280. 
 35.  Larsen PL, Tingsgaard PK, Harcourt J, Sofsrud G, Tos M. Nasal polyps and their 
relation to polyps/hypertrophic polypoid mucosa in the paranasal sinuses: a macro-, 
endo-, and microscopic study of autopsy materials. Am J Rhinol 1998; 12(1):45-51. 
 36.  Cauna N, Cauna D, Hinderer KH. Innervation of human nasal glands. J Neurocytol 
1972; 1(1):49-60. 
 37.  Cauna N, Manzetti GW, Hinderer KH, Swanson EW. Fine structure of nasal polyps. 
Ann Otol Rhinol Laryngol 1972; 81(1):41-58. 
 38.  Greiff L, Erjefalt I, Svensson C, Wollmer P, Alkner U, Andersson M et al. Plasma 
exudation and solute absorption across the airway mucosa. Clin Physiol 1993; 
13(3):219-233. 
 39.  Stoop AE, van der Heijden HA, Biewenga J, van der Baan S. Clinical aspects and 
distribution of immunologically active cells in the nasal mucosa of patients with nasal 
polyps after endoscopic sinus surgery and treatment with topical corticosteroids. Eur 
Arch Otorhinolaryngol 1992; 249(6):313-317. 
 40.  Stoop AE, van der Heijden HA, Biewenga J, van der BS. Eosinophils in nasal polyps 
and nasal mucosa: an immunohistochemical study. J Allergy Clin Immunol 1993; 
91(2):616-622. 
 41.  Fokkens WJ, Holm AF, Rijntjes E, Mulder PG, Vroom TM. Characterization and 
quantification of cellular infiltrates in nasal mucosa of patients with grass pollen 
allergy, non-allergic patients with nasal polyps and controls. Int Arch Allergy Appl 
Immunol 1990; 93(1):66-72. 
 42.  Denburg JA, Otsuka H, Ohnisi M, Ruhno J, Bienenstock J, Dolovich J. Contribution 
of basophil/mast cell and eosinophil growth and differentiation to the allergic tissue 
inflammatory response. Int Arch Allergy Appl Immunol 1987; 82(3-4):321-326. 
 43.  Ohno I, Lea RG, Flanders KC, Clark DA, Banwatt D, Dolovich J et al. Eosinophils in 
chronically inflamed human upper airway tissues express transforming growth factor 
beta 1 gene (TGF beta 1). J Clin Invest 1992; 89(5):1662-1668. 
Nasal polyposis: an eosinophil mediated disease? 
34
Chapter 1   
 44.  Xaubet A, Mullol J, Lopez E, Roca-Ferrer J, Rozman M, Carrion T et al. Comparison 
of the role of nasal polyp and normal nasal mucosal epithelial cells on in vitro 
eosinophil survival. Mediation by GM-CSF and inhibition by dexamethasone. Clin 
Exp Allergy 1994; 24(4):307-317. 
 45.  Hamilos DL, Leung DY, Huston DP, Kamil A, Wood R, Hamid Q. GM-CSF, IL-5 
and RANTES immunoreactivity and mRNA expression in chronic hyperplastic 
sinusitis with nasal polyposis (NP). Clin Exp Allergy 1998; 28(9):1145-1152. 
 46.  Bachert C, Wagenmann M, Hauser U, Rudack C. IL-5 synthesis is upregulated in 
human nasal polyp tissue. J Allergy Clin Immunol 1997; 99(6 Pt 1):837-842. 
 47.  Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct 
demonstration of delayed eosinophil apoptosis as a mechanism causing tissue 
eosinophilia. J Immunol 1997; 158(8):3902-3908. 
 48.  Lee CH, Rhee CS, Min YG. Cytokine gene expression in nasal polyps. Ann Otol 
Rhinol Laryngol 1998; 107(8):665-670. 
 49.  Min YG, Lee CH, Rhee CS, Kim KH, Kim CS, Koh YY et al. Inflammatory cytokine 
expression on nasal polyps developed in allergic and infectious rhinitis. Acta 
Otolaryngol 1997; 117(2):302-306. 
 50.  Sanchez-Segura A, Brieva JA, Rodriguez C. T lymphocytes that infiltrate nasal polyps 
have a specialized phenotype and produce a mixed TH1/TH2 pattern of cytokines. J 
Allergy Clin Immunol 1998; 102(6 Pt 1):953-960. 
 51.  Bartels J, Maune S, Meyer JE, Kulke R, Schluter C, Rowert J et al. Increased eotaxin-
mRNA expression in non-atopic and atopic nasal polyps: comparison to RANTES and 
MCP-3 expression. Rhinology 1997; 35(4):171-174. 
 52.  Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids inhibit 
mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in 
human airway inflammation with eosinophilia. J Immunol 1999; 163(3):1545-1551. 
 53.  Shin SH, Park JY, Jeon CH, Choi JK, Lee SH. Quantitative analysis of eotaxin and 
RANTES messenger RNA in nasal polyps: association of tissue and nasal eosinophils. 
Laryngoscope 2000; 110(8):1353-1357. 
 54.  Symon FA, Walsh GM, Watson SR, Wardlaw AJ. Eosinophil adhesion to nasal polyp 
endothelium is P-selectin-dependent. J Exp Med 1994; 180(1):371-376. 
 55.  Jahnsen FL, Haraldsen G, Aanesen JP, Haye R, Brandtzaeg P. Eosinophil infiltration 
is related to increased expression of vascular cell adhesion molecule-1 in nasal polyps. 
Am J Respir Cell Mol Biol 1995; 12(6):624-632. 
 56.  Tingsgaard PK, Bock T, Larsen PL, Tos M. Topical budesonide treatment reduces 
endothelial expression of intercellular adhesion molecules (vascular cell adhesion 
molecule-1 and P-selectin) and eosinophil infiltration in nasal polyps. Acta 
Otolaryngol (Stockh) 1999; 119(3):362-368. 
Nasal polyposis: an eosinophil mediated disease? 
35
Chapter 1   
 57.  Palframan RT, Collins PD, Severs NJ, Rothery S, Williams TJ, Rankin SM. 
Mechanisms of acute eosinophil mobilization from the bone marrow stimulated by 
interleukin 5: the role of specific adhesion molecules and phosphatidylinositol 3-
kinase. J Exp Med 1998; 188(9):1621-1632. 
 58.  Mygind N, Lildholdt T. Nasal polyps treatment: medical management. Allergy 
Asthma Proc 1996; 17(5):275-282. 
 59.  Vento SI, Ertama LO, Hytonen ML, Wolff CH, Malmberg CH. Nasal polyposis: 
clinical course during 20 years. Ann Allergy Asthma Immunol 2000; 85(3):209-214. 
 60.  Lundblad L, Sipila P, Farstad T, Drozdziewicz D. Mometasone furoate nasal spray in 
the treatment of perennial non-allergic rhinitis: a nordic, multicenter, randomized, 
double-blind, placebo-controlled study. Acta Otolaryngol 2001; 121(4):505-509. 
 61.  Blomqvist EH, Lundblad L, Anggard A, Haraldsson PO, Stjarne P. A randomized 
controlled study evaluating medical treatment versus surgical treatment in addition to 
medical treatment of nasal polyposis. J Allergy Clin Immunol 2001; 107(2):224-228. 
 62.  English GM. Nasal polypectomy and sinus surgery in patients with asthma and aspirin 
idiosyncrasy. Laryngoscope 1986; 96(4):374-380. 
 63.  Rudack C, Bachert C, Stoll W. Effect of prednisolone on cytokine synthesis in nasal 
polyps. J Interferon Cytokine Res 1999; 19(9):1031-1035. 
 64.  Rudack C, Bachert C. Glucocorticosteroids rapidly inhibit allergen-induced expression 
of E- selectin in vitro in a mucosal model of allergic rhinitis. Allergy 2000; 55(4):363-
368. 
 65.  Bachert C, Gevaert P. Effect of intranasal corticosteroids on release of cytokines and 
inflammatory mediators. Allergy 54[Suppl 57], 116-123. 1999.  
 
 66.  Henriksson G, Norlander T, Forsgren J, Stierna P. Effects of topical budesonide 
treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in 
nasal polyps. Am J Rhinol 2001; 15(1):1-8. 
 67.  Naclerio RM, Adkinson NF, Jr., Creticos PS, Baroody FM, Hamilton RG, Norman PS. 
Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E 
antibodies. J Allergy Clin Immunol 1993; 92(5):717-721. 
 68.  Godthelp T, Fokkens WJ, Kleinjan A, Holm AF, Mulder PG, Prens EP et al. Antigen 
presenting cells in the nasal mucosa of patients with allergic rhinitis during allergen 
provocation. Clin Exp Allergy 1996; 26(6):677-688. 
 69.  Badia L, Lund V. Topical corticosteroids in nasal polyposis. Drugs 2001; 61(5):573-
578. 
 70.  Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. 
Arch Otolaryngol Head Neck Surg 1998; 124(5):513-518. 
Nasal polyposis: an eosinophil mediated disease? 
36
Chapter 1   
 71.  Tos M, Svendstrup F, Arndal H, Orntoft S, Jakobsen J, Borum P et al. Efficacy of an 
aqueous and a powder formulation of nasal budesonide compared in patients with 
nasal polyps. Am J Rhinol 1998; 12(3):183-189. 
 72.  Lund VJ, Flood J, Sykes AP, Richards DH. Effect of fluticasone in severe polyposis. 
Arch Otolaryngol Head Neck Surg 1998; 124(5):513-518. 
 73.  Virolainen E, Puhakka H. The effect of intranasal beclomethasone dipropionate on the 
recurrence of nasal polyps after ethmoidectomy. Rhinology 1980; 18(1):9-18. 
 74.  Hartwig S, Linden M, Laurent C, Vargo AK, Lindqvist N. Budesonide nasal spray as 
prophylactic treatment after polypectomy (a double blind clinical trial). J Laryngol 
Otol 1988; 102(2):148-151. 
 75.  Krouse HA, Phung ND, Klaustermeyer WB. Intranasal beclomethasone in severe 
rhinosinusitis and nasal polyps. Ann Allergy 1983; 50(6):385-388. 
 76.  van Camp C, Clement PA. Results of oral steroid treatment in nasal polyposis. 
Rhinology 1994; 32(1):5-9. 
 77.  Parnes SM. The role of leukotriene inhibitors in allergic rhinitis and paranasal 
sinusitis. Curr Allergy Asthma Rep 2002; 2(3):239-244. 
 78.  Parnes SM. Targeting cysteinyl leukotrienes in patients with rhinitis, sinusitis and 
paranasal polyps. Am J Respir Med 2002; 1(6):403-408. 
 79.  Parnes SM. The role of leukotriene inhibitors in patients with paranasal sinus disease. 
Curr Opin Otolaryngol Head Neck Surg 2003; 11(3):184-191. 
 80.  Ragab S, Parikh A, Darby YC, Scadding GK. An open audit of montelukast, a 
leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp 
Allergy 2001; 31(9):1385-1391. 
 81.  Haye R, Aanesen JP, Burtin B, Donnelly F, Duby C. The effect of cetirizine on 
symptoms and signs of nasal polyposis. J Laryngol Otol 1998; 112(11):1042-1046. 
 82.  Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics 
following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131(1):46-52. 
 83.  Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M et al. Effect of 
omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. 
JAMA 2001; 286(23):2956-2967. 
 84.  Casale TB. Anti-immunoglobulin E (omalizumab) therapy in seasonal allergic rhinitis. 
Am J Respir Crit Care Med 2001; 164(8 Pt 2):S18-S21. 
 85.  Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-
IgE antibody, reduces asthma-related emergency room visits and hospitalizations in 
patients with allergic asthma. J Allergy Clin Immunol 2003; 111(1):87-90. 
Nasal polyposis: an eosinophil mediated disease? 
37
Chapter 1   
 86.  Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F et al. Omalizumab 
improves asthma-related quality of life in patients with severe allergic asthma. J 
Allergy Clin Immunol 2003; 111(2):278-284. 
 87.  Frew AJ. Anti-IgE and asthma. Ann Allergy Asthma Immunol 2003; 91(2):117-118. 
 88.  Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of 
omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at 
high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001; 
17(4):233-240. 
 89.  Johansson SG, Haahtela T, O'Byrne PM. Omalizumab and the immune system: an 
overview of preclinical and clinical data. Ann Allergy Asthma Immunol 2002; 
89(2):132-138. 
 90.  Taylor-Clark T, Salagean EM, Salib R, Lau L, DiGiovanna, Brennan et al. The 
influence of intranasal pre-treatment with anti-eotaxin monoclonal antibody, CAT-
213, on the nasal response to allergen challenge in rhinitis. Allergy 58[S74], 6. 2003.  
 
 
 
Nasal polyposis: an eosinophil mediated disease? 
38
 
 
 
 
 
 
 
CHAPTER 2 
 
 
 
EOSINOPHILS AND INTERLEUKIN-5 IN NASAL POLYPS: 
TARGETS FOR THERAPY? 
 
 
39
Chapter 2   
EOSINOPHILS AND INTERLEUKIN-5 IN NASAL POLYPS: 
TARGETS FOR THERAPY? 
 
INTRODUCTION 
For more than 100 years, eosinophils have been readily recognized by microscopic 
examination of blood, bone marrow and other tissues. Maturated and differentiated in the 
bone marrow, eosinophils are released at a low rate into the blood circulation, and their levels 
only represent 1-2% of the total peripheral leukocytes in healthy subjects. Eosinophils 
circulate in the blood with a half-life of 18 hours, before entering the tissue, which serves as 
the primary site for the cells1. Traditionally viewed as killer-effector cells in helminth 
parasitic infections they are more recently viewed as pro-inflammatory cells in allergic 
diseases. Eosinophils are known to be attracted from the peripheral blood circulation towards 
inflamed tissues where they can modulate the inflammatory process by releasing a range of 
toxic basic proteins, lipid mediators, cytokines and superoxide anions.  One of the most 
characteristic features of eosinophils is the membrane-bound specific granule containing the 
cytotoxic proteins including major basic protein (MBP), eosinophil cationic protein (ECP), 
eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase (EPO)1. It was the 
characteristic staining of the granules with acidic dye eosin that rendered the cell its name 
when P. Ehrlich identified it in 1879 1. Since eosinophils are one of the most cytotoxic cells in 
the body, mobilization and activation is under the tight control of cytokines and chemokines. 
Eosinophils leave the bone marrow with a so-called “non-primed” phenotype that is refractory 
to activation. Upon interaction with cytokines and/or chemokines these cells become prone 
for activation by physiologically relevant activators. This process is referred to as “priming”. 
Virtually all eosinophil responses are under control of this priming mechanism which acts as a 
safety lock preventing specific activation of this highly cytotoxic cell.  
Interleukin 5 (IL-5) is the key cytokine in an eosinophil’s life span: it supports 
eosinophilopoiesis and eosinophil differentiation, contributes to eosinophil migration, tissue 
localisation and function, and prevents eosinophil apoptosis. Given the likely role of 
eosinophils in nasal polyps, this chapter reviews IL-5 and IL-5 receptor research, with 
emphasis on strategies to interfere with IL-5 function especially in nasal polyposis. 
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BIOLOGY OF INTERLEUKIN-5 
Cellular source of IL-5 
The human IL-5 gene, composed of four exons and three introns, has been mapped to the long 
arm of chromosome 5, in close proximity to the cytokines IL-3, IL-4 and GM-CSF 2. 
Expression of IL-5 appears to be predominantly regulated at the transcriptional level 1. 
Within lymphocyte lineages, the major source of IL-5 is a subset of helper T-cells 3. Among 
the myeloid lineages, mast cells and eosinophils are the major producers of IL-5. T- cells are 
involved in the control of growth and effector functions of cell types that contribute to allergic 
inflammatory responses 1;3. They do not store IL-5, but upon appropriate stimulation, 
synthesize and immediately release this cytokine. Immuno-histochemical staining revealed 
that besides in T-cells, IL-5 can also be found in mast cells and eosinophils. However, 
regulation of its production is different in these latter cell types, which rapidly release 
preformed IL-5 from storage granules upon cellular activation 4;5. Thus, in allergic diseases 
eosinophils could maintain the inflammation by autocrine stimulation. It is of note that 
sensitized mast cell-deficient mice are fully capable of producing high amounts of IL-5 6, 
whereas T cell-deficient mice lack the ability to produce a substantial IL-5 driven cellular 
response 7. As a third source of IL-5, human bronchial and nasal epithelial cells grown in 
culture constitutively express IL-5 mRNA and protein, which is up-regulated on stimulation 
with tumor necrosis factor (TNF)-alpha8. Finally, malignant and virally transformed cells 
have been identified to produce IL-5. Reed-Sternberg cells in patients with Hodgkin’s disease 
express mRNA and proteins of various cytokines and growth factors, including IL-5 9. 
Similarly, cell supernatants from Epstein-Barr virus transformed B-cells contain large 
amounts of IL-5 10.  
 
The role of interleukin-5 for eosinophilia 
Due to the restricted expression pattern of its receptor, human IL-5 selectively functions on 
eosinophils and basophils, two predominant effector cell types in allergic inflammation 11. IL-
5 has numerous effects on precursor of eosinophils and on the mature eosinophils. (a) It 
stimulates growth and differentiation of myelocytes of the eosinophil lineage in the bone 
marrow 1. (b) It regulates the pro-inflammatory function of eosinophils by promoting the 
release of the eosinophil granular proteins: major basic protein, eosinophil cationic protein 
and eosinophil peroxidase. Eosinophils incubated for four days with IL-5 released up to 60% 
of their granule proteins 12. (c) IL-5 is weakly chemotactic on mature eosinophils, mostly by 
priming the cells for enhanced responsiveness to other chemotactic mediators, like IL-8, 
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RANTES or platelet-activating factor 12. IL-5 up-regulates the adhesion of eosinophils to 
endothelium, thereby further increasing eosinophilic accumulation 13. (d) Eosinophils present 
at sites of inflammation, persist because of IL-5-induced inhibition of programmed cell death 
or apoptosis 14;15. Apart from its actions on eosinophils, IL-5 also increases histamine and 
leukotriene production in basophils 16. Furthermore, Rizzo et al recently demonstrated an 
exaggerated contraction of IL-5-treated, isolated normal human bronchus smooth muscle cells 
in response to acetylcholine 17. This cholinergic contractility was blocked by neutralizing anti-
IL-5 and anti-IL-5 receptor antibodies, and occurred independently of an eosinophil influx. 
They further showed a clear expression of the IL-5 receptor in bronchus muscle, and to a 
    
lesser extent in saphenous vein and atrial muscle.    
Figure 1: Model of Eosinophil recruitment in nasal polyposis 
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Generation of mice tory role of IL-5 in 
eosinophil development 18. IL-5-/- mice have normal baseline eosinophil and immunoglobulin 
levels and generally exhibit normal T- and B-cell development. However, IL-5-/- mice do not 
develop eosinophilia in response to helminth and nematode infections19;20. It is of note that in 
the case of IL-5 deficiency, IL-3 or GM-CSF, which can also act on eosinophils in vitro, 
cannot take over the function of IL-5 in vivo21. This might suggest the existence of a strictly 
IL-5-dependent eosinophilic progenitor. Nevertheless, low background levels of eosinophils 
were always present in knockout mice, to leave a small number of IL-5-independent 
eosinophils. Recently, Foster and coworkers have shown that local chemokine networks in the 
allergic lung regulate eosinophil accumulation independently of IL-5, and that this mechanism 
plays an important role in disease processes22. In the absence of IL-5 and eotaxin, tissue 
eosinophilia is abolished in BALB/c mice and so is AHR18;23. Furthermore, inhibition of 
eotaxin alone does not abolish eosinophilia and AHR, thus targeting both pathways is 
required23. These studies indicate that pathways operated by local chemokine systems (in 
particular those which involve CCR3, the eotaxin receptor) play an important role in 
regulating the recruitment of eosinophils into tissues independently of IL-5, and that this 
mechanism is linked to the induction of disease. Importantly, this mechanism also operates in 
the absence of blood eosinophilia22.  
IL-5 has a variety of functions on the murine immune system ranging from stimulation of 
immunoglobulin release to enhancing B-cell growth and differentiation 24. Although there is a 
well-known association between eosinophilia and IgE levels, IL-5 does not appear to be 
involved in the IgE response, where IL-4 is the major controlling cytokine. Although IL-5 is 
able to induce in vitro IgA and IgM production in human B-cells, a physiologically functional 
role in controlling antibody production in the human immune system is yet to be determined 
25. 
The IL-5 protein 
The hIL-5 precursor is 134 residues long, and includes a signal peptide of 19 amino acids 26. 
Mature hIL-5 has a calculated molecular mass of 13,149 kDa, which is in accordance with the 
observation that the E. coli-derived protein migrates as a single 13-kDa band on SDS-PAGE 
gels in the presence of reducing agents. However, under non-reducing conditions, IL-5 is 
detected as a molecule of 27 kDa. It has been shown that IL-5 exists as a cross-linked 
homodimer 27. Mutagenesis of cysteine residues on position 44 and 86 identified both residues 
as essential in the generation of S-S bridges, and showed that both monomers are arranged in 
an anti-parallel (i.e. head-to-tail) manner 28. Reduction and alkylation of these two residues in 
lacking the IL-5 gene has demonstrated the obliga
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recombinant IL-5 lead to a biologically inactive monomer, illustrating that dimer formation 
via disulfide bonds is essential for biological activity 27-29. 
 
PROPERTIES OF THE INTERLEUKIN 5 RECEPTOR (IL-5R) SYSTEM 
IL-5 mediates its biological effects upon binding and activation of a membrane bound 
receptor (IL-5R). This receptor is composed of two subunits: a ligand-specific α-chain (IL-
5Rα) and a shared β-chain 30. The use of this latter receptor is shared with the receptors for 
IL-3 and GM-CSF, which both also have their own specific α-chains. For this reason, the β-
subunit is often referred to as β common or βc. This observation provides the molecular basis 
for the overlapping biological activities of these three cytokines. The α-chain binds to the 
cytokine with low affinity and when the β-chain associates to any of the α-chins, a high 
affinity receptor is formed 31-34. All three receptors are expressed on eosinophils and the IL-
5R is specifically expressed on eosinophils and their precursors. 
 
The ligand-specific IL-5Rα-chain 
The nucleotide sequence of the human IL-5Rα (hIL-5Rα) cDNA predicts a polypeptide of 
420 residues 31-34. It contains a 20 residue-long signal peptide, an extracellular domain of 322 
amino acids, a 20 residue-long tr nsa membrane domain, and a cytoplasmic tail of 58 amino 
mbrane bound IL-5Rα, suggesting that the transmembrane and cytoplasmic domains of IL-
tically to IL-5 binding31-34.   
acids. The predicted molecular mass for the α-chain is 45.5kDa, indicating that N-linked 
glycosylation of one or more of the potential N-glycosylation sites, contributes to the apparent 
moluclar mass of 60 kDa. This receptor binds IL-5 with intermediate (Kd ∼ 500 pM 1 nM) 
affinity in man and upon association with the βc-chain, a high affinity binding of 
approximately 150 pM is observed. The SOL IL-5Rα binds IL-5 with an affinity similar to 
me
5Rα contribute little energe
 
The βc-chain 
The βc-chain is a 897 amino acids protein, including a 16 residue-long signal peptide, an 
extracellular part of 424 amino acids, a 27 residue-long transmembrane domain, and a 
cytoplasmic tail of 430 amino acids. The mature protein has a molecular mass of 120-130 
kDa, and also is likely to be glycosylated. This receptor has no detectable affinity for one of 
the three cytokines, but plays an essential role in the formation of the high affinity complex 
and in signal transduction. 
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nd TM IL-5Rα expression/interaction 
learly, IL-5 can affect the expression 
f its own receptor, and hence of eosinophil responsiveness, at the transcriptional, at splicing 
in level. Northern blot analysis of normal blood eosinophils illustrates that IL-
rsible switch from SOL toward TM hIL-5Rα isoform expression. 
Figure 2: Eosinophils, IL-5, SOL a
 
IL-5 and regulation of expression of its receptor subunits 
The IL-5Rα-chain is expressed mainly on eosinophils and basophils, and on certain muscle 
cells 17. Human eosinophils express, through alternative splicing three different transcripts 
from the same IL-5Rα gene 31-34, two soluble and one membrane-bound receptor. The 
expression of the latter depends on the utilization of a specific exon, leading to the loss of the 
membrane anchor. When expressed in heterologous cells, this SOL IL-5Rα protein shows 
receptor antagonist activity in vitro 31;32;35;36. The expression level of SOL and TM IL-5Rα 
may control this agonist / antagonist balance 37. Recent publications have demonstrated a 
complex pattern of regulation of hIL-5Rα expression. C
o
and at the prote
3, IL-5 and GM-CSF down-regulate IL-5Rα expression at the mRNA level 38. These authors 
showed that this regulation occurs very rapidly (reaching maximum inhibition within 2 
hours), in a dose-dependent manner, which does not require protein synthesis. In a stable 
promyelocytic FDC-P1 cell-line containing a hIL-5Rα-chain minigene, in which cDNA and 
genomic DNA segments were combined 34, it was shown that IL-5 itself, but not IL-3 or GM-
CSF, could stimulate a reve
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These results were confirmed using primary human cord blood-derived CD34+ cells34. On 
ored TM 
 IL-5 
tially 
 were 
e IL-
rway 
t the 
-5 driven proteolytic cleavage of the membrane bound 
isoform 40. Finally, IL-5 induced activation of its receptor also results in a proteasomal 
degrad ptor complex 42. As a 
onsequence, signalling is terminated by deletion of the cytoplasmic phosphorylated residues. 
the lysosomes.  
peripheral blood eosinophils, Hellman et al. recently demonstrated that surface-anch
IL-5Rα was strongly down-modulated by recombinant IL-5, intermediately with both
and GM-CSF, and weakly with only GM-CSF, indicating that GM-CSF binding par
affects surface IL-5 receptor expression 39. Furthermore, the proportion of CD69-positive 
eosinophils was significantly up-regulated to the same level by IL-5, GM-CSF as well as by 
the combination of both cytokines, indicating that activation of eosinophils, judged by CD69 
up-regulation, is not mandatory linked to TM IL-5Rα down-regulation. Liu and co-workers 
could recently show a different control mechanism for expression of the membrane bound IL-
5Rα on airway or circulating eosinophils 40;41. After allergen challenge, IL-5Rα and βc
markedly reduced on airway eosinophils, and this in contrast to circulating cells, solubl
5Rα concentrations were significantly elevated in bronchoalveolar lavages, and ai
eosinophils exhibited a lack of responsiveness to IL-541. These authors postulate tha
reduced expression is due to an IL
 
ation of the βc cytoplasmic domain in the activated rece
c
The remnant of the βc is endocytosed and further degraded in 
 
IL-5R signal transduction 
Signal transduction via the IL-5 receptor involves ligand binding and receptor 
dimerization,43;44. This involves the association of the IL-5Rα-chain with βc, which takes 
place by non-covalent as well as covalent means. The covalent linkage of IL-5Rα and βc is 
probably the most functionally relevant one as it is associated with tyrosine phosphorylation 
of the receptor 45. IL-5 activates Lyn, Syk, and JAK2 and propagates signals through the Ras-
MAPK and JAK-STAT pathways. Studies suggest that Lyn, Syk, and JAK2 tyrosine kinases 
and SHP-2 tyrosine phosphatase are important for eosinophil survival1;46. In contrast to their 
survival-promoting activity, Lyn and JAK2 appear to have no role in eosinophil degranulation 
or expression of surface adhesion molecules. Raf-1 kinase, on the other hand, is critical for 
eosinophil degranulation and adhesion molecule expression1;46.  
The precise role of the α subunit in IL-5 signalling is less clear. Apart from ligand binding, 
this subunit is essential for signal transduction, since deletion of its cytoplasmic part, which 
contains a critical JAK binding site, completely abolishes signalling 47. There is a growing 
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body of evidence that, although IL-3, IL-5 and GM-CSF use the same β subunit, they also 
provoke cytokine-specific signals.  
 
CLINICAL POTENTIAL FOR INTERLEUKIN-5 BLOCKAGE  
IL- 5 is normally not found at high levels in healthy individuals. Next to nasal polyposis, a 
variety of diseases of the respiratory tract, skin, gut and of the haematopoietic system are 
associated with eosinophilia and with elevated levels of IL-5 mRNA and protein in bone 
marrow, in circulation and in tissue. Examples include allergic and non-allergic respiratory 
diseases, aspirin sensitivity, atopic dermatitis, hypereosinophilic syndrome, Churg-Strauss 
syndrome, food and drug allergies, and helminth infections (see also table 1). Indeed, in 
asthma as well as in nasal polyposis, elevated eosinophil numbers and IL-5 levels are 
described. Furthermore, segmental bronchial provocation of asthmatic patients results in 
eosinophil infiltration and accumulation in lung and also in the nose 48;49. Similarly, nasal 
provocation resulted in eosinophil infiltration in the nasal and bronchial mucosa 50.  
 
Table 1 : Eosinophil-Associated Diseases 
- Parasitic infections 
- Allergic diseases 
Asthma, allergic rhinitis, urticaria, allergic bronchopulmonary aspergillosis (ABPA),  
drug hypersensitivity reactions 
- Respiratory tract 
ilic pneumonia, Loeffler’s syndrome, hypersensitivity pneumonitis Nasal polyposis, eosinoph
- Toxic reactions 
 Eosinophilia myalgia syndrome (L-tryptophan), toxic oil syndrome 
- Neoplastic and myeloproliferative disorders 
Idiopathic hypereosinophilia syndrome (IHES), eosinophilic leukemia, lymphoma, angioimmunoplastic 
lymphadenopathy, immunotherapy with interleukin-2 
- Connective tissue diseases 
Hypersensitivity vasculitis, Churg-Strauss syndrome, hypereosinophilic fasciitis 
- Skin disorders 
 Atopic dermatitis, scabies, eosinophilic cellulitis 
- Immunodeficiency syndromes 
 Wiskott-Aldrich syndrome, hyper IgE syndrome 
- Gastrointestinal diseases 
 Eosinophilic gastroenteritis, inflammatory bowel diseases  
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Interfering with IL-5 or IL-5R synthesis 
The biological actions of IL-5 can be inhibited either by blocking the interaction IL-5/IL-5R 
using antibodies or IL-5 mutants, but also by preventing expression of IL-5 or components of 
s receptor. One way to achieve this is the use of antisense oligonucleotides. These are short, 
A o the target protein. 
d-induced 
llergic peritonitis model 51;52.  
nd binding 
tein-based IL-5 antagonists have been reported, including single point 
mutants of IL-5 that occupy the receptor , neutralizing 
t  against IL-5, and the SOL IL-5Rα isoform that sequesters the ligand in 
solutio
o odies 
uman sed in several human clinical 
trials. m
specific Abs are highly selective for their targets 
e same drug metabolism, resulting in predictable biological effects 
and low  pharmacokinetics 
 m dictable and the circulating half-life is often between days and weeks. Third, 
e binding of polypeptide hormones and cytokines with their 
cepto ult for small molecular weight compounds. 
d sts are high, tissue penetration of mAbs may be restricted due to 
the peutic mAbs are given through 
it
synthetic DNA sequences, which specifically hybridise to the mRN f 
This hybridisation results in the prevention of mRNA transport, splicing, transcription, but 
can also lead to degradation of the mRNA by endogenous ribonuclease H. Karras and co-
workers showed that administration of an antisense oligonucleotide directed against IL-5 
resulted in decreased IL-5 protein expression, and furthermore led to reduced lung 
eosinophilia and Ag-mediated late-phase airway hyper-responsiveness in a mouse model of 
asthma 51. The fact that the abrogation of the late-phase airway response was not complete, 
suggested that, besides IL-5, additional pathways may contribute to airway hyper-reactivity.  
The IL-5Rα-chain is another interesting target for antisense therapy. Antisense 
oligonucleotides were designed to reduce expression of the TM and SOL IL-5Rα isoforms in 
vitro, and to suppress eosinophilia in vivo upon IL-5 treatment or in a ragwee
a
 
Interfering with liga
A number of pro
but fail to initiate receptor activation 53
an ibodies directed
n 54. 
M noclonal antib
H ized monoclonal antibodies (mAbs) have recently been u
Abs offer clear advantages over traditional small molecular weight drugs. First, 
 mAbs can be rapidly developed. Second, m
and do not compete with th
 risk of unfavorable drug interactions, respectively. Moreover, the
of Abs are pre
mABs can interfere with th
re rs, which appears to be extremely diffic
A versely, production co
their size and oral delivery is problematic. Currently, ra
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parenteral administration, although technologies allowing biological agents be delivered 
t 
dosing) 57. SB240563 (Mepolizumab) was tested in mild 
sthmatics and caused a significant reduction in peripheral blood eosinophils and in post-
 did not alter FEV1 values upon allergen challenge 58. In 
 but only 52% reduction in the bone marrow and a 55% decrease in the bronchial 
locking IL-5 activity in vivo therefore appears to be much more 
dermatitis with a drop of eosinophil counts, IL-5, eotaxin and ECP levels in serum63.  
through the inhaled route are under development.   
The profound inhibitory effect of anti-IL-5 mAbs on the development of lung eosinophilia 
and on airway hyper-responsiveness was demonstrated in several animal studies. 
Intraperitoneal as well as intranasal application of the anti-IL-5 mAb, TRFK-5, led to a long 
lasting inhibition of pulmonary eosinophilia and bronchial obstruction in mice 55. In a monkey 
model of Ascaris-allergic asthma, Egan and coworkers could abolish inflammatory cell 
migration and airway hyperreactivity for up to three months by treating the monkeys with a 
single dose of a neutralizing humanized monoclonal antibody against hIL-5 56. The promising 
results of treatment with IL-5 mAbs observed in animal models made this approach a 
favourite candidate for targeting eosinophilic inflammation in humans. Similar anti-IL-5 
treatment in humans, however, failed to demonstrate clinical efficacy in two independen
studies. A single-dose phase I clinical trial was conducted with SCH55700 in patients with 
severe persistent asthma and demonstrated a significant decrease in peripheral blood 
eosinophils (lasting up to 90 days) and a trend towards improvement in lung function at the 
higher doses (30 days after 
a
challenge sputum eosinophils but
another clinical trial, Flood-Page and coworkers observed a significant differential effect of 
IL-5 blockade on eosinophil counts in various body compartments.59;60 After multiple dosing 
with mepolizumab, another anti-IL-5 mab, the authors found 100% reduction in blood 
eosinophils,
mucosa60. Completely b
difficult than in vitro. Perhaps, the local tissue microenvironment, and/or the existence of IL-
5-dependent autocrine activation mechanisms may limit in vivo antagonism 14;61. Furthermore, 
only very limited amounts of IL-5 may be required to maintain eosinophil action and survival 
in the local tissue microenvironment. Hence, the in vivo levels of humanized anti-IL-5 mABs 
may be insufficient to block local effects. Therefore, complete detailed reports on the phase II 
trials in asthma, but also in other eosinophil-associated diseases such as nasal polyposis and 
atopic dermatitis are required to fully evaluate and understand the underlying mechanisms of 
anti-IL-5 treatment. Indeed, in recently published case reports in patients with 
hypereosinophilic syndrome, successful treatment with mepolizumab and reslizumab was 
demonstrated62;63. Anti-IL5 therapy effectively controlled the associated eosinophilic 
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Soluble IL-5Rα       
The precise in vivo role of the SOL IL-5Rα protein requires more detailed study. Secreted 
receptor variants are a hallmark of the receptor family to which the IL-5Rα belongs. This 
mere evolutionary conservation underscores their functional importance, but the precise 
physiological role may differ from case to case. Models in which the antagonistic effects 
prevail include surface receptor down-modulation and ligand capture. On the other hand, 
secreted receptors may bind their ligands in circulation, protecting them from proteolytic 
breakdown and prolonging their serum half-life or facilitating ligand-mediated signaling. SOL 
IL-5Rα protein has antagonistic properties in vitro as demonstrated in eosinophil 
differentiation assays as well as in proliferation assays using IL-5 responsive cell lines 31;64. It 
captures IL-5 in solution, and this IL-5/IL-5Rα complex is unable to associate and activate 
membrane bound βc chains 32;64. Recently, the antagonistic effect of recombinant SOL IL-
5Rα was demonstrated using nasal tissue explants. Culturing tissue with recombinant SOL 
IL-5Rα almost completely attenuated the ragweed-induced decrease in eosinophil precursors 
and increase in MBP-immunoreactive cell numbers 65. This observation leads one to consider 
that endogenous production of soluble receptor may regulate IL-5 function in vivo. However, 
one of the potential problems of utilizing soluble receptors therapeutically is that they may 
actually prolong cytokine activity by reducing clearance rates1. 
 
Interfering with signal transduction    
An intrinsic disadvantage of interfering with IL-5 function at the extracellular level is that all 
cellular responses are indiscriminately eliminated, resulting in possible unwanted side-effects. 
As an alternative, intervention at the level of intracellular signalling following receptor 
activation should be considered. Blockage of only a subset of (cell-specific) signals, or signal 
cascades, may be achieved by interfering with specific protein-protein interactions in a given 
pathway, or by blockage of specific modifying enzymes, such as kinases and phosphatases. 
An example of cascade specific inhibition of IL-5 signalling was recently provided by Alam 
and co-workers 66;67. They characterised the binding site of Lyn kinase on the βc receptor, and 
used this sequence information to design a cell-permeable βc-derived peptide. This inhibitor 
furthermore blocked IL-5-dependent eosinophil differentiation and survival, but not 
eosinophilic degranulation in vitro. When applied in vivo, the Lyn-binding peptide 
significantly inhibited airway eosinophil influx in a mouse model of asthma66. 
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ANTAGONISING THE IL-5 FUNCTION IN NASAL POLYPS 
mediators, and 3) no attribution of airway smooth muscle cells is expected in NP.   
eased tissue eosinophilia in-
14.  However, as in asthma, only antagonizing the effect of IL-5 in nasal polyposis in vivo 
Interleukin 5 remains an interesting molecular target for pharmacological intervention in 
eosinophilic diseases. It’s role as a central, non-redundant player in eosinophil function in 
vivo has been very well documented over the past years. Furthermore, within the 
haematopoietic system, it delivers specific signals to the eosinophilic and basophilic cells. 
Recent observations point to an additional function on airway smooth muscle cells, 
suggesting that IL-5 may directly contribute to bronchial hyper-responsiveness. Yet, initial 
studies using humanised anti-IL-5 monoclonal antibodies in asthma have been disappointing. 
Since than the eosinophil is in deep crisis and there is considerable confusion as to whether 
this cell is important in allergic diseases. If so, under what conditions? 
In this context, similar studies in nasal polyposis may be of particular interest to understand 
these findings: Furthermore, nasal polyps have the advantage of being: 1) easily visualized by 
nasal endoscopy, 2) accessible for the local measurement of IL-5, IL-5Rα and other 
The role of eosinophils in nasal polyposis is strongly suggested by observational studies and 
by in vitro data, however never firmly proven. Indeed, the increased concentrations of IL-5 
and severe tissue eosinophilia were found in NP tissue and treatment of eosinophil-infiltrated 
polyp tissue with neutralizing anti-IL-5 monoclonal antibody (mAB), but not anti-IL-3 or 
anti-GM-CSF mAbs, resulted in eosinophil apoptosis and decr
vitro
would be the ultimate test of the IL-5 / eosinophil hypothesis. 
  
  
  
  
 
 
↑  ↑  
↑  ↑  
↑   ↑   
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Figure 3: Theoretical model of Anti-IL-5 treatment 
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Chapter 3 
AIMS OF THE STUDY 
 
The aims of this thesis were to investigate the role of eosinophils in the pathogenesis of nasal 
polyposis. Especially the regulation of interleukin-5 and the interleukin-5 receptor α isoforms 
were studied with emphasis on future therapeutic strategies in nasal polyposis. 
 
Chapter 4:  To identify the most important factors in polyp growth, we did histologic 
studies on early stage manifestations of eosinophilic nasal polyps compared to 
their surrounding normal mucosa and mature polyps. Second we measured 
eosinophilic inflammatory mediators (IL-5, eotaxin, ECP, LTC4-D4-E4, TGF-
β1) and extracellular matrix components (fibronectin, hyaluronic acid, 
albumin) in nasal polyp tissue, to investigate a possible relationship between 
eosinophilic inflammation and polyp constituents. Third we studied the effect 
of oral glucocorticoids on the eosinophilic inflammation in five nasal polyps 
that received oral corticoids prior to surgery. 
 
Chapter 5:  To investigate the possible impact of atopy on local IgE and eosinophilic 
inflammation in nasal polyposis, we measured total and specific IgE to 
common inhalant allergens in NP and non-polyp tissue homogenates.  
 
Chapter 6:  To determine the relationship between nasal carriage of Staphylococcus 
aureus, IgE formation to S. aureus enterotoxins and nasal polyposis. 
Furthermore, whether IgE is produced locally in nasal polyps or is a result of 
extravasation, we compared IgE specificities in tissue and serum. In this 
context B- and T-lymphocyte accumulations in NP tissue were histologically 
characterised.  
 
Chapter 7:  To develop specific ELISAs for studying the SOL IL-5Rα isoform at the 
protein level and to set up a PCR-based approach to monitor the expression of 
the SOL IL-5Rα mRNA, and to test the diagnostic potential of SOL IL-5Rα in 
eosinophil-associated disease such as nasal polyposis. In this context, SOL IL-
5Rα was determined in various human samples including serum, nasal 
secretion and nasal tissue homogenates 
Aims of the study 
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Chapter 8:  To study the expression of interleukin 5 receptor α isoforms in nasal polyp 
patients and controls, we established a real-time PCR, FACS and ELISA to 
investigate levels of SOL and TM-IL-5Rα transcripts and proteins in blood 
and in tissue. Furthermore, we studied whether in vitro stimulation of 
peripheral blood eosinophils with IL-5 could regulate the IL-5Rα isoform 
expression similar to the expression found in tissue eosinophils. Finally, we 
tested the biological activity of SOL-IL-5Rα in an hIL-5-driven proliferation 
assay.  
 
Chapter 9:  The primary objective of this study was to determine the safety and 
pharmacokinetics of Reslizumab (humanized anti-IL-5 monoclonal antibodies; 
SCH55700) given as a single intravenous dose of 3 mg/kg to subjects with 
severe nasal polyposis. In addition, the activity of Reslizumab on the clinical 
course of severe nasal polyps, on peripheral and nasal eosinophilic 
inflammation was evaluated. After all, this anti-IL-5 study gives us the 
ultimate opportunity to test role of IL-5 and eosinophils in nasal polyposis. 
Aims of the study 
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NASAL POLYPOSIS: FROM CYTOKINES TO GROWTH. 
Bachert C*, Gevaert P*, Holtappels G, Cuvelier C, Van Cauwenberge P. 
Am J Rhinol 2000; 14(5): 279-90.       * Equal contribution 
ABSTRACT  
Nasal polyposis (NP) is a chronic inflammatory condition, which is mostly characterised by 
an infiltration of eosinophils. How this eosinophilic inflammation leads to polyp formation 
remains largely unclear. In order to identify the most important factors in polyp growth, first 
we report the histological features of two early stage manifestations of eosinophilic nasal 
polyps compared to their surrounding normal mucosa and mature polyps. Histomorphologic 
analysis of these early stage manifestations of NP showed the presence of eosinophils, 
forming a subepithelial cap over a pseudocyst area, which was filled with albumin. In mature 
NP, a large pseudocyst area containing albumin was surrounded by subepithelial eosinophilia. 
Second, in an approach to quantify and to study possible relations between eosinophilic 
inflammation and changes in extracellular tissue components we measured interleukin-5 (IL-
5), eotaxin, eosinophil cationic protein (ECP), leucotrienes (LTC4/D4/E4), transforming 
growth factor-beta 1 (TGF-β1), fibronectin, hyaluronic acid and albumin in nasal tissue 
homogenates of 31 subjects. Nasal polyp samples (n=16) were obtained during routine 
endonasal sinus surgery, whereas control samples (n=15) were obtained from the inferior 
turbinate during septum surgery. In the group of polyp patients 11 received no treatment, 
whereas 5 were treated with oral glucocorticoids (GCS) within 4 weeks prior to surgery.  IL-5 
was measurable in 8 of 11 untreated NP, whereas IL-5 could not be detected in all 15 controls 
nor in 4 of 5 oral corticoid treated polyps. The comparison between the untreated polyp group 
and controls showed significantly higher concentrations of IL-5, eotaxin, ECP and albumin in 
polyp supernatants, whereas TGF-β1 was significantly lower. In the oral GCS treated group,  
ECP and  albumin were significantly reduced compared to untreated nasal polyps. The same 
tendency, but not reaching significance was seen for eotaxin and fibronectin, while no 
difference was found for LTC4/D4/E4 and hyaluronic acid between the groups. Our 
observations suggest a deposition of albumin (and possibly other plasma proteins) and 
extracellular matrix proteins, regulated by the subepithelial eosinophilic inflammation, as a 
possible pathogenic principle of polyp formation and growth. IL-5 and eotaxin are found to be 
key factors for eosinophilic accumulation and activation in NP. Oral corticoid treatment may 
lead to the shrinkage of NP by downregulation of the eosinophilic inflammation and reduction 
of the extravasation and deposition of albumin in NP. 
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INTRODUCTION  
Nasal polyposis (NP) is a chronic inflammatory disease of the paranasal sinuses, with a 
prevalence of about 1 - 4 % in the general population. In subgroups of patients having 
specified airway diseases - allergic fungal disease, acetylsalicylic acid sensitivity, and asthma 
- much higher frequencies are found 1. Most patients complain of nasal obstruction, secretion, 
loss of smell, headache and reduced general well-being. NP are benignant growths of the 
nasal and sinus mucosa which are mainly situated in the middle meatus. Their preferred site 
of origination was found to be the mucous membrane of the outlets from the sinuses 2. 
Histopathologically NP consist of oedematous connective tissue covered with respiratory 
epithelium. The supepitehlial area is characterised by an eosinophilic inflammation in more 
than 80% of the cases, however, also non-eosinophilic NP exists and has to be careful 
differentiated, such as choanal polyps, or NP on the basis of chronic sinusitis or cystic 
fibrosis.  Similarly, eosinophils are the major effector cells in allergic disease such as asthma 
and rhinitis.  However, whereas atopy is a major risk factor for asthma, its contribution to 
polyp pathogenesis is questionable. Most studies have failed to show a higher occurrence of 
positive skin tests to inhaled allergens in patients with polyps than in the general population 2-
4. Extensive studies by Settipane showed that the prevalence of nasal polyps is higher in non-
allergic rhinitis and asthma than in their allergic counterparts 5. As polyp tissue is more 
readily accessible, it has been suggested to use nasal polyps as an ideal model for study of 
eosinophil-dominated immune inflammation in the airway mucous membrane. 
The treatment of nasal polyps with systemic and topical corticoids is common clinical use.  
However, there is no medical or surgical treatment which guarantees cure and most clinicians 
treat polyp patients on an individual basis. Management of patients with severe nasal 
polyposis is still unsatisfactory and recurrences remain a problem with a general rate of 
recurrence of up to 40% 4. Future progress in therapy seems to be closely linked to a better 
understanding of aetiology and pathogenesis of NP. 
The pathogenesis of nasal polyps is far from clear. Woakes believed that formation of NP 
began as exudate in the nasal mucosa and that growth of nasal polyps was due to vascular 
stalk and vascular congestion 6. Eggston et al. hypothesised that recurrent infections lead to 
chronic vascular changes in the nasal mucosa, blocking of intracellular fluid transport and 
oedema of the lamina propria7. Tos & Mogensen have suggested that early stage of polyp 
formation was characterised by infiltration and oedema of the nasal mucosa, rupture of the 
epithelium, and production of granulation tissue 8. 
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In order to identify the most important factors in polyp growth, first we report the histological 
features of two early stage manifestations of eosinophilic nasal polyps compared to their 
surrounding normal mucosa and mature polyps. Second we measured eosinophilic 
inflammatory mediators (interleukin(IL)-5, eotaxin, eosinophil cationic protein (ECP), 
leucotrienes (LT)C4-D4-E4, transforming growth factor (TGF)-β1 ) and extracellular matrix 
components (fibronectin, hyaluronic acid, albumin) in nasal polyp tissue homogenates and 
compared  those with normal nasal mucosa, in order to investigate a possible relationship 
between eosinophilic inflammation and polyp constituents.  Third we studied the effect of oral 
glucocorticoids on the eosinophilic inflammation and the extracellular matrix components in 
five nasal polyps that were treated with oral corticoids prior to surgery. 
 
MATERIAL AND METHODS 
Patients 
Nasal tissue was obtained from 16 polyp and 15 control patients at the department of 
Otorhinolaryngology of the University Hospital of Ghent, Belgium. Nasal polyp samples 
were obtained during routine endonasal sinus surgery, whereas control samples where 
obtained from the inferior turbinates during septal surgery. Bilateral nasal polyposis was 
diagnosed based on history, clinical examination, nose endoscopy and sinus CT-scan. In the 
group of polyp patients, 11 received no treatment, whereas 5 were treated with oral corticoids 
, more precisely a cumulative dose of minimum 150mg methyl-prednisolone within the last 4 
weeks prior to surgery. The atopic status was evaluated by skin prick tests to common 
inhalant allergens, which were positive in 6 out of 15 controls and 9 out of 16 nasal polyp 
patients. A history of asthma was reported in 4 controls and 5 polyp patients. Informed 
consent was obtained from all the subjects, and the study was approved by the ethics 
committee of the Ghent University. 
 
Immunohistochemistry 
Within the group of nasal polyposis, two patients with an early stage of polyp formation 
localised on the middle turbinate were selected. Those patients had no allergy, no asthma, no 
aspirin sensitivity, nor previous treatment with systemic or topical corticoids prior to surgery.  
Parts of the middle turbinate with normal appearance, bearing a small polyp formation, were 
removed, further specimen were taken from the mature bilateral polyps. Samples were fixed 
in 4% formaldehyde (Phosphate buffered 6.8-7.2, Klinipath, Netherlands). The samples were 
embedded in paraffin and cut into 5µm sections and mounted on poly-L-lysin-coated slides. 
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After deparaffinization in parasolve, slides were hydrated through graded ethanol before use. 
For cellular staining, tissue sections were treated with trypsin for 20 minutes at 37°C to 
enhance immunohistohemical reactivity. Mouse anti-human eosinophil cationic protein (ECP) 
clone EG2 (1/400, Pharmacia, Sweden), mouse antihuman mast cell tryptase clone AA 1 
(1/500, Dako, Denmark) and mouse antihuman α-smooth muscle actin monoclonal antibodies 
were used with the APAAP (alkaline phosphate-anti-alkaline phosphate) technique.  For 
protein staining, sections were microwaved and incubated in blocking solution (TBS, 0.3% 
perhydrol, 0.1% Na-azide) for 20 minutes to block endogeneous peroxidase activity.  Two 
polyclonal antibodies, rabbit anti-human albumin (1/40.000, Dako, Denmark), and rabbit 
antihuman fibronectin (1/4000, Dako, Denmark) were selected and stained using an LSAB-kit 
(Dako, Denmark). Sections were counterstained with hematoxylin and mounted. 
Measurement of mediators and plasmatic proteins in controls and mature nasal polyps 
All (n=31) freshly obtained specimen were weighed, and 0.5g tissue was transferred into 5 ml 
of 0.9% NaCl solution and homogenised at 1000 rpm for 5 minutes on ice. After 
homogenisation, suspensions were centrifuged at 3000 rpm for 10 minutes. Aliquots of the 
supernatants were prepared and stored at –80°C for analysis.  Concentrations of IL-5, eotaxin, 
LTC4/D4/E4, TGF-β1 and fibronectin were measured on tissue supernatants by using 
commercially available ELISA kits (R&D System, USA ). ECP was measured by CAP 
system (Parmacia, Sweden), hyaluronic acid by RIA (Pharmacia, Sweden) and albumin by 
nephelometry.  
 
Statistical analysis 
Between group comparisons were made by using the non parametric Mann Whitney test. 
Spearman rank  correlation coefficient was used to asses the relationships between the 
parameters.  P < 0.05 was considered  statistically significant. 
 
RESULTS 
Histologic study of early stage polyps  
In the following, we differentiate between ‘early stage’ and ‘mature’ nasal polyps. The 
analysis was focused on the description of the inflammatory cells, i.e. mast cells, eosinophils 
and myofibroblasts, and extracellular proteins, fibronectin and albumin, in nasal polyps.  
The main characteristic of the early stage polyp formation is the presence of pseudocysts in 
the core of the polyp. The extracellular matrix in this region contains a loose connective 
tissue, fibroblasts and only a few inflammatory cells. In contrast, there is an accumulation of 
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inflammatory cells at the top of the early stage polyp (Fig. 1). In mature polyps, oedema is 
major, many pseudocysts are visible, but the cellular component is less expressed.  
 
The cellular component 
Numerous EG2-stained eosinophils were present at the top of the early stage polyps, forming 
a subepithelial cap over the pseudocyst area. In contrast, the basis of the polyp and the 
adjacent mucosa has a normal appearance and showed no eosinophilia. In mature polyps, the 
location of eosinophils seemed less organised, some regions are fully infiltrated by them, 
others less. Most eosinophils are localised subepithelially and some infiltrate into the 
epithelium. 
In contrast, mast cells were found in the pedicle and the adjacent mucosa, but not in the top 
and core of the early stage polyps. In mature polyps, mast cells were diffusely distributed over 
the polyp, without any accumulation.  
The distribution of myofibroblasts was limited to the stalk and the centre of the polyps, near 
to the pseudocysts, whereas they were scattered within mature polyps. No myofibroblasts 
were seen in the adjacent mucosa 
 
The protein component 
The overall staining of albumin in the normal mucosa and the subepithelial regions of polyps 
is dense and compact. In the core of the early stage polyp and of mature polyps, staining is 
less compact. However, albumin staining is pronounced and resembles a network-like 
structure within the pseudocysts (Fig. 2). Fibronectin deposition was noticed together with 
eosinophils at the top of small polyps, and formed a network-like structure in the polyp centre 
(Fig. 3).  In the adjacent mucosa, fibronectin staining was much less intense.  
 
Concentrations of mediators and plasmatic proteins 
In an approach to quantify the eosinophilic inflammation and the extracellular matrix 
components, we measured the concentrations of IL-5, eotaxin, ECP, LTC4/D4/E4, TGF-β1 , 
fibronectin, hyaluronic acid and albumin in inferior turbinate and nasal polyps tissue 
homogenates (table 1 and Fig. 4).   IL-5 was measurable in 8 of 11 untreated nasal polyps, 
whereas IL-5 could not be detected in all 15 controls nor in 4 out of 5 oral corticoid treated 
polyp patients.  Comparison between controls and untreated nasal polyps showed significant 
higher concentrations of eotaxin, ECP and albumin in polyp supernatants, whereas TGF-β1 
was significantly lower. Fibronectin, hyaluronic acid and LTC4/D4/E4 levels were not 
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different between controls and untreated nasal polyps. When we compared controls and oral 
corticoid treated polyps, there were no significant differences except for fibronectin, which 
was lower in the oral treated NP. Concentrations of ECP and albumin were significantly 
reduced in oral corticoid treated polyps compared to their untreated counterparts. The same 
tendency, but not reaching significance, was seen for eotaxin and fibronectin. TGF-β1 tissue 
concentration was higher in the oral corticoid treated polyps compared to untreated polyps 
without reaching statistical significance, while no difference was found for LTC4/D4/E4 and 
hyaluronic acid. Within the group of untreated NP, IL-5 and eotaxin were correlated with 
ECP, whereas albumin correlated with fibronectin.  Comparing the atopic with non-atopic 
patients within the control and within the nasal polyp group didn’t reveal any significant 
differences for the above mentioned parameters. 
 
DISCUSSION 
The aim of this study was to identify cells and mediators possibly involved in polyp formation 
and growth, their interrelationship as well as changes following oral steroid treatment. 
In a first part we first report the histological features of two early stage manifestations of 
human eosinophilic nasal polyps compared to their surrounding normal mucosa and mature 
polyps. Histomorphologic analysis of these early stage manifestations of NP showed the 
presence of eosinophils, forming a subepithelial cap over a pseudocyst area, which was filled 
with albumin. In mature NP, a large pseudocyst area containing albumin was surrounded by 
subepithelial eosinophilia. The retention of albumin, most likely driven by the eosinophilic 
inflammation, therefore seems to be a hallmark of the polyp formation. 
Second, in an approach to quantify and to study possible relations between eosinophilic 
inflammation and changes in the concentrations of extracellular tissue components, we 
measured IL-5, eotaxin, ECP, LTC4/D4/E4, TGF-β1, fibronectin, hyaluronic acid and 
albumin in nasal tissue homogenates of control and NP patients. IL-5, eotaxin, ECP and 
surprisingly albumin were significantly upregulated in untreated polyps compared to controls, 
supporting the histologic findings and linking eosinophilic inflammation to albumin 
deposition in NP.  
Third, oral corticoid treatment could reduce IL-5, eotaxin, ECP, albumin and fibronectin 
concentrations in NP, reaching significance for ECP and albumin. This clearly demonstrates 
that the eosinophil activation together with albumin deposition can be reduced by oral GCS 
treatment, leading to the shrinkage of nasal polyps. 
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Table 1: Influence of GCS Treatment on Polyp tissue 
 
 Controls 
(n=15) 
versus 
 
Untreated NP   
(n=11) 
versus Oral GCS NP 
(n=5) 
versus 
controls 
IL-5 (pg/ml) not detectable  159,1  
1 of 5 
detectable  
Eotaxin (pg/ml) 78,0 p = 0,008 965,9 ns 403,2 ns 
ECP (µg/l) 666,5 p = 0,003 5134,8 p = 0,036 1035,4 ns 
TGF-β1 (pg/ml) 9952 P < 0,001 2585 ns 5203 ns 
Albumin (g/l) 8,576 p < 0,001 19,646 p = 0,020 12,477 ns 
Fibronectin (µg/ml) 22,65 ns 20,16 ns 14,04 p = 0,032 
Hyaluronan (pg/ml) 8781 ns 9471 ns 7008 ns 
LTC4/E4/D4 (pg/ml) 2932 ns 4267 ns 2688 ns 
Median concentrations of IL-5, eotaxin, ECP, TGF-β1, albumin, fibronectin, hyaluronic acid and LTC4/D4/E4 
in inferior turbinates (controls), untreated, and orally corticoid treated nasal polyp tissue homogenates. 
Statistical analyses were performed by the Mann Whitney test for unpaired comparisons. p < 0,05 was 
considered statistically significant (ns = not significant). 
 
Nasal polyps have been described in numerous publications and several theories on their 
formation have been postulated. They have been regarded as a neoplastic disorder, a result of 
glandular hyperplasia 9or altered ion transport mechanisms10. Tos described polyp formation 
in the middle ear of rats and proposed that polyp formation is initiated by the rupture of the 
epithelium, followed by a prolapse of granulation tissue8;11;12. Norlander manipulated the 
respiratory mucosa of white rabbits to induce polyp formation13. However, to the best of our 
knowledge, histological documentation of the first crucial stages of nasal polyp formation in 
human has not been described up until now.  
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Figure 1: (A) An early stage nasal polyp on a middle turbinate, Albumin stained, overview 
(original magnification: 40X). (B) Subepithelial eosinophilic inflammation in the mature polyp, 
EG2 stained (original magnification: 200X). 
Nasal polyposis: from cytokines to growth. Am J Rhinol 2000; 14(5):279-90. 
71
Chapter 4 
Nasal polyps are characterised by a marginal, subepithelial eosinophilic inflammation and a 
central oedema with pseudocyst formation. Even in the early stage polyps, this key principal 
could be found regularly. Numerous EG2-stained eosinophils were present at the top of the 
early stage polyp, forming a subepithelial cap over the pseudocyst area.  Activated, EG2-
positive eosinophils have been described to predominate in polyp stroma and to participate in 
the development and maintenance of mature polyp disease14;15.  According to our findings, the 
same principal seems to be true for the early stage polyps. 
In contrast to eosinophils, mast cells were not found in the top and core of the early stage 
polyps, but in the pedicle and the adjacent mucosa. In mature polyps, mast cells were more 
diffusely distributed without any accumulation. Drake-Lee showed that mast cells are more 
abundant in the submucosa and were not more frequent in the epithelium of nasal polyps 16. 
Ultrastructural studies of nasal polyps in human have described degranulation of mast cells17. 
Our results indicate that mast cells are absent in the early stage nasal polyp, which at least 
suggests that mast cells are not directly involved in the initiation of polyp formation.  
A rather small number of myofibroblasts were found mainly in the stalk and the centre of the 
early stage polyps, near to the pseudocysts, whereas no myofibroblasts were seen in the 
adjacent mucosa. Wang and Escudier have shown that myofibroblasts were more abundant in 
nasal polyps compared to normal nasal mucosa and that their local development could be 
controlled by TGF-β 18. They suggested the involvement of myofibroblasts in NP formation 
and growth by inducing extracellular matrix accumulation.  
 
    
 
Figure 2: Albumi-stained early stage polyp (A) and mature polyp (B), showing network-like albumin deposition 
in the pseudocysts (original magnification: 200X). 
 
 
Nasal polyposis: from cytokines to growth. Am J Rhinol 2000; 14(5):279-90. 
72
Chapter 4 
Fibronectin deposition was noticed together with eosinophils at the top of small polyps, and it 
formed an network-like structure in the polyp centre and within pseudocysts. It has been 
shown, in vitro, that human eosinophils preferentially survive on tissue fibronectin compared 
with plasma fibronectin19. Recently a correlation among oedematous morphology, eosinophil 
infiltration, and fibronectin expression was described in NP20. According to Greiff, NP could 
consist of oedematous tissue, which is very rich in plasma proteins21. To our knowledge, 
however, there are no previous studies on albumin staining in nasal polyps. In the present 
study we demonstrate that albumin is retained in the pseudocyst area of mature and early 
stage NP, surrounded by an eosinophilic inflammation.  
 
    
Figure 3: Fibronectin stained early stage polyp (A) and mature polyp (B). Fibronectin deposition is noted 
espescially subepithelially in the area with eosinophilic inflammation and is denser in the early stage polyps 
than in mature NP (Original magnification: 100X). 
 
Eosinophils contain an armoury of distinctive cytoplasmatic granules necessary for killing 
parasites, which also contribute to tissue damage and inflammation. Four principal granule 
proteins have been identified including major basic protein (MBP), eosinophil cationic protein 
(ECP), eosinophil peroxidase (EPO) and eosinophil-derived neurotoxin (EDN). In addition, 
eosinophils contain preformed cytokines such as granulocyte-macrophage colony-stimulating 
factor (GM-CSF), IL-2, IL-4, IL-5, TGF-β and tumor necrosis factor-α (TNF-α) 22. 
Eosinophil granule proteins such as ECP have been shown to increase vascular permeability 
in a hamster cheek pouch model23. Here we show high ECP concentrations together with high 
albumin concentrations in nasal polyps versus controls, supporting the hypothesis that 
eosinophils could induce plasma exudation. Biewenga found higher albumin concentrations in 
nasal secretions of polyp patients compared to healthy subjects24. According to Perrson et al, 
in non-polyp airways - in health and in disease - plasma exudation may not readily produce 
oedema, but may rather result in a quantitative lumenal entry of plasma25. In polyps, however, 
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the extravasated plasma - for reasons of distance, binding force, or by some barrier or 
extracellular matrix abnormality – may not as easily find its way to the airway surface. Our 
observations suggest a central deposition of albumin (and possibly other plasma proteins) and 
extracellular matrix proteins such as fibronectin, regulated by the subepithelial eosinophilic 
inflammation, as a possible pathogenic principle for polyp formation and growth. 
A sustained eosinophilic inflammation is the hallmark of nasal polyps, which is also true in 
the early stage of polyp formation. This can be explained by an increase of eosinophilic 
migration into the tissue, by prolonged survival of these cells, or by a combination of both 14. 
The recruitment of granulocytes to sites of inflammation is a complex process that potentially 
may be regulated by cytokines and chemokines. Induction of eosinophil proliferation in the 
bone marrow, promotion of the release of eosinophils from the bone marrow, and inhibition 
of eosinophil apoptosis can be promoted by IL-3, IL-5 and GM-CSF (Th2 cytokines), while 
IL-1β, IL-4, IL-5, and TNF-α may regulate trafficking by activating adhesion molecules in 
the vascular endothelium 26. 
Several chemokines of the CC-family, including eotaxin and RANTES, have been reported to 
attract and activate eosinophils via high affinity binding to the CC-chemokine receptor 
CCR327;28.  RANTES immunoreactivity was reported in nasal polyps 29. However, in an 
earlier study we did not find a difference in RANTES protein concentrations between nasal 
polyps and control tissue 14.   
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Figure 5: Spearman rank correlations between IL-5 and ECP, and eotaxin and ECP in all nasal 
polyps (n=16). The concentrations of IL-5, eotaxin and ECP are expressed in pg/ml. 
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Figure 4: Measurement of IL-5, ECP, eotaxin, TGF-β1, albumin, fibronectin, hyaluronic acid
and LTC4/D4/E4 in inferior turbinates (controls), untreated and orally corticoid treated nasal
polyp tissue homogenates.  In the basic Box-and-whisker plot, the central box represents the
values from the lower to upper quartile (25 to 75 percentile). The middle line represents the
median. The horizontal line extends from the minimum to the maximum value, excluding
"outside" and "far out" values, which are displayed as separate points. Statistical analyses
performed by the Mann Whitney two-tailed test for unpaired comparisons (ns = not significant). 
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Recently, Jahnsen et al. showed significantly increased mRNA expression for eotaxin and 
eotaxin-2 in NP compared to turbinate mucosa27. It was also shown that eotaxin secreted from 
inflamed tissue may play an important role in initiating both blood and tissue eosinophilia 26. 
In an in vivo model system, eotaxin has been reported to co-operate with IL-5 in inducing 
eosinophil infiltration. Furthermore, IL-5 is not only essential for mobilising eosinophils from 
the bone marrow, but also plays a critical role in regulating eosinophil homing and migration 
into tissues in response to eotaxin26. Corresponding to these findings, we here demonstrate IL-
5 and eotaxin both being upregulated in NP, furthermore showing a significant correlation to 
eosinophil activation as evaluated by ECP concentrations in tissue. 
Eosinophilic infiltration into tissues is usually followed by elimination of these cells by 
programmed cell death. Cytokine-mediated inhibition of apoptosis clearly contributes to the 
accumulation of eosinophils in tissues30;31. Cytokines such as IL-3, IL-5, GM- CSF or γ-IFN 
dramatically increase the life-span of eosinophils by inhibition of the programmed cell death 
in vitro 14. Comparing protein levels of different cytokines and chemokines in NP versus 
control mucosal tissue, we were able to demonstrate an impressive upregulation of IL-5 
synthesis in NP in several studies14;32;33. Furthermore, NP but not control nasal tissue, 
expressed IL-5 mRNA. Simon et al. demonstrated that anti-IL-5 mAb, but not anti-IL-3 or 
anti-GM-CSF mAb decreased tissue eosinophil numbers by inducing apoptosis in an elegant 
polyp model 31.  
IL-5 is essential for the maturation and differentiation of eosinophils, and is involved in the 
homing, activation, and degranulation of these cells. It is well established that IL-5 can act 
both on eosinophil production from bone marrow progenitors and on circulating mature 
eosinophils via a specific receptor34. Activated TH2 cells, mast cells, basophils, eosinophils 
and recently airway epithelial cells have been shown to be potential cellular sources of IL-5 
35. In nasal polyps, we previously demonstrated that eosinophils may represent a major source 
of IL-5, thus creating a possible autocrine loop for activation and survival14. 
Eosinophils were also suggested to be an important source of TGF-β in nasal polyps36-39. 
TGF-β is a potent fibrogenic cytokine that stimulates extracellular matrix formation, acts as a 
chemoattractant for fibroblasts, but largely inhibits the growth and activity of invading 
inflammatory cells40. There are three principal isoforms of TGF-β, namely, TGF-β1, β2 and 
β3. TGF-β1 is described to be the main isoform in fibrosis and in nasal polyps36. 
Corresponding to our data, Eisma showed a decreased expression of TGF-β1 and enhanced 
expression of TGF-β2 in nasal polyps versus normal control tissue37. Alam et al demonstrated 
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that TGF-β inhibits the synthesis of IL-5, abrogates the survival-prolonging effect of 
hematopoietins ( IL-5 and GM-CSF) on eosinophils, and induces apoptosis40.  They suggested 
that there is a fine balance between the production of TGF-β and IL-5 by eosinophils and that 
TGF-β may act as a homeostatic regulatory mechanism that counteracts the action of IL-5 and 
programs cell death. Other data showed that TGF-ß in low concentrations can induce 
eosinophil chemotaxis, whereas higher concentrations reduce eosinophil survival mediated by 
IL-5, IL-3 and GMCSF41.  This corresponds to our findings in NP, were we found high 
concentrations of IL-5 and low concentrations of TGF-β1 compared to normal nasal mucosa.  
Nasal polyps may be treated by long-term local glucocorticosteroid (GCS) therapy, short-term 
systemic corticoid therapy, or endoscopic sinus surgery2. The clinical efficacy of topical 
corticoids in nasal polyps has been confirmed by several placebo controlled studies, showing 
a reduction of symptoms and polyp scores 42-48. The effect of systemic corticoids on nasal 
polyps is generally recognised but less well studied. Van Camp and Clement 49 reported 25 
NP patients who were treated with oral GCS and reported a positive effect on all symptoms. 
However, within five months after successful oral GCS therapy, a strong tendency for 
recurrence was found. Nevertheless, GCS have a prominent anti-inflammatory effect and are 
found to be effective in the treatment of eosinophil related inflammatory disease such as 
asthma. Several studies already showed that GCS may reduce the numbers of eosinophils in 
polyp tissue27;50-53. This could be due to a reduction of eosinophil influx, a shortening of 
eosinophil survival or a combination of both. GCS have been shown to reduce the endothelial 
expression of adhesion molecules54;55 and suppress eotaxin levels in NP, both important for a 
reduction of eosinophil recruitment 56.    
In this study, we found that IL-5 was measurable in 8 of 11 untreated NP, whereas IL-5 could 
not be detected in 4 of 5 oral GCS treated polyps. This suppression of IL-5 could well explain 
the reduction in eosinophil activation, demonstrated by a significantly suppressed ECP level 
in our study. As discussed before, eosinophil granule proteins such as ECP are known to 
affect vascular permeability 23. Microvascular effects of GCS in NP have not been explored 
specifically. Biewenga showed decreased albumin and immunoglobulin levels in nasal 
secretions of patients with GCS-treated NP 24. Interestingly, in our study, GCS treatment also 
showed a significant reduction of albumin retention in polyp tissue. These data support the 
hypothesis that GCS lead to the shrinkage of NP by down-regulation of the eosinophilic 
inflammation and reduction of the extravasation and deposition of albumin in NP extracellular 
matrix. 
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SUMMARY 
 Our findings support the hypothesis that eosinophils are the major effector cells in the 
pathogenesis of nasal polyps. Even in the early stage of polyp formation, the inflammatory 
reaction is mainly based on eosinophils. Their accumulation may be explained by an 
increased migration into the tissue, a prolonged survival, or a combination of both, based on 
the regulation by cytokines and chemokines. IL-5 and eotaxin are found to be essential for the 
accumulation and activation of eosinophils. Here we demonstrate that IL-5 and eotaxin are 
both up-regulated in nasal polyp supernatants, whereas TGF-ß1 is down-regulated. The 
correlation of these factors with eosinophil activation, evaluated by ECP-measurement, 
indicates their crucial role in eosinophil inflammation.  
Our observations furthermore suggest the deposition of plasmatic proteins such as albumin 
and extracellular matrix proteins, regulated by the subepithelial eosinophilic inflammation, as 
a possible pathogenic principle of polyp formation and growth. Oral GCS treatment 
significantly reduced ECP and albumin content in NP, suggesting that GCS could lead to the 
shrinkage of NP by down-regulation of the eosinophilic inflammation and reduction of the 
deposition of albumin in NP extracellular matrix. 
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ABSTRACT  
Background: Nasal polyps (NP) are characterized by eosinophilic inflammation and often 
coexist with asthma. However, the role of atopy and IgE in NP pathogenesis is unclear.  
Objective: To determine whether there is an association between total and specific IgE to a 
variety of allergens in polyp and non-polyp tissue and markers of eosinophilic inflammation 
or skin test results. 
Methods: Homogenates were prepared from nasal tissue of 20 NP and 20 non-polyp subjects 
and analyzed for concentrations of IL-5, IL-4, eotaxin, LTC4/D4/E4, sCD23 and histamine 
(ELISA). ECP, tryptase, total and specific IgE for inhalant allergens and Staphylococcus 
aureus enterotoxins were measured (ImmunoCAP).  
Results:  The concentrations of total IgE, IL-5, eotaxin, ECP, LTC4/D4/E4, and sCD23 were 
significantly higher in NP tissue, compared to non-polyp tissue. Total IgE was significantly 
correlated to IL-5, ECP, LTC4/D4/E4, sCD23 and to the number of eosinophils in NP. Based 
on the presence of specific IgE antibodies in tissue, three NP groups were defined: Group NP 
I demonstrated no measurable specific IgE, Group NP II selected specific IgE. The third 
group demonstrated a multiclonal specific IgE, including IgE to Staphylococcus enterotoxins, 
a high total IgE and a high prevalence of asthma.  
Conclusions:  These studies suggest that there is an association between increased levels of 
total IgE, specific IgE and eosinophilic inflammation in nasal polyps, which may be of 
relevance in the pathophysiology of nasal polyposis. Similarly, the presence of specific IgE to 
SEA and SEB also points to a possible role of bacterial superantigens.  
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INTRODUCTION    
Clinically, nasal polyps (NP) are characterized by edematous masses in the nasal and 
paranasal cavities, leading to nasal obstruction, secretion, loss of smell, headache and reduced 
general well being. Nasal polyposis is believed to be a multifactorial disease that is frequently 
associated with asthma and aspirin sensitivity, but the mechanisms underlying the etiology of 
this disease are so far ill defined1;2.  
Although an allergic etiology of NP had been presumed since the early 1930s3, this 
suggestion was challenged in the 1970s, when a retrospective study by Settipane et al4 
demonstrated that more NP were found in the non-atopic group compared to atopics, and 
subsequent studies demonstrated that multiple positive skin tests were less common in NP 
patients, compared to the general population5. However, tissue IgE concentrations have been 
found to be increased, irrespective of skin test results, suggesting a possible local IgE 
production5;6. Remarkably, studies of seasonal allergic patients with NP have demonstrated 
that symptoms and markers of eosinophilic inflammation are not influenced by the season5;7. 
Thus, the relationship between NP, IgE and allergy is not clearly understood so far. 
A drawback in elucidating the etiology and pathologic mechanisms of this disease is the lack 
of a widely accepted classification, which includes clinical history and histology, to 
differentiate between the various forms of NP. Stammberger8 has recently proposed a 
classification for NP and suggested that bilateral polyps are frequently linked to asthma and 
aspirin sensitivity. Indeed, bilateral polyps are the most predominant type of NP, covering 80-
90% of polyp disease in Europe and USA, and are associated with tissue eosinophilia in most 
cases9.  
A key to understanding polyp pathophysiology is the regulation of recruitment, activation and 
survival of eosinophils, as well as their effect on polyp formation and growth10. We have 
demonstrated that synthesis of IL-5 and survival of eosinophils is significantly increased in 
NP tissue compared with non-polyp control tissue11;12. Additionally, ex-vivo studies 
demonstrated that eosinophil survival was decreased by incubation with anti-IL-5 neutralizing 
monoclonal antibodies, suggesting a functional role for IL-5 in the regulation of eosinophil 
survival12.  
In the current study, we aimed to investigate the possible impact of atopy (skin prick test 
positivity) and local IgE on eosinophilic inflammation. Therefore, total and specific IgE to 
common inhalant allergens were measured in NP and non-polyp tissue homogenates. Since 
Staphylococcus aureus enterotoxins have been shown to modify atopic dermatitis13;14 and 
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unstable asthma15;16, we also investigated the nasal tissues for the presence of specific IgE to 
these enterotoxins, to elucidate whether or not these may also play a role in the 
pathophysiology of NP. 
 
METHODS 
Patients 
Nasal tissue was obtained from 20 bilateral NP and 20 non-polyp patients, outside the pollen 
season, at the Department of Otorhinolaryngology, Ghent University Hospital. Approximately 
0.5 cm3 tissue strips were collected from the surface of each inferior turbinate (turbinotomy, 
0.2 to 0.5g of tissue) or bilateral NP (0.2 to 2.0g of tissue), during routine septal and sinus 
surgery, respectively.  
 Bilateral polyposis was diagnosed based on history, clinical examination, nasal endoscopy 
and sinus CT-scan, according to the classification of Stammberger8. A history of asthma was 
reported in 4 non-polyp and 11 polyp patients, with two subjects in the polyp group also 
demonstrating a history of aspirin sensitivity. The atopic status of all patients was evaluated 
by skin prick tests using a standard panel of allergens, according to the guidelines of the 
European Academy of Allergology and Clinical Immunology17. The reaction to a skin prick 
test was considered positive, if the wheal area caused by allergen was greater than 7mm² 
(diameter greater than 3 mm). The panel of allergens comprised: grass pollen mix (Dactylis 
glomerata, Festuca elatior, Lolium perenne, Phleum pratense, Poa pratensis); mites 
(Dermatophagoides Pteronyssinus, Dermatophagoides farinae, Tyrophagus putrescentiae, 
Acarus siro, Lepidoglyphus destructor); moulds (Alternaria alternata, Aspergillus fumigatus, 
Cladosporium herbarum, Penicillium notatum) and Curvularia spicifera (ALK-Abelló, 
Denmark). Negative and positive controls (10 mg/ml histamine solution) were also included 
with each skin prick test. Patients treated with oral corticoids within the last 4 weeks prior to 
surgery were excluded. The ethical committee of the Ghent University Hospital approved the 
study, and informed consent was obtained from all subjects. 
Measurement of cytokines, mediators and IgE in tissue homogenates 
All (n=40) freshly obtained tissue specimens were weighed, and 1 ml of 0.9% NaCl solution 
was added per every 0.1g tissue. The tissue was then homogenized with a mechanical 
homogenizer (B. Braun Melsungen, Germany) at 1000 rpm for 5 minutes on ice as described 
previously18. After homogenization, the suspensions were centrifuged at 3000 rpm for 10 
minutes at 4°C, and the supernatants separated and stored at – 80°C until analysis. All 
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supernatants were assayed for IL-5, IL-4, eotaxin, sCD23, histamine (R&D System, 
Minneapolis, USA) and LTC4/D4/E4 (Amersham Pharmacia Biotech, Buckinghamshire, UK) 
by ELISA using commercially available kits.  ECP, tryptase, total and specific IgE were 
measured by the Uni-CAP system (Pharmacia & Upjohn, Upsala, Sweden)19;20. Specific IgE 
was determined for grass pollen mix (Dactylis glomerata, Festuca elatior, Lolium perenne, 
Phleum pratense, Poa pratensis); house dust mix (Hollister-Stier Labs, Dermatophagoides 
pteronyssinus, Dermatophagoides farinae, Blatella germanica); moulds mix (Alternaria 
alternata, Aspergillus fumigatus, Cladosporium herbarum, Penicillium notatum, Candida 
albicans, Helminthosporium halodes); Staphylococcus aureus enterotoxins SEA and SEB; 
and Curvularia spicifera Bipolaris. ImmunoCap coated with human serum albumin or glycine 
were used to evaluate any non-specific binding of IgE. 
Immunohistochemistry 
Samples were fixed in 4% formaldehyde (phosphate buffered 6.8-7.2, Klinipath, Duiven, 
Netherlands) and embedded in paraffin wax prior to cutting into 5µm sections and mounting 
on poly-L-lysin-coated slides. After deparaffinization in parasolve (Prosan, Merelbeke, 
Belgium), the sections were hydrated through graded ethanol and stained (Pappenheim) for 
standard histomorphologic analysis. For mast cell staining, tissue sections were treated with 
trypsin (0,1%; Sigma-Aldrich, Bornem, Belgium) for 20 minutes at 37°C (to enhance 
immunohistohemical reactivity) and then incubated with mouse anti-human mast cell tryptase 
clone AA 1 (1/500, Dako, Glostrup, Denmark) for 1h, prior to staining by the standard 
APAAP (alkaline phosphate-anti-alkaline phosphate) technique21;22. Sections were 
counterstained with hematoxylin. 
All tissue sections were examined with an Olympus light microscope by two independent 
observers, blinded to the experimental conditions. The numbers of eosinophils and mast cells 
were counted in the epithelium and in the adjacent lamina propria in 10 randomly selected 
fields (final magnification X400) and the results were expressed as the mean number of 
positive cells per field. 
Statistical analysis 
Data are expressed as median and interquartile range (IQR). When comparisons were made 
between groups, significance between-group variability was first established using Kruskal-
Wallis test. The Mann Whitney U-test was then used for between-group comparison. 
Spearman rank correlation coefficient (r) was used to assess the relationships between the 
parameters.  P-values less than 0.05 were considered statistically significant. 
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RESULTS  
Protein concentrations and immmunohistochemistry in non-polyp vs. polyp tissue 
Analysis of total IgE, IL-5, ECP, LTC4/D4/E4, eotaxin and sCD23 in supernatants prepared 
from tissue homogenates demonstrated that the concentrations of these mediators were 
significantly higher in NP tissue, compared to non-polyp tissue (Table I). In contrast, no 
significant differences were found in the levels of IL-4, histamine and tryptase.  
Similarly, immunohistochemical analysis of whole NP and non-polyp tissue samples 
demonstrated that the numbers of eosinophils in both the epithelium and in the lamina propria 
were also significantly higher in NP tissue, compared to non-polyp tissue (Table I). Contrary 
to the findings for eosinophils, however, significantly higher numbers of mast cells were 
found in the lamina propria of non-polyp tissue, compared with polyp tissue, and there were 
no differences in epithelial mast cells. 
 
Table I. Statistical comparisons between non-polyp and nasal polyp tissue. 
 
ELISA 
Inferior turbinates  
(n=20, Median and IQR) 
Mann Whitney 
test 
Nasal polyps   
(n=20, Median and IQ range) 
Total IgE (kU/l) 22.3 (6.6 – 142.4) p < 0.001 479.6 (199.7 – 1479.0) 
sCD23 (U/ml) All BDL p < 0.001 5 BDL;  17.5 (5.5 – 32.0) 
IL-5 (pg/ml) 19 BDL p < 0.001 5 BDL;  205.2 (47.5 – 353.3) 
IL-4 (pg/ml) 17.1 (12.7 – 33.9) p = 0.578 18.3 (11.1 – 29.6) 
LTC4/D4/E4 (pg/ml) 2932.5 (1387.2 – 3713.4) p = 0.025 4594.7 (3405.4 – 6011.6) 
ECP (µg/ml) 539.8 (118.4 – 899.6) p < 0.001 10077.5 (3518.7 – 22740.7) 
Eotaxin (pg/ml) 16 BDL p < 0.001 1 BDL; 1516.7 (461.6 – 3534.1) 
Histamine (mM) 20.4 (9.0 – 43.2) p = 0.055 31.2 (20.7 – 67.8) 
Tryptase (mg/ml) 11.1 (5.4 – 15.7) p = 0.197 6.7 (3.5 – 11.2) 
Immunohistochemistry    
Eosinophils in epithelium 0.1 (0 – 0.2) p = 0.017 0.8 (0.1 – 2.9)  
Eosinophils in lamina propria 4.2 (1.8 – 15.4) p = 0.003 52.5 (9.6 – 76.0) 
Mast Cells epithelium 0.6 (0.2 – 1.9) p = 0.853 0.7 (0.2 – 1.4) 
Mast Cells lamina propria 7.8 (5.7 – 18.8) p = 0.003 3.9 (1.9 – 6.2) 
The concentrations (Median, IQR) of total IgE, sCD23, IL-5, IL-4, LTC4/D4/E4, ECP, eotaxin, histamine and 
tryptase were measured in homogenates of non-polyp (inferior turbinate) and nasal polyp tissue. The number of 
eosinophils and mast cells were counted on Pappenheim and tryptase stained paraffin slides. Statistical analyses 
were performed by the Mann Whitney U-test. P < 0.05 was considered statistically significant. (BDL= below 
detection level) 
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Total IgE in atopic vs. non-atopic subjects  
In 10 out of 20 non-polyp and in 13 out of 20 NP patients, the skin prick test was positive for 
at least one allergen. In the non-polyp group, 5 patients with positive skin prick tests and 
symptoms to grass pollens or to house dust mite showed elevated total IgE and corresponding 
elevated specific IgE concentrations for grass pollens or house dust mite in tissue 
homogenates. The median (IQR) IgE concentrations in non-polyp tissue were 11.9 (4.7 – 
38.4) kU/l in non-atopic subjects and 45.9 (16.0 – 389.4) kU/l in atopic subjects (p < 0.05).  
 Comparison between atopic and non-atopic patients within the NP group did not show any 
significant differences for any of the above-mentioned parameters. In NP tissue of non-atopic 
and atopic patients, the total IgE concentrations were found to be 836.0 (49.5 – 5011.1) kU/l 
and 467.0 (203.9 – 1354.5) kU/l, respectively (Figure 1). Additionally, there was no 
correlation between the levels of IgE and skin prick test positivity in these individuals. 
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Figure 1. Comparison of IgE, IL-4, IL-5 and ECP concentrations between non-atopic and atopic nasal polyps 
showing no significant differences between the groups. The Box-and-whisker plot represents the median, the 
lower to upper quartile, the minimum to the maximum value, excluding "outside" and "far out" values, which are 
displayed as separate points. Statistical analyses performed by the Mann Whitney U-test (NS = not significant).  
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However, assessment for any correlations between IgE and other indices of inflammation 
demonstrated that in NP tissue the concentration of total IgE was significantly correlated with 
concentrations of sCD23 (r = 0.737; p < 0.001), ECP (r = 0.457; p < 0.05), LTC4/D4/E4 (r = 
0.588; p < 0.01), and IL-5 (r = 0.676; p < 0.001), and numbers of eosinophils in both the 
epithelium (r = 0.731; p < 0.001) and the lamina propria (r = 0.497; p < 0.05). In contrast,  
total IgE in non-polyp tissue was correlated with histamine (r = 0,654; p < 0.05) and tryptase 
(r = 0.538; p < 0.05). 
 
Nasal polyp groups based on specific IgE in nasal tissue 
A positive ImmunoCap to inhalant allergens was detectable in tissue homogenates of 15 out 
of 20 nasal polyp patients. In 2 of 9 samples tested against ImmunoCap with either non-
allergenic protein (HSA) or no protein (glycine), positive reactions were obtained. The lack of 
correlation with total IgE supports the hypothesis of a specific response. The reaction with 
HSA of the atopic patient with a skin test positive to Guinea pig could be due to allergenic 
similarities. IgE antibody to carbohydrate matrix of the ImmunoCap could explain the other 
reaction.  
Based on the presence of specific IgE antibodies in tissue homogenates, we were able to 
arbitrarily distinguish three nasal polyp groups (Table II): group NP I was characterized by no 
measurable specific IgE and a low total IgE. In group NP II, selected specific IgE directed to 
house dust mite mix, grass pollen or mould mix were measurable and total IgE was increased. 
The third group (NP III) demonstrated a multiclonal IgE and high total IgE tissue 
concentrations (> 450 kU/l).  sIgE to Staphylococcal enterotoxins SEA and SEB was also 
measured consistently in this group of patients, whereas these specific antibodies were not 
detectable in any of the other specimens. 
Whereas in NP I, no patient suffered from asthma, in NP III, 8 out of 10 patients had a history 
of asthma and 2 patients reported a clinical history of aspirin sensitivity. Furthermore, the 
numbers of eosinophils in the tissue and the concentrations of total IgE, sCD23, ECP, 
LTC4/D4/E4, eotaxin and IL-5, but not histamine, tryptase or IL-4, were significantly higher 
in NP III, compared to non-polyp controls and NP I subjects (Figure 2). 
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Table II. Nasal polyp groups based on the presence of specific IgE in nasal polyp tissue. 
 
Nasal polyp 
Groups Skin prick test Asthma Total IgE  Specific IgE   to (kUA/l)  
Dummy Caps 
      (kU/l) gx1 hx2 mx2 SEA,SEB C. Bip Glycine HSA 
NP Group I Non atopic  negative - 8.2 BDL BDL BDL BDL BDL / / 
   negative - 49.5 BDL BDL BDL BDL BDL / / 
 Atopic 
 hdm, 
mx,  - 212.3 BDL BDL BDL BDL BDL / / 
   gx,  - 9.7 BDL BDL BDL BDL BDL / / 
   hdm - 140.6 BDL BDL BDL BDL BDL / / 
NP Group II Non atopic  negative - 1131.8 BDL 4.7 BDL BDL BDL / / 
 Atopic  hdm, gx  asthma 195.5 31.0 BDL BDL BDL BDL / / 
   hdm asthma 343.2 BDL BDL 12.4 BDL BDL / / 
   hdm asthma 317.6 BDL 16.3 BDL BDL BDL / / 
   hdm - 1114.2 BDL 7.6 BDL BDL BDL BDL BDL 
NP Group III Non atopic  negative - 5011.1 11.0 9.7 7.9 9.8 6.1 BDL BDL 
   negative asthma 710.7 6.4 6.9 5.6 6.5 4.4 BDL BDL 
   negative - 836.0 3.8 4.7 5.2 5.7 3.0 BDL BDL 
   negative APA 5189.9 5.1 5.8 6.8 4.8 4.0 BDL BDL 
 Atopic  gx asthma 488.6 11.1 19.0 10.0 15.4 9.8 BDL BDL 
   gx asthma 2948.4 4.4 5.2 4.9 5.7 2.6 2.3 9.8 
   hdm asthma 467.0 17.5 9.4 6.5 36.1 BDL / / 
   hdm, gx  asthma 1594.7 75.9 40.1 76.6 4.1 7.4 BDL BDL 
   hdm, gx  APA 470.7 9.6 10.9 8.2 7.0 4.4 / / 
   hdm asthma 1612.0 4.2 4.3 4.1 3.7 2.6 1.4 2.3 
Nasal polyp patients are grouped based on the presence of specific IgE in nasal polyp tissue: NP I (undetectable 
specific IgE), NP II (selected specific IgE), NP III (multiclonal IgE).   The atopic status was evaluated by skin 
prick tests to common inhalant allergens: grass pollen mixture (gx), mites (hdm), moulds (mx) and Bipolaris. 
Skin prick tests for Staphylococcus aureus were not available and therefore not performed. APA: Patients 
suffering from the triad of aspirin sensitivity, polyposis and asthma. Polyp total IgE concentrations (kU/l) and 
specific IgE (kUA/l) were determined for grass pollen mix (gx1), house dust mix (hx2), mould mix (mx2), S 
aureus enterotoxins (SEA and SEB) and Curvularia spicifera Bipolaris (C. Bip). Specific IgE to HSA and glycine 
was determined to exclude unspecific binding. Data from each individual are given separately (/ = not tested; 
BDL = below detection level). 
 
DISCUSSION  
This is the first report to describe a relationship between concentrations of total and specific 
IgE and the severity of eosinophilic inflammation in human nasal polyp tissue. Remarkably, 
these findings are unrelated to skin prick test results and symptoms, differing from a typical 
atopic disease such as allergic rhinitis. We could demonstrate a multiclonal specific IgE in 
50% of NP samples. The presence of specific IgE antibodies to Staphylococcal enterotoxins 
SEA and SEB in these samples points to a possible role of bacterial superantigens as disease 
modifiers.  
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In line with previous studies11;12;18;23-25, we were able to demonstrate a significant 
upregulation of IL-5 protein in NP, showing a firm correlation to ECP protein. It is widely 
accepted that IL-5 is an important cytokine for mature eosinophil activation26. The important 
functional role of IL-5 in NP has been demonstrated by experiments showing the induction of 
programmed cell death by neutralizing monoclonal antibodies (anti-IL-5 mAb)12. In addition, 
our study has also demonstrated that the increased concentration of eotaxin was correlated to 
ECP, suggesting a key role of this C-C chemokine for eosinophil recruitment in collaboration 
with IL-5.  
Upregulated total IgE concentrations were paralleled by an increase of the soluble low affinity 
IgE receptor sCD23. Membrane-bound CD23 on B-cells was described to downregulate IgE 
formation upon binding to IgE27, and the soluble receptor could interfere by capturing IgE and 
prevention of binding to the receptor. Thus, high concentration of sCD23 would be consistent 
with elevated total IgE.  
We further analyzed specific IgE to common inhalant allergens and selected moulds in 
comparison to skin prick test results in non-polyp mucosa from the inferior turbinate of atopic 
and non-atopic patients. As expected, increased total IgE and specific IgE in the inferior 
turbinates of subjects allergic to inhalant allergens was found in correspondence with the skin 
prick test results. In marked contrast, atopy based on positive skin prick tests to inhalant 
allergens was not related to total or specific IgE in NP homogenates. Contrary to other 
reports28, no impact of atopy could be found on any of the mediators or cytokines in the polyp 
group, questioning the role of common allergens in nasal polyp pathophysiology.  
Based on the finding of specific IgE, we were able to differentiate three groups of NP 
patients: 
- Group NP I with undetectable specific IgE and low total IgE (5-220 kU/l)  
- Group NP II with selected specific IgE antibodies and increased total IgE (190-1150 kU/l) 
- Group NP III with multiclonal specific IgE and high total IgE (450-5200 kU/l)  
In the last group, representing 50% of the polyp patients in this study, all polyps demonstrated 
specific IgE responses to SEA and SEB, which were not found in any other subject. 
Following the classification into these three groups of polyps, we could demonstrate that total 
IgE, sCD23, IL-5 and ECP all follow a common pattern, with significantly increased 
concentrations in NP III, compared to either non-polyp or polyp group I samples. This is the 
first study to show that total IgE is related to IL-5 and ECP protein concentrations, and thus 
possibly to eosinophilic inflammation. Interestingly, 8 out of 10 patients in this group also 
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suffered from asthma, indicating not only a more severe local, but also systemic disease in 
these patients.  
In contrast to other publications5;29;30, we could not find increased histamine or tryptase levels 
within polyps compared to non-polyp tissue, questioning the role of mast cells in the 
pathogenesis of mature  NP. In line with our finding, however, significantly lower numbers of 
mast cells were found in the lamina propria of NP compared to non-polyp tissue. Whilst it 
could be speculated that mast cells in NP were undetectable by immunohistochemistry due to 
degranulation, the lack of increased histamine and tryptase concentrations in NP tissue does 
not support this view.  
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Figure 2.  Measurement of IgE, sCD-23, IL-5, and IL-4 tissue concentrations in inferior turbinates (non-polyp) 
and nasal polyp groups: NP I (undetectable specific IgE), NP II (selected specific IgE), NP III (multiclonal IgE).  
The Box-and-whisker plot represents the median, the lower to upper quartile, the minimum to the maximum 
value, excluding "outside" and "far out" values, which are displayed as separate points. Statistical analyses 
performed by the Mann Whitney U-test (NS = not significant).  
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The high IgE protein concentrations could be preferentially derived from the serum, as an 
extravasation and deposition of serum proteins in polyp tissue has been shown31. However, 
allergen-induced heavy-chain switching to IgE occurs locally within the nasal mucosa of 
patients with seasonal allergic rhinitis31 and increased local IL-4 mRNA, IgE heavy chain 
(Cε) and IgE heavy chain promoter (Iε) RNA32 has been demonstrated after allergen 
exposure. Thus, a local IgE production also seems possible in NP. Interestingly, although IL-4 
has been shown to be necessary for IgE synthesis, we could not demonstrate increased IL-4 
protein concentrations in NP with high total IgE compared to non-polyp tissue. This, 
however, confirms our previous findings12, where IL-4 mRNA expression in nasal polyp 
samples was also found to be low and not significantly different from controls. On the other 
hand, it has been demonstrated that only a small quantity of IL-4 is necessary to induce IgE 
synthesis in the presence of high IL-5 concentrations33;34,  and that IL-13 may replace IL-435. 
Furthermore, Leung et al36;37 have demonstrated an increased IgE production, induced by 
SSAg, in lymphocytes from patients with SAR in the absence of exogeneous IL-4.  
Although the demonstration of specific IgE to SSAg within polyp tissue in the present study 
proves former contact to enterotoxins, the exact role of specific IgE needs further 
clarification. IgE to SSAg has been demonstrated to mediate basophil degranulation36;37 and 
SSAg are thought to act as superantigens through unconventional interaction with the T-cell 
receptor16;38. There is recent evidence that SSAg may also play an important role in atopic 
dermatitis13. Anti-SEB IgE titers have been shown to correlate with the severity of disease in 
patients with mild to severe atopic dermatitis14. The majority of T cells found in lesional skin 
expressed a T cell receptor Vß repertoire that corresponded to the SSAg produced by the 
colonizing S aureus strain39. However, enterotoxins may also function as classic antigens 
through antigen-presenting cells resulting in specific sensitization36, since SSAg also induce 
the synthesis of chemokines in a human epithelial cells40 and may thus recruit T-cells and 
eosinophils to the site of infection. Furthermore, SEB has also been shown to induce a 
lymphocyte-dependent airway inflammation, including recruitment of eosinophils, in mice16.  
It is unclear whether the different groups of NP defined in the present study represent 
different disease entities or rather an evolution from group NP I to III. So far, we were unable 
to relate specific IgE to the age of the patient or duration of disease. Furthermore, it has to be 
elucidated whether SSAg´s represent causative or only modulating factors, being dependent 
upon a former damage of the mucosa by unrelated pathomechanisms.  
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In summary, our studies have demonstrated that in marked contrast to allergic rhinitis, 
specific IgE in nasal polyps is unrelated to skin prick test positivity, and total IgE correlates to 
markers of eosinophilic inflammation, but not to mast cell activation markers. In 50% of 
bilateral eosinophilic NP, a multiclonal IgE, including specific IgE to Staphylococcal 
enterotoxins A and B, has been demonstrated, suggesting a possible role of superantigens as 
disease modifiers. We suggest that nasal polyps may have pathophysiologic principles in 
common with atopic dermatitis and asthma with respect to the role of SSAg. Furthermore, we 
have developed a concept to differentiate bilateral nasal polyps into further three sub-groups, 
based on our findings for the presence of specific IgE antibodies within polyp tissue. 
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LOCAL IGE FORMATION TO STAPHYLOCOCCUS AUREUS 
ENTEROTOXINS IN NASAL POLYP TISSUE 
 
Gevaert P, Holtappels G, Johansson SGO, Cuvelier C, van Cauwenberge P, Bachert C 
Allergy 2004 (In press)  
 
ABSTRACT 
Background: Bilateral nasal polyposis (NP) is characterized by high concentrations of IgE in 
NP-tissue, which show no relation to the atopic status. We aimed to study the relationship 
between systemic and local IgE formation, nasal carriage of Staphylococcus aureus and nasal 
polyposis. 
Methods: In serum and nasal tissue homogenates from 24 NP patients and 12 controls, we 
determined concentrations of total IgE and IgE antibodies to inhalant allergens and S. aureus 
enterotoxins (SAEs; A,B,C,D,E,TSST) by ImmunoCAP. Tissue cryosections were stained for 
CD3, CD20, CD38, CD23, FcεRI, IgE and SEA/SEB.  
Results: We demonstrated a higher incidence of S. aureus colonisation (17/24) and IgE 
antibodies to SAEs in NP tissue (12/24) compared to controls (resp. 3/12 and 0/12). Total IgE 
and IgE antibodies in serum and NP-tissue were dissociated due to local polyclonal IgE 
formation in NP-tissue. Staining of NP tissue revealed follicular structures characterised by 
B- and T- cells, and lymphoid accumulations with diffuse plasma cell infiltration.  
Conclusions: We demonstrated the organisation of secondary lymphoid tissue in polyp tissue 
and a polyclonal hyper-immunoglobulinemia E associated with the presence of IgE antibodies 
to SAEs, colonization with S. aureus, and tissue eosinophilia in a relevant subgroup of polyp 
patients. 
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INTRODUCTION 
A hallmark of bilateral nasal polyposis in western countries is the pronounced tissue 
eosinophilia that can be found in about 70 to 90 % of cases as well as elevated local IgE 
levels in polyp fluid 1-5. Therefore, an allergic aetiology of nasal polyps has been presumed, 
but never firmly demonstrated 6. In a retrospective study by Settipane and Chafee, polyps 
were present in 2.8% of atopic patients, but in 5.2% of non-atopic subjects 7. Furthermore, 
nasal polyps occur more frequently in subgroups of patients with asthma and aspirin 
sensitivity 8. About 40 to 80% of patients with aspirin sensitivity suffer from polyposis, and 
about 15% of polyp patients are hypersensitive to aspirin 9. In studies involving large series of 
patients with nasal polyposis, asthma was found in 20% to 70%, and non-allergic asthma is 
significantly more frequently linked to polyps compared to allergic asthma 8;9. In a recent 
study we could demonstrate that atopy based on positive skin prick tests to inhalant allergens 
was not related to total IgE or IgE antibodies in NP tissue and that there was no impact of 
atopy on the levels of IL-5, IL-4, eotaxin, LTC4/D4/E4, sCD23, ECP and number of tissue 
eosinophils in NP tissue 2. Whether the high concentrations of IgE antibodies in polyp tissue 
are the result of a local production or are preferentially derived from the serum remains to be 
elucidated. In about half of the polyp specimen we demonstrated polyclonal IgE formation 
specific IgE to Staphylococcus aureus enterotoxins (SAE), high levels of local IgE antibodies, 
and a high prevalence of asthma 2. Similarly, we demonstrated that IgE antibodies to SAE 
were more often found in serum from patients with severe asthma than in those with mild 
asthma 10. Recent evidence suggests that SAE could modify airway disease by acting as 
superantigens 11;12. Superantigens are microbial or viral protein toxins with potent 
immunostimulatory properties. These properties are attributable to their unique ability to 
crosslink major histocompatibility complex (MHC) class II molecules with T cell receptors 
forming a trimolecular complex that activates a much larger number of resting T cells (as 
many as one in five T cells) than does a conventional antigen (one in 105-106 T cells) 13. 
Several bacterial superantigens have been described, of which the family of classical 
Staphylococcal aureus enterotoxins (SEA, SEB, SEC, SED, SEE and TSST) are the most 
widely studied. In addition, Staphylococcal protein A (SPA)14 as well as the SAE TSST-1 
have also been demonstrated to possess B-cell superantigen moieties, inducing polyclonal IgE 
synthesis 15;16. Because of the widespread carriage of S. aureus and the ubiquitous expression 
of their toxins it is clear that the nasal immune system is under constant challenge by these 
extremely powerful agents, which are therefore likely to influence the response to other 
challenges. 
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It was therefore tempting to study the relationship between nasal carriage of Staphylococcus 
aureus, IgE formation to Staphylococcus aureus enterotoxins and nasal polyposis. 
Furthermore, we aimed to determine whether IgE is produced locally in nasal polyps or is a 
result of extravasation, by comparison of IgE specificities in tissue and serum and by analysis 
of B- and T-lymphocyte accumulations in tissue.   
 
METHODS 
Patients 
Nasal tissue and serum were obtained from 12 control and 24 bilateral NP patients at the 
Department of Otorhinolaryngology, Ghent University Hospital. All control subjects (median 
age 33.6 years, range 18-71 years; 5 F/ 7 M) were skin prick test negative, in generally good 
health, and none had a history of nasal or sinus disease, allergic disease (asthma, rhinitis, 
dermatitis), upper respiratory tract infection in the previous month, use of any intranasal 
medications, decongestants, antihistamines or oral steroids during the last month. Bilateral 
polyposis was diagnosed based on history, clinical examination, nasal endoscopy and sinus 
CT-scan. The median age of NP patients was 46 years (range 22-78 years; 7 F/ 17 M). A 
history of asthma was reported in 8 nasal polyp patients. Twelve patients were atopic, as 
indicated by positive cutaneous skin prick test responses to common aeroallergens 17. The 
panel of allergens comprised: grass pollen mix (Dactylis glomerata, Festuca elatior, Lolium 
perenne, Phleum pratense, Poa pratensis); mites (Dermatophagoides Pteronyssinus, 
Dermatophagoides farinae, Tyrophagus putrescentiae, Acarus siro, Lepidoglyphus 
destructor); moulds (Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarum, 
Penicillium notatum) and Curvularia spicifera (ALK-Abelló, Denmark). Negative and 
positive controls (10 mg/ml histamine solution) were also included with each skin prick test. 
Patients treated with oral corticosteroids within the last 4 weeks prior to surgery were 
excluded. The ethical committee of the Ghent University Hospital approved the study, and 
informed consent was obtained from all subjects. 
 
Measurement of total IgE, IgE antibodies and albumin in serum and tissue homogenates 
All samples were immediately processed, separated and stored in aliquots at – 80°C until 
analysis. Approximately 0.5 cm3 tissue strips were collected from the surface of each inferior 
turbinate (turbinotomy, 0.2 to 0.5g of tissue) or bilateral NP (0.2 to 2.0g of tissue), during 
routine septal and sinus surgery, respectively. All (n=24) freshly obtained tissue specimens 
were weighed, and 1 ml of 0.9% NaCl solution was added per every 0.1g tissue. The tissue 
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was then homogenized with a mechanical homogenizer (B. Braun Melsungen, Germany) at 
1000 rpm for 5 minutes on ice as described previously4. After homogenization, the 
suspensions were centrifuged at 1500 g for 10 minutes at 4°C, and the supernatants separated. 
Blood samples were allowed to clot at room temperature for 20-30 minutes, centrifuged at 
1500 g for 10 minutes at 4°C, and serum was separated.  
All supernatants and sera were assayed for total IgE and IgE antibodies by the UniCAP 
system (Pharmacia Diagnostics, Upsala, Sweden)18 and for albumin by nephelometry. IgE 
antibodies were determined for Staphylococcus aureus enterotoxins (SEA, SEB, SEC, SED, 
SEE and TSST-1); grass pollen mix (Dactylis glomerata, Festuca elatior, Lolium perenne, 
Phleum pratense, Poa pratensis); trees mix (Alnus incana, Betula verrucosa, Corylus 
avellana, Quercus alba, Salix caprea); house dust mix (Hollister-Stier Labs, 
Dermatophagoides pteronyssinus, Dermatophagoides farinae, Blatella germanica) and 
moulds mix (Alternaria alternata, Aspergillus fumigatus, Cladosporium herbarum, 
Penicillium notatum, Candida albicans, Helminthosporium halodes). ImmunoCAP coated 
with human serum albumin or glycine were used to evaluate any non-specific binding of IgE. 
 
Immunohistochemistry  
Specimens were snap frozen in liquid nitrogen cooled methyl butane and stored at –80°C. 
Cryostat sections were prepared (6µm) and mounted on SuperFrost Plus glass slides, packed 
in aluminium paper and stored at –30°C until staining.  
Sections were stained for CD3, CD20, CD38, CD23, FcεRI and IgE. Specimens were fixed in 
acetone. Endogenous peroxidase activity was blocked with 0.3 % hydrogen peroxide in TBS 
containing 0.1% sodium azide for 20 minutes. Primary antibodies or negative controls, 
consisting of the corresponding isotype control, were incubated for 1 hour and detected using 
the LSAB technique conjugated with peroxidase according to the manufacture’s instructions 
(labelled streptavidin-biotin, Dako, Copenhagen, Denmark). The peroxidase activity was 
detected using AEC Substrate chromogen (Dako), which results in a red-stained precipitate. 
Finally sections were counterstained with Hematoxyline and mounted. 
Biotinylated SAE staining and blocking experiments 
Specimens were fixed in acetone and endogenous peroxidase was blocked. Biotinylated SEA 
(40 µg/ml) and a mixture of non-biotinylated SEA/ biotinylated SEA (1000µg/ml / 40 µg/ml), 
to determine the specificity of the biotinylated SAE staining, (Toxin Technology ,Sarasota, 
US) were applied and incubated overnight at 4°C. The sections were rinsed with TBS and 
incubated with streptavidine-conjugated peroxidase (Dako) for 30 minutes. After rinsing with 
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TBS, sections were incubated with AEC chromogen (Dako) for 10 minutes rinsed, 
counterstained with hematoxyline and mounted.  
 
Statistical analysis 
Data are expressed as median and interquartile range (IQR). When comparisons were made 
between groups, significance of between-group variability was first established using the 
Kruskal-Wallis test. The Mann Whitney U-test was then used for between-group comparison. 
Spearman rank correlation coefficient (r) was used to assess the relationship between the 
parameters. The Chi-square test was used for comparison of frequencies. P-values less than 
0.05 were considered statistically significant. 
 
RESULTS 
Nasal culture from the middle meatus demonstrated staphylococcal colonisation in 17/24 NP 
patients and in 3/12 controls (p=0.02). Table I demonstrates a significant increase in 
concentrations of IgE, albumin, and eosinophil counts in nasal polyp tissue compared to 
control tissue. Total IgE and IgE antibody concentrations were in all cases higher in tissue 
compared to serum. The IgE/albumin ratios in polyp tissue and in serum were dissociated, 
indicating that tissue IgE is rather the result of a local IgE production than of extravasation.  
Furthermore, IgE antibodies in polyp tissue only showed a partial relation to IgE antibody in 
serum and to skin prick tests (Table II). In a subgroup of sixteen patients a particular pattern 
of IgE expression was found in NP tissue. This polyclonal type of IgE expression is 
characterised by IgE antibodies to all measured common aeroallergens and is associated with 
the highest levels of IgE antibodies in NP tissue. IgE specific to SAE could be demonstrated 
in 12 out of 24 NP tissue homogenates and in 3 out of 24 serum samples of NP subjects, but 
in none of the controls. Eosinophil counts and IgE concentrations were significantly higher in 
those nasal polyps positive for IgE antibodies to SAEs than in SAE negative samples 
(p<0.001) (Figure 1).  
Follicular structures were found in 6 out of 24 NP samples, whereas diffuse lymphoid 
accumulations were found in all NP samples (Figure 2). Follicular structures stained positive 
for IgE, CD3, CD20, and CD23, whereas FcεRI was found only outside the follicle (Figure 
3). Plasma cells expressing CD38 were absent from the inner area of the follicular structures, 
but prominent in the diffuse lymphoid accumulations. The latter stained positive for IgE, 
CD3, CD20 and, FcεRI, but not for CD23 (Figure 3). SAE binding was positive in follicular 
structures and in some areas with lymphoid accumulations. The specificity of the SAE 
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binding was confirmed by staining with an excess of non-biotinylated SEA to biotinylated 
SEA, which completely blocked the signal. Follicular structures or SAE staining were not 
found in control tissue.  
 
Table I: IgE concentrations and eosinophil counts in controls versus nasal polyps 
 
NASAL TISSUE 
Controls  
(n=12) 
Median (± IQR) 
versus 
 
Nasal polyps 
(n=24) 
Median (± IQR) 
IgE (kU/l) 17 (7-25) p < 0.001 654 (156-1263) 
Albumin (g/l) 15.6 (12.7-17.3) p = 0.002 19.7 (17.7-23.2) 
IgE/Albumin 1.28 (0.90-2.14) p < 0.001 27.08 (10.2-59.8) 
SAE IgE ab + (%) All negative (0%) p = 0.009 12/24 (50 %) 
Eosinophils (%) 0.3 (0.1-0.7) p < 0.001 11.5 (2.9-24.3) 
SERUM    
IgE (kU/l) 31 (15-64) p = 0.004 160 (50-291) 
Albumin (g/l) 48.1 (46.2-49.7) NS 44.5 (40.9-54.3) 
IgE/Albumin 0.32 (0.67-1.19) p = 0.04 3.5(1.12-6.93) 
SAE IgE ab + (%) 0/8 (0%) NS 3/24 (12.5%) 
Eosinophils (%) 0.9 (0.4-1.8) p < 0.001 4.8 (2.6-7.1) 
 
 
DISCUSSION 
We demonstrated the organisation of secondary lymphoid tissue in nasal polyp tissue and a 
polyclonal hyper-immunoglobulinemia E associated with the presence of IgE specific to 
SAEs, colonization with S. aureus, and increased eosinophilic inflammation in a relevant 
subgroup of nasal polyp patients. Furthermore, the dissociation in IgE levels and IgE 
antibodies between nasal polyp tissue and serum suggests that IgE in NP are mainly due to a 
local production. We demonstrated binding of biotinylated SAE to follicular structures and in 
lymphoid accumulations in NP tissue. The follicular structures were mainly characterized by 
an accumulation of B-cells and T cells, whereas lymphoid accumulations showed diffuse 
plasma cell infiltration. These data suggest an organization of secondary lymphoid tissue with 
polyclonal B-cell activation in nasal polyps due to chronic microbial colonization and release 
of enterotoxins, which is likely to be the cause of IgE switch and formation. 
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Figure 1: Comparison of total IgE concentrations, IgE/albumin ratio’s and eosinophil percentages in serum and 
nasal tissue of controls, NP patients without or with IgE antibodies to SAE (NP+SE). The Box-and-whisker plot 
represents the median and the 10th, 25th, 75th, 90th percentile. Statistical analyses performed by the Mann 
Whitney U-test (NS = not significant). 
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The nasal vestibule is the ecologic reservoir for S. aureus, with about 25% of the population 
being permanent carriers19. A large proportion of the population (approximately 60%) 
harbours S. aureus intermittently, and the strains change with varying frequency 19. Notably, 
only a minority of people (approximately 20%) almost never carries S. aureus 19. The 
differences could be due to host factors and/or to competition between members of the nasal 
flora (e.g. Corynebacterium spp.)20. Indeed, a higher incidence of S. aureus colonisation of 
skin or mucous membranes may be due to injuries, abnormal leukocyte function and 
inflammation (e.g. atopic dermatitis), viral infections (e.g. influenza), metabolic abnormalities 
(e.g. diabetes mellitus and uraemia) and miscellaneous other conditions (e.g. malnutrition, old 
age, malignancies, etc). Whereas nearly all strains of S. aureus produce enzymes and 
haemolysins that contribute to their pathogenicity, it has been generally accepted that only 
some strains produce superantigens. However, recent data using multiplex PCR-DNA enzyme 
immunoassays and considering both, the newly described SAE genes (SEG, SEH, SEI, and 
SEJ) and the classical toxins (SEA, SEB, SEC, SED, SEE and TSST), demonstrated that the 
overall rate of toxin gene-positive isolates reached 73.0%. More than half of the isolates 
(55.0%) harboured the combination of SEG and SEI, whereas other toxin genes amplified 
were TSST (20.3%), SEA (15.9%), and SEC (11.2%)20. In the present study we demonstrate a 
significantly higher incidence of nasal colonisation with S. aureus in NP patients (71%) than 
in controls (25%). However, only in 50% of polyp tissues, IgE antibodies to classical SAE´s 
were detectable. These data probably underestimate the impact of enterotoxins, as contact to 
only the classical, but not to the newly described enterotoxins was studied due to the current 
lack of validated tests for IgE antibodies to the latter. 
Detailed analysis of Table II reveals two patterns of IgE expression: “the allergic type” and 
“the polyclonal type” that can be found either isolated or combined. The “allergic” type of 
IgE expression is characterized by increased concentrations of total IgE and IgE antibody 
specificities in nasal tissue that correspond those in serum and to the skin prick test results. In 
clear contrast, the “polyclonal” IgE expression is a local process and IgE antibodies found in 
polyp tissue are only partially reflected in serum of the same patients and are independent of 
the skin prick results. Notably, this polyclonal expression pattern is associated with a hyper-
immunoglobulinemia and only a small fraction of the total can be explained by IgE 
antibodies. Polyclonal expression was described in 16/24 NP tissues and was associated with 
IgE antibodies to SAEs in 12 cases, indicating that other than the classic enterotoxins might 
have acted as superantigens (most probably from S. aureus, but possibly also from other 
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germs). Furthermore, 12 of the 16 polyp patients showed a combined expression pattern, with 
the polyclonal type of IgE expression in addition to an existing allergy. 
The earliest quantitative studies on humoral responses to antigenic stimuli showed that the 
amount of measurable specific antibody produced often only represented a small fraction of 
the newly synthesized total 16. Parasites, viruses, fungi and bacteria can obliterate specific 
immune responses by triggering the machinery of polyclonal lymphocyte responses, thus 
resulting in a lack of specificity of antibodies or T-cell responses to the microbial agents 21. 
There is convincing evidence that cytokines released form activated T-cells may substitute 
non-specifically for TH cells in stimulating B cells22. Two types of polyclonal stimuli exist 
that can trigger B lymphocyte proliferation and differentiation in the absence of antigen: (i) 
those derived from microbial products, such as lipopolysaccharide or unmethylated single-
stranded DNA motifs (CpG oligonucleotides), which stimulate B cells via TLR4 (Toll-like 
receptor 4) and TLR9, respectively; and (ii) T cells activated by a third-party antigen, which 
stimulate B cells in a noncognate fashion via CD40 ligand 23 and cytokine production, 
referred to as bystander help. Recent data indicated that memory B cells have two response 
modes. In the antigen-dependent mode, they undergo a massive expansion and differentiation 
towards short-lived plasma cells 24;24;25. In contrast, in the polyclonal mode, all memory B 
cells respond to microbial stimuli by undergoing continuous proliferation and differentiation. 
In this way, a constant level of plasma cells and immunoglobulin in serum could theoretically 
be maintained throughout a human life-span 26. Because this mechanism is non-specific, it 
would act indiscriminately to maintain the broad spectrum of antibody specificities generated 
during the antigen-driven immune response as well as non-antibody active immunoglobulin 
molecules. The protection is relative to a particular pathogen or toxin and may be mediated by 
pre-formed antibodies, by rapid secondary responses or by a combination of both 24;25. 
However, in the case of powerful bacterial toxins such as superantigens, protection relies 
entirely on pre-existing neutralizing antibodies since there is no time to mount a secondary 
response to achieve protection.  
The high IgE concentrations in polyp tissue could be preferentially derived from the serum, as 
an extravasation and deposition of serum proteins in polyp tissue has been shown 1. However, 
IgE has been found in NP tissue enriched over serum suggesting that IgE synthesis occurs 
locally in the mucosa. In mucosal tissues of allergic rhinitis and asthma patients, mRNA for 
the ε-chain of IgE was associated with a significant proportion of B-cells by using in situ 
hybridization 27-30. This supports the hypothesis of local IgE synthesis since mRNA 
expression would be required for synthesis and secretion of IgE. Using immunohistochemical 
Organisation of secondary lymphoid tissue and local IgE formation to S aureus enterotoxins in polyp tissue. 
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methods, different research groups have reported varying success in visualizing IgE protein 
associated with B-cells in nasal mucosa. Recently, however, KleinJan et al. visualized IgE 
protein in association with both B-cells and plasma-cells in the nasal mucosa of patients with 
allergic rhinitis 31. In our present study we describe two prominent IgE positive areas:  first, 
the follicular structures, which are characterised by an organisation of T-cells (CD3) and B-
cells (CD20), found in 6 out of 24 NP samples; second, in all polyps we found diffuse 
lymphoid accumulations that contain T-cells (CD3) and plasma-cells (CD38). B-cell foci have 
been described before in nasal polyp tissue 32, associated with a reduced expression of activin 
A in those areas, which points to a reduced suppression of plasma cells development 32;33. 
There is increasing evidence that SAEs can directly affect the frequency and activation of the 
B-cell repertoire. Functional studies in B-cells have shown that S. aureus protein A induces 
proliferation of these cells, following signal transduction involving protein kinase C (PKC), 
mitogen-activated protein kinase (MAP kinase), serum responsive factor (SRF) and Bcl-2 
gene expression 34. Studies with TSST-1 have shown that this staphylococcal superantigen 
may play an important role in the modulation of allergic disease, since it can augment isotype 
switching and synthesis of IgE, both in vitro 23 and in vivo, in a SCID mouse model 35. 
Although TSST-1-induced activation of B-cells in vitro is indirect and dependent on increased 
expression of CD40 ligand on T-cells, a more recent study has also provided evidence for a 
direct effect by demonstrating TSST-1-induced expression on B-cells of B7.2 15, a molecule 
that has been shown to enhance Th2 responses and to be involved in IgE regulation. 
An augmented local synthesis of IgE may, under appropriate circumstances, increase allergic 
reactivity, but when it is excessive, it has been suggested to actually suppress specific 
reactivity by saturation of Fcε receptors on mast cells through polyclonal IgE and/or an 
inhibition of specific antibody synthesis to environmental allergens by the polyclonal 
response 36. These mechanisms could explain why nasal symptoms and markers of nasal 
mucosal inflammation did not increase in relation to natural seasonal allergen exposure in 
highly ragweed-allergic patients with polyps 37 and why nasal provocation in nasal polyps is 
largely unsuccessful although elevated IgE levels are present 38;39. However, the backside of 
this local polyclonal IgE production may be the permanent triggering of the IgE-mast cell-
FcεRI cascade that maintains polyp growth40.  
 
Conclusion 
We demonstrate the organization of secondary lymphoid tissue in nasal polyposis with 
polyclonal B-cell activation and hyper-immunoglobulinemia E associated with the presence 
Organisation of secondary lymphoid tissue and local IgE formation to S aureus enterotoxins in polyp tissue. 
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Figure 2 Nasal polyp tissue stained for IgE demonstrating a follicular 
structure (FO)  and lymphoid accumulations (LA) (x10)
111
Follicle-like structure (FO)    Lymphoid accumulations (LA)
SEA SEA
CD3
CD20 
CD38
IgE
CD3
CD20 
CD38
IgE
Figure 3: Follicular structures and lymphoid accumulations in 
nasal polyp tissue are stained for CD3, CD20, CD38, IgE, and SAE 
binding (x40).
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of locally formed IgE antibodies to staphylococcal enterotoxins, and increased eosinophilic 
inflammation in a relevant subgroup of nasal polyp patients. The increased prevalence of 
colonization with Staphylococcus aureus and subsequent chronic microbial stimulation in NP 
may be a causative or disease modulating factor, being dependent upon a former damage of 
the mucosa by unrelated pathomechanisms.  
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ABSTRACT 
BACKGROUND: Alternative splicing of the IL-5Rα-subunit leads to the generation of a 
signaling, membrane-anchored (TM) isoform, or a secreted (SOL), antagonistic variant. 
Given the key role of IL-5 in eosinophil function, we investigated SOL IL-5Rα expression 
pattern in an eosinophil-associated disease such as nasal polyposis (NP). 
METHODS: SOL IL-5Rα ELISA and quantitative real-time PCR were established and 
applied in serum, nasal secretion and nasal tissue of controls (n=12) and NP patients (n=42) 
with or without asthma.  
RESULTS: Analysis of serum, nasal secretion and nasal tissue samples revealed that SOL IL-
5Rα protein concentrations were significantly increased in NP versus control tissue. Within 
the NP group, there was a significant up-regulation of SOL IL-5Rα in patients with systemic 
airway disease. These findings were confirmed at the mRNA level, using an optimised real-
time RT-PCR procedure. 
CONCLUSIONS: This report demonstrates SOL IL-5Rα transcript and protein up-regulation 
in nasal polyposis. SOL IL-5Rα differentiates nasal polyps with or without concomitant 
asthma. Since SOL IL-5Rα is strongly up-regulated for disease and has antagonistic 
properties in vitro, our studies shed new light onto the mechanisms of specific immuno-
modulatory therapies, such as anti-IL-5. 
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INTRODUCTION 
Interleukin-5 is a haematopoietic growth factor essential for eosinophil development, 
activation and survival. The eosinophil is regarded as an important effector cell in various 
chronic pathologies including asthma, allergic rhinitis and nasal polyposis. However, the 
recent failure to demonstrate clinical efficacy of humanized antibodies directed against IL-5 
in human asthma trials, has led to a re-evaluation of the role of eosinophils 1. A better 
understanding of the biology of IL-5 and the regulation of its receptors seems to be mandatory 
to understand the effect of anti-IL-5 treatment in eosinophil-associated diseases.  
Nasal polyposis is an excellent model for eosinophil-associated diseases, as 80 to 90% of 
bilateral nasal polyps are characterized by abundant eosinophilic infiltration. Nasal polyps are 
swellings of the lamina propria mucosa, a pathology that is frequently associated with asthma 
and often treated by surgical removal of polyps that block airways, facilitating the use of this 
tissue for investigation. High amounts of IL-5 can be detected at the mRNA as well as at the 
protein level in NP 2;3. The highest levels of IL-5 protein were observed in polyp homogenates 
of patients with generalized eosinophilic diseases such as asthma and aspirin sensitivity 2;4;5. 
The biological signal from IL-5 is mediated through a receptor consisting of a specific IL-5-
binding α-chain, and a signal-transducing common β-chain, which is shared with the 
receptors for IL-3 and GM-CSF 6;7. When the β-chain associates with the specific IL-5-
binding α-chain, a high affinity complex is formed 8. In contrast to the pan-haemopoietic βc-
chain, the IL-5Rα receptor seems to be expressed on a restricted range of cell types in 
humans, principally eosinophils, basophils, and their precursors. However, recent publications 
have demonstrated eosinophil-independent airway hyperresponsiveness and IL-5Rα gene 
expression in human bronchus smooth muscle 9;10. 
The IL-5 receptor α-subunit (IL-5Rα) can appear in either a membrane-anchored (TM) active 
form or a soluble (SOL) variant with antagonistic properties in vitro 6;11. The various 
expression patterns of these forms are regulated at the transcriptional level by alternative 
splicing 12. The antagonistic properties of SOL IL-5Rα have been demonstrated in binding 
assays, eosinophil differentiation assays 11 and in nasal tissue explants 13. It is suggested that 
eosinophils are able to control their responsiveness to IL-5 by regulated expression of the IL-
5Rα isoforms. Surprisingly, mature, circulating eosinophils predominantly express the SOL 
IL-5Rα transcript (own data) 11, which raises the question whether this reflects a role in vivo. 
However, until now the human SOL IL-5Rα protein could not be demonstrated in clinical 
samples or in supernatants of cultured eosinophils.  
Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. 
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The aims of this study were to develop specific ELISAs for studying the SOL IL-5Rα isoform 
at the protein level and to set up a PCR-based approach to monitor the expression of the SOL 
IL-5Rα mRNA, and to test the diagnostic potential of SOL IL-5Rα in eosinophil-associated 
disease such as nasal polyposis. 
 
METHODS 
Patients 
We collected serum, nasal secretions and nasal polyp tissue of 42 nasal polyp patients (13 F/ 
29 M; mean age 42.6 years, range 22-78 years) during routine sinus surgery at the Department 
of Otorhinolaryngology at the Ghent University Hospital, Belgium. Bilateral polyposis was 
diagnosed based on history, clinical examination, nasal endoscopy, and sinus CT-scan. A 
history of asthma was reported in 18 nasal polyp patients, with nine subjects additionally 
demonstrating a history of aspirin sensitivity. Twenty-one patients were atopic, as indicated 
by positive coetaneous skin prick test responses to common aeroallergens. Subjects were 
excluded if they had received any steroids or antibiotics during the month before the surgery.  
Control serum, nasal secretions and nasal tissue (inferior turbinates) were obtained from 
twelve subjects during routine septal surgery. All control subjects (5 F/ 7 M; mean age 33.6 
years, range 18-71 years) were skin prick test negative, in generally good health, and none 
had a history of nasal or sinus disease, allergic disease (asthma, rhinitis or dermatitis), upper 
respiratory tract infection in the previous month, use of any intranasal medications, 
decongestants, antihistamines or oral steroids. The ethics committee of the Ghent University 
Hospital approved this study and a written informed consent was obtained from all subjects. 
 
IL-5Rα ELISA 
Production of monoclonal antibodies 
For the production of monoclonal antibodies (mAbs) against SOL IL-5Rα, Balb/C mice were 
immunized with 30µg Baculovirus-secreted human IL-5Rα in CFA/IFA. Monoclonal 
antibodies were generated by fusing spleen cells of these immunized mice with SP2/0 
myeloma cells. Stable hybridomas were obtained by screening on SOL IL-5Rα coated plates. 
Eleven hybridomas that produced specific antibodies against SOL IL-5Rα were selected and 
were classified into 4 complementation groups. All these hybridomas were grown under 
serum-free conditions. The supernatants were harvested and purified on Protein A Sepharose 
4 Fast Flow (Pharmacia, Uppsala, Sweden).  
Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. 
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Characterization of the monoclonal antibodies  
A chequer board experiment was set up whereby each mAb was cross-paired with the other 
mAbs in an ELISA format. Briefly, microtiter plates were coated with SOL IL-5Rα. For this, 
sub-saturating concentrations for each biotinylated antibody were determined first. Then 
competition between biotinylated and unlabeled antibodies for binding to coated SOL IL-5Rα 
was performed.  
FDC-P1-Cl7 originated by transfection of the FDC-P1 cell line to stably express the TM IL-
5Rα at high levels. Cells were incubated with mAbs at 2µg/ml, stained with Alexa488 
conjugated anti-mouse Ig (Molecular Probes, Leiden, The Netherlands) and analysed by 
FACS. Non-transfected FDC-P1 cells were used as a negative control. 
Development of an ELISA for soluble IL-5Rα 
Very careful assessment of antibody selection resulted in the development of several different 
ELISA’s. Based on background, sensitivity and reproducibility in human samples, a sandwich 
ELISA for SOL IL-5Rα detection was selected with combinations of mAbs from group 2 
(15B8) and 4 (1G3) (Innogenetics, Ghent, Belgium).  
Microtiter plates (Maxisorb, Nunc Denmark) were coated overnight with 1G3 at 2 µg/ml. The 
plates were washed once with washing buffer (PBS + 0.02% Tween20) and blocked for 30 
minutes with blocking buffer (PBS + 0.1% casein). The plates were incubated for 2h at room 
temperature on a shaker with the samples or standards diluted in blocking buffer. A cellular 
extract of COS cells transfected with IL-5Rα was used as standard. The concentration of the 
extract was determined with purified Baculo IL-5Rα as standard. After washing, the plates 
were incubated for 1h with the biotinylated mAb 15B8 at 0.5µg/ml in blocking buffer. The 
plates were washed and incubated for 30 minutes with HRP-conjugated streptavidin (Jackson, 
West Grove, Pennsylvania, US) at 100 ng/ml. After washing, the plates were incubated with 
TMB (Roche, Brussels, Belgium) in phosphate-citrate buffer at pH 4.3 for 30 minutes. The 
reaction was stopped by acidification and the plates were read at 450-620 nm.  
In vitro bioassay for hIL-5 
Ba/F3-hIL-5R-Luc originated by transfection of the Ba/F3 cell line to stably express the IL-
5Rα. Additionally, luciferase cDNA, driven by a constitutive CMV promoter, was co-
transfected and stably integrated into the cell line. Chemiluminescent luciferase detection 
correlated with proliferation that was dependent on the hIL-5 concentration. 
To evaluate the neutralizing capacity of the mAbs the cells were incubated with a low 
concentration of hIL-5 alone or together with a varying concentration of the mAbs. After 48 
Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. 
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hours of incubation, the cells were assayed for luciferase by chemiluminescence 
measurement. 
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Figure 1: Characterization of monoclonal 
antibodies and SOL IL-5Rα ELISA 
a) FACS analysis using mAb 1G3 in the 
upper – and 15B8 in the lower histogram. 
Open and filled curves represent control 
FDC-P1 and hIL-5Rα-expressing FDC-P1-
Cl7 cells, respectively.  
 
b) To exclude interference of IL-5 with the 
SOL IL-5Rα ELISA, standard curves (7.8 
to 500 pg/ml SOL IL-5Rα) were run in 
blocking buffer (PBS + 0.1% casein) in the 
absence () or presence of 250 pg/ml 
rhIL-5 (U). A similar experiment was 
carried out in serum that was diluted 1/5 in 
blocking buffer in the absence () or 
presence of 250 pg/ml rhIL-5 (S).  
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Characterization of the IL-5Rα ELISA 
The reproducibility of the SOL IL-5Rα ELISA was assessed in five different serum samples 
by serial testing (20 times). The recovery in the ELISA was determined by spiking 400 pg/ml 
of recombinant IL-5Rα in seven different serum samples. To exclude possible interference of 
IL-5 in ELISA for SOL IL-5Rα the standard curve (in blocking buffer; PBS + 0.1% casein) 
was run both with and without the addition of 250 pg/ml rhIL-5 (R&D Systems, Minneapolis, 
USA). A similar experiment was carried out on 5 different serum samples. All serum samples 
were diluted 1/5 in blocking buffer (PBS + 0.1% casein) and a 2-fold dilution series ranging 
from 500 pg/ml to 7.8 pg/ml SOL IL-5Rα was added. Further, blocking experiments were 
carried out on three serum and three tissue samples by pre-incubation with 2 µg/ml capture 
antibody (1G3) for two hours at 4°C. 
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Measurement of IL-5 Rα protein concentrations 
All freshly obtained samples were immediately processed, separated and stored in aliquots at 
– 80°C until analysis. Blood samples were allowed to clot at room temperature for 20-30 
minutes, centrifuged at 1500 g for 10 minutes at 4°C. Nasal secretions were obtained by 
placing sinus packs (IVALON® 4000 plus) in both nasal cavities for exactly 5 minutes. The 
quantity of secretions collected was determined by comparing the weight of the sinus pack 
before and after insertion. In order to mobilize the nasal secretions out of the sinus pack, three 
millilitres of 0.9% NaCl solution were added to the tube, which was stored at 4°C for two 
hours. The sinus pack was then placed into the shaft of a syringe (placed into another tube) 
and centrifuged at 1500 g for 10 minutes at 4°C to recover all fluid. Nasal tissue specimens 
were weighed, and 1 ml of 0.9% NaCl solution was added for every 0.1 g of tissue. The tissue 
was then homogenized with a mechanical homogeniser (B. Braun Melsungen, Germany) at 
1000 rpm for 5 minutes on ice as described previously 4;5. After homogenisation, the 
suspensions were centrifuged at 1500 g for 10 minutes at 4°C, and the supernatants separated 
and stored at – 80°C until analysis.  
All samples were assayed by a research ELISA for SOL IL-5Rα (described above, 
Innogenetics, Gent, Belgium) and IL-5 (R&D Systems, Minneapolis, USA). For comparison 
to an established marker, eosinophil cationic protein (ECP) (3) was measured by the Uni-CAP 
system (Pharmacia & Upjohn, Uppsala, Sweden). 
 
IL-5Rα Real Time PCR  
As a standard, we used PCR products generated from plasmids containing the cDNA 
sequences for SOL hIL-5Rα. The cDNA sequence of the SOL isoform was amplified using a 
forward primer complementary to a common sequence of hIL-5Rα (nts 1033 to 1056) and a 
SOL hIL-5Rα specific reverse primer (nts 1279 to 1298).  All primers were designed using 
the Primer Express 2.0 Software (Applied Biosystems, Foster City, US) and purchased from 
Invitrogen.  The PCR resulted in a unique band that was purified by using the PCR Gel 
extraction QIAquick (Qiagen, Hilden, Germany) spin columns. The purified fragments were 
quantified using PicoGreen reagent (Molecular Probes, Leiden, The Netherlands). Equimolar 
10-fold dilutions of the PCR products were used to generate standard curves.  
Measurement of SOL IL-5 Rα mRNA in blood and nasal tissue 
RNA was isolated from snap frozen blood and nasal tissue of 7 controls and 20 NP patients 
using the Rneasy Kit (Qiagen, Hilden, Germany). Total RNA was quantified using RiboGreen 
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Kit (Molecular Probes) and 0.5 µg was reverse transcribed using Superscript II 
Reverse Transcriptase (Invitrogen) and random hexamers (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). cDNA equivalent to 25 ng was used to perform the Real Time PCR. 
The Real Time amplifications were performed using the 1X SYBR Green I Mastermix 
(Qiagen, Hilden, Germany) and a set of primers including a common and a specific primer for 
SOL hIL-5 Rα. All the PCRs were performed in a 5700 SDS thermal cycler (Applied 
Biosystems, Foster City, US). Each sample was tested in duplicate. The quantity of each 
amplicon was calculated from the values of each standard curve and normalized by the 
quantities obtained for β-actin transcripts 14.   
 
Statistical analysis 
Data are expressed as median and interquartile range (IQR). When comparisons were made 
between groups, significant between-group variability was first established using Kruskal-
Wallis test. The Mann Whitney U-test was then used for between-group (unpaired) 
comparison. Spearman rank correlation coefficient (r) was used to assess the relationships 
between the parameters. The intra- and inter-assay precision was expressed as coefficient of 
variation (%CV). The ability of a test to discriminate diseased cases from normal cases was 
evaluated using Receiver Operating Characteristic (ROC) curve analysis. The cut-off values 
corresponding with the highest accuracy (minimal false negative and false positive results) 
were selected and the subsequent sensitivity and specificity were used. Further, comparison of 
ROC curves was performed to test the statistical significance difference between the areas 
under two ROC curves. P-values less than 0.05 were considered statistically significant. 
 
RESULTS 
IL-5Rα ELISA 
Careful assessment of antibody selection from different complementation groups resulted in 
several useful ELISA’s. Based on background, sensitivity and reproducibility in human 
samples, one sandwich ELISA consisting of two monoclonal antibodies (1G3/15B8biot) for 
detection of SOL IL-5Rα was selected.  
These antibodies were further characterized by FACS analysis and using an IL-5-specific 
bioassay. As shown in Figure 1a, strong staining of cells expressing the IL-5Rα is observed 
for both antibodies. In an in vitro bioassay on Ba/F3-hIL-5R-Luc cells, 15B8 was shown to 
neutralize IL-5 activity, whereas all other antibodies (including 1G3) were non-neutralizing. 
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Because 15B8 is a neutralizing antibody, the potential non-capture of an IL-5 occupied 
soluble receptor could bias the results of the ELISA. However, competition experiments 
between IL-5 and 15B8, analysed by FACS, revealed that at equimolar concentrations 15B8 
was able to chase IL-5 from its receptor, even when IL-5 was added 1 hour before 15B8. This 
indicates that the possibility to underestimate the level of receptor, in samples with IL-5 
present, is low or negligible, particularly when 15B8 is used as secondary antibody. 
Furthermore, standard curves in buffer and in human serum were not affected by addition of 
IL-5, excluding cross interference by endogenous IL-5 (Figure 1b). 
The established ELISA reached a sensitivity of 8 pg/ml for detection of SOL IL-5Rα. The 
intra-assay precision was assessed in five different serum samples by serial testing (20 times) 
in one run. The coefficient of variation (%CV) ranged from 3.1% to 7.0%. The inter-assay 
precision was determined in five different serum samples by determinations in 20 separate 
runs, resulting in a %CV of less than 10% and therefore acceptable. The average recovery - 
after addition of 400 pg/ml of recombinant SOL IL-5Rα in human serum - was 95% with a 
range between 83% and 103%. Addition of 2 µg/ml capture antibody (1G3) significantly 
blocked (86 to 97%) SOL IL-5Rα detection in human serum samples.  
SOL IL-5Rα protein expression is increased in nasal polyposis 
Analysis of SOL IL-5Rα, IL-5, and ECP in supernatants prepared from tissue homogenates 
demonstrated that the concentrations of these mediators were significantly higher in NP 
tissue, compared to normal control tissue (Table I). Within the NP group, there was a 
significant increase of SOL IL-5Rα in patients with concomitant asthma compared to patients 
without asthma. SOL IL-5Rα/IL-5 ratio’s were calculated in all NP samples and 3 to 1200 
times higher SOL IL-5Rα levels were present compared to IL-5 concentrations. Furthermore, 
within the NP group SOL IL-5Rα/IL-5 ratios were significantly higher in NP tissue with 
concomitant asthma (Figure 2a). Increased eosinophil percentages were found in NP tissue 
with and without concomitant asthma compared to control tissue (Table I). Assessment for 
any correlations between SOL IL-5Rα and eosinophilic markers demonstrated that in NP 
tissue, SOL IL-5Rα significantly correlated with concentrations of IL-5 (r = 0.405; p = 
0.006), ECP (r = 0.843; p < 0.001), and percentage of eosinophils (r = 0.536; p < 0.001). 
With nasal secretions we aimed to have a less invasive and easy to use technique in 
comparison with nasal biopsy to monitor SOL IL-5Rα concentrations. Within the nasal polyp 
group SOL IL-5Rα and ECP concentrations were higher in secretions of NP patients with 
asthma than those without asthma (Table I). Using 2341 pg/ml SOL IL-5Rα as best cut-off 
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value, the sensitivity was 83% and specificity was 100% for the differentiation of NP patients 
with or without asthma, whereas with a best cut-off value for ECP of 1546 µg/l, a sensitivity 
of 44% and specificity of 95% could be reached (Figure 3a). Comparison of areas under the 
ROC curves for SOL IL5Rα and ECP were significantly different in favour of SOL IL-5Rα 
(p = 0.023) (Figure 3b). A significant correlation between SOL IL-5Rα concentrations in 
nasal secretions and nasal tissue confirms that sampling of nasal secretions might be a 
valuable alternative for biopsies for SOL IL-5Rα monitoring (Figure 3c).  
In serum we found increased SOL IL-5Rα concentrations in NP patients with concomitant 
asthma compared to controls and NP patients without asthma (Table I). Whereas SOL IL-5Rα 
could be measured in all serum samples, IL-5 protein concentrations were only measurable in 
four subjects (all with concomitant asthma). SOL IL-5Rα concentrations correlated 
significantly (r = 0.595; p = 0.005) between serum and nasal tissue samples. 
 
 
Table I:  SOL IL-5Rα expression in nasal tissue and serum 
 
Nasal Tissue 
Controls  
(n=12) 
Median (± IQR) 
 
versus 
 
Nasal polyps 
(n=24) 
Median (± IQR) 
 
versus 
 
Nasal polyps & 
Asthma 
(n=18) 
Median (± IQR) 
 
versus 
controls 
 
Sol IL-5 Rα (pg/ml) 885 (43-301) p = 0.004 2496 (1244-7287) p < 0.001 26096 (17640-34287) p < 0.001 
IL-5 (pg/ml) All BDL p = 0.002 100 (43-301) p = 0.04 230 (112-420) p < 0.001 
Ratio Sol IL-5 Rα / IL-5 / / 21 (11-41) p = 0.002 95 (32-284) / 
ECP (µg/l) 220 (94-306) p < 0.001 3268 (856-7036) p < 0.001 15737 (11331-28544) p < 0.001 
Eosinophils (%) 0.3 (0-0.7) p = 0.001 5.3 (1.2-21.72) NS 20.7 (8.7-24.6) p < 0.001 
Nasal Secretion       
Sol IL-5 Rα (pg/ml) 519 (301-595) p = 0.07 667 (430-1135) p < 0.001 7568 (3389-12869) p < 0.001 
IL-5 (pg/ml) All BDL / 15/24 BDL NS 118,72 (30-172) p = 0.006 
ECP (µg/l) 139 (45-300) p = 0.03 516 (200-853)  p = 0.02 1064 (389-2243) p < 0.001 
Serum       
Sol IL-5 Rα (pg/ml) 286 (237-426) NS 369 (282-562) p = 0.01 759 (475-1030) p = 0.005 
ECP (µg/l) 12 (11-16) NS 25 (18-29)  NS 43 (23-65) p = 0.008 
Eosinophils (%) 0.9 (0.4-1.8) p = 0.002 4.8 (2.6-7.1) p = 0.007 9.4 (6.8-16.9) p < 0.001 
Median and interquartile ranges (IQR) of SOL IL-5Rα, IL-5, ECP concentrations and eosinophil percentages are compared in nasal tissue, 
nasal secretions and serum of controls and nasal polyp patients with or without asthma. BDL= Below detection level. NS=Not significant. 
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SOL IL-5Rα mRNA Real-Time PCR 
 Analysis of peripheral blood and nasal tissue samples revealed that relative amounts of SOL 
IL-5Rα isoform (copies of mRNA/µl), were significantly higher in samples of patients with 
NP compared to controls. Within the NP group, there was a significant increase of SOL IL-
5Rα mRNA in NP tissue from patients with concomitant asthma compared to patients without 
asthma. A similar tendency was observed for SOL IL-5Rα in peripheral blood (Figure 4). 
There was a significant correlation between SOL IL-5Rα in peripheral blood and nasal tissue 
(r = 0.668; p = 0.006). Assessment for any correlations between SOL IL-5Rα mRNA isoform 
expression and eosinophilic markers demonstrated that relative amounts of SOL IL-5Rα 
mRNA were significantly correlated with protein concentrations of IL-5 (r = 0.619; p = 
0.002), SOL IL-5Rα (r = 0.659; p = 0.001), ECP (r = 0.617; p = 0.003), and the percentage of 
eosinophils (r = 0.779; p < 0.001) in nasal tissue. In peripheral blood samples, relative 
amounts of SOL IL-5Rα mRNA were correlated to ECP (r = 0.604; p = 0.02) and percentage 
of eosinophils (r = 0.761; p=0.001), but not to SOL IL-5Rα serum concentrations.  
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 in nasal polyp tissue 
Concentrations of SOL IL-5 Rα, IL-5 and SOL IL-
5 Rα/IL-5 in nasal tissue homogenates of 15 
controls(C), 24 nasal polyps (NP) and 18 nasal 
polyp patients with concomitant asthma 
(NP+Asth). The Box-and-whisker plot represents 
the median, the lower to upper quartile, and the 
minimum to the maximum value, excluding "far 
out" values. Statistical analyses were performed 
using the Mann Whitney U-test and p-values less 
than 0.05 were considered statistically significant 
(NS = not significant).   alpha expression in nasal polyposis. 
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DISCUSSION: 
This paper demonstrates human SOL IL-5Rα protein in clinical samples such as serum, nasal 
secretion and tissue homogenates. So far, only expression of the murine SOL IL-5Rα protein 
could be demonstrated in sera and ascitic fluids of mice bearing chronic B-cell leukaemia 15. 
We have established a sensitive, specific and reliable ELISA that enables determination of 
SOL IL-5Rα concentrations in various human body fluids such as serum, nasal secretions, 
urine, and peritoneal fluid (not all data shown). In human serum, the SOL IL-5Rα protein is 
detectable in all samples with a median concentration of 210 pg/ml in healthy controls. 
Notably, we found that the SOL IL-5Rα was up-regulated in samples from patients with nasal 
polyposis. These findings were confirmed at the mRNA level, using an optimised real-time 
RT-PCR procedure.  
Nasal polyposis is an excellent model for eosinophil-associated diseases and is often 
associated with asthma and/or aspirin sensitivity. IL-5 can be detected at the mRNA as well 
as at the protein level in high amounts by immunohistochemistry and by in situ hybridisation, 
and could be co-localized to eosinophils 3. Highest levels of IL-5 protein were observed in 
polyp homogenates of patients with generalized eosinophilic diseases such as asthma and 
aspirin sensitivity 2;4;5. Our data now reveal that SOL IL-5Rα mRNA and protein are up-
regulated in nasal polyposis and are correlated with eosinophil counts, ECP and IL-5 
concentrations. In addition, SOL IL-5Rα levels in nasal tissue or blood of NP patients are up-
regulated and related to the extension of disease, more specifically with the involvement of 
local (NP) or systemic airway disease (NP with concomitant asthma). With the collection of 
nasal secretion we aimed to have a less invasive and easy to use technique in comparison to 
the nasal biopsy to determine SOL IL-5 Rα concentrations. In nasal secretion, SOL IL-5 Rα 
concentrations were well detectable and there was a strong correlation to the SOL IL-5 Rα 
concentrations in nasal tissue confirming that collection of nasal secretion is a valuable 
alternative for biopsies. Furthermore, ROC curve analysis demonstrates that SOL IL-5 Rα in 
nasal secretion seems to be a superior marker than an established marker such as ECP for the 
differentiation of NP patients with or without asthma. Taken together, our results indicate 
that the measurement of SOL IL-5Rα in serum and nasal secretion can be used for 
objectively monitoring severity of nasal polyposis, and may offer an attractive alternative for 
currently used clinical scoring parameters.  
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Figure 3:  SOL IL-5Rα protein expression in nasal secretions 
A) Concentrations of SOL IL-5 Rα and ECP in nasal secretions of 24 nasal polyps (NP) and 18 nasal polyp 
patients with concomitant asthma (NP+Asth). The mentioned cut-off values are selected corresponding with the 
highest accuracy (minimal false negative and false positive results). B) Comparison of ROC curves of SOL IL-
5Rα and ECP in the differentiation between nasal polyps with or without concomitant asthma. The statistical 
significance difference between the areas under the ROC curves was tested and p-values less than 0.05 were 
considered statistically significant. C) Correlation between SOL IL-5Rα concentrations in nasal secretions and 
nasal tissue confirms that sampling of nasal secretions might be a valuable alternative for biopsies SOL IL-5Rα 
monitoring. 
 
We demonstrate abundant SOL IL-5Rα expression in NP with concomitant asthma often 
dramatically exceeding the IL-5 concentrations. Indeed, in nasal tissue SOL IL-5Rα levels up 
to 1200 times higher than IL-5 concentrations can be found. It therefore appears that in the 
most severe disease manifestations, a regulatory system may operate to antagonize the 
ongoing eosinophilic inflammation by the synthesis of SOL IL-5Rα. It has been shown that 
differential splicing of the IL-5Rα gene can generate different mRNA isoforms: a signaling 
competent membrane-anchored TM IL-5Rα isoform, and at least one secreted variant (SOL 
IL-5Rα). The expression of the latter depends on the utilization of a specific exon, leading to 
the loss of the membrane anchor. When expressed in heterologous cells, this SOL IL-5Rα 
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protein shows receptor antagonist activity in vitro 6;11;16;17. However, the precise in vivo role 
of the SOL IL-5Rα protein requires more detailed study. Secreted receptor variants are a 
hallmark of the receptor family to which the IL-5Rα belongs. This mere evolutionary 
conservation underscores their functional importance, but the precise physiological role may 
differ from case to case. Models in which the antagonistic effects prevail include surface 
receptor down-modulation and ligand capture. On the other hand, secreted receptors may bind 
their ligands in circulation, protecting them from proteolytic inactivation and prolonging their 
serum half-life or facilitating ligand-mediated signaling. The SOL IL-5Rα protein has 
antagonistic properties in vitro as demonstrated in eosinophil differentiation assays as well as 
in proliferation assays using IL-5 responsive cell lines 11;18. It captures IL-5 in solution, but 
this IL-5/IL-5Rα complex is unable to associate and activate membrane bound βc chains 6. 
Recently, the antagonistic effect of recombinant SOL IL-5Rα has been demonstrated on nasal 
tissue explants. Culturing tissue with recombinant SOL IL-5Rα almost completely attenuated 
the ragweed-induced decrease in eosinophil precursors and increase in MBP-immunoreactive 
cell numbers 13. This observation suggests that endogenous production of soluble receptor 
may regulate IL-5 function in vivo. However, the observed correlation between SOL IL-5Rα 
levels and disease severity questions the antagonistic role for the SOL IL-5Rα in vivo. 
A number of protein-based IL-5 antagonists have been reported, including SOL IL-5Rα that 
sequesters the ligand in solution 18, single point mutants of IL-5 that occupy the receptor but 
fail to initiate receptor activation 7;19, and neutralizing antibodies directed against IL-5 20. 
Treatment of eosinophil-infiltrated polyp tissue with neutralizing anti-IL-5 monoclonal 
antibody (mAB) resulted in eosinophil apoptosis and decreased tissue eosinophilia in vitro 21. 
In a monkey model of Ascaris-allergic asthma, Egan and coworkers could abolish 
inflammatory cell migration and airway hyperreactivity for up to three months by treating the 
monkeys with a single dose of the SCH55700 (Reslizumab) neutralizing humanized 
monoclonal antibody against hIL-5 22. Similar anti-IL-5 treatment in humans, however, failed 
to demonstrate clinical efficacy in two independent studies. A single-dose phase I clinical trial 
was conducted with SCH55700 in patients with severe persistent asthma and demonstrated a 
significant decrease in peripheral blood eosinophils (lasting up to 90 days) and a trend 
towards improvement in lung function at the higher doses (30 days after dosing) 23. SB240563 
(Mepolizumab) was tested in mild asthmatics and caused a significant reduction in peripheral 
blood eosinophils and in postchallenge sputum eosinophils but did not alter FEV1 values upon 
allergen challenge 1.  
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Figure 4:  SOL IL-5Rα mRNA expression (real-time PCR) 
Relative amounts of SOL hIL-5Rα / β-actin (copies mRNA/µL) in nasal tissue (a) and in peripheral blood (b) of 
7 controls(C), 10 nasal polyps (NP) and 9 nasal polyp patients with concomitant asthma (NP+Asth). Statistical 
analyses performed using the Mann Whitney U-test (NS = not significant).  
 
Our findings suggest that high amounts of SOL IL-5Rα may not be capable of controlling 
eosinophilia in vivo. In line with this, antagonizing IL-5 activity in patients with humanized 
anti-IL-5 mABs was largely unsuccessful. Completely blocking IL-5 activity in vivo therefore 
appears to be much more difficult than in vitro. Perhaps, the local tissue microenvironment, 
and/or the existence of IL-5-dependent autocrine activation mechanisms 3,21 may limit in vivo 
antagonism 2. A reassessment of the in vivo role of the SOL IL-5Rα may therefore help to 
understand recent findings in anti-IL5 treatment. Accurate measurement of SOL IL-5Rα 
levels may distinguish responders from non-responders, or help in the titration of anti-IL-5 
doses. Assessment of endogeneous SOL IL-5Rα levels might then be considered as a tool for 
management of anti-IL-5 therapy. With reliable methods now in place to monitor SOL IL-
5Rα protein and mRNA expression, detailed studies of the mechanisms controlling IL-5 
activity under normal conditions and in eosinophil-associated diseases can now be performed.  
 
CONCLUSION: 
This report demonstrates the presence of the SOL IL-5Rα transcript and protein in various 
human samples including serum, nasal secretion and nasal tissue homogenates. SOL IL-5Rα 
is up-regulated in nasal polyposis and differentiates nasal polyps with or without concomitant 
asthma. Since SOL IL-5Rα is strongly up-regulated for disease and has antagonistic 
properties in vitro, our studies shed new light into the mechanisms of specific immuno-
modulatory therapies, such as anti-IL-5. 
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Cauwenberge P,  Tavernier J, Bachert C; Submitted 2003. 
 
SUMMARY  
Regulated alternative splicing of the IL-5Rα-subunit results in a signaling, transmembrane 
(TM) isoform, or a soluble (SOL). We examined SOL and TM-IL-5Rα expression and 
regulation at both protein and transcript level in vitro and in vivo by FACS, ELISA and real-
time PCR. SOL and TM-IL-5Rα protein and mRNA expression were significantly increased 
in peripheral blood and nasal tissue from nasal polyp (NP) patients versus control subjects. In 
polyp tissue, SOL-IL-5Rα expression correlated to disease severity and eosinophil 
percentages, whereas TM-IL-5Rα levels were inversely correlated to eosinophils and SOL-
IL-5Rα expression. Tissue eosinophils are activated (increased CD69) and show a decreased 
TM-IL-5Rα expression compared to blood eosinophils. Human blood eosinophils were 
incubated with IL-5 for 2 and 24 hours, which caused a significant down-regulation of TM-
IL-5Rα mRNA and protein, and up-regulation of SOL-IL-5Rα protein. In a hIL-5-driven 
proliferation assay, SOL-IL-5Rα proved to be antagonistic only in very high quantities and 
therefore the endogenous concentrations might be insufficient to block IL-5 activity.  This 
report demonstrates that expression of SOL and TM-IL-5Rα differs according to the 
eosinophil activation state and localization in the body and may therefore be involved in the 
fine-tuning of the eosinophil homeostasis. 
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INTRODUCTION 
Interleukin 5 (IL-5) plays a central role in an eosinophil’s life span: it supports 
eosinophilopoiesis and eosinophil differentiation, contributes to eosinophil migration, tissue 
localization and function, and prevents eosinophil apoptosis1;2. Given the likely role of 
eosinophils in chronic inflammatory diseases, recent research focused at antagonizing the IL-
5 function. It appears from recent studies that, although this can easily be achieved in vitro3;4, 
blocking IL-5 function in vivo is much more difficult than originally anticipated5;6. Flood-
Page and coworkers observed a significant differential effect of IL-5 blockade on eosinophil 
counts in various body compartments7. After multiple dosing with mepolizumab, there was a 
100% median reduction in eosinophils in blood, 79% in bronchoalveolar lavage, but only a 
52% in the bone marrow and a 55% decrease in the bronchial mucosa7. The exact reason for a 
different effect of anti-IL-5 in different body compartments is unclear, but recent data 
indicated varying IL-5 sensitivity and IL-5 receptor expression at different stages of the cell’s 
maturation and localization8. 
The interleukin 5 receptor (IL-5R) is a complex consisting of two chains 9. The α-chain is 
ligand-specific and binds IL-5 with intermediate affinity (Kd of 500 pM). Association with 
the βc-chain leads to a high affinity receptor complex (Kd of approximately 150 pM). The βc-
chain does not bind IL-5 by itself but provides the major determinants for signaling and is 
shared with the receptors for IL-3 and GM-CSF, which also have their own ligand-specific α-
subunits. In contrast to the pan-haemopoietic βc-chain, the IL-5Rα receptor seems to be 
expressed on a restricted range of cell types in humans, principally eosinophils, basophils, and 
their precursors. However, recent publications have demonstrated eosinophil-independent 
airway hyperresponsiveness and IL-5Rα gene expression in human bronchus smooth muscle 
10;11. 
Regulated alternative splicing of the IL-5Rα-subunit leads to the generation of either a 
signaling, membrane-anchored (TM) isoform, or a soluble (SOL) variant with antagonistic 
properties in vitro 9;12. It is suggested that eosinophils are able to control their responsiveness 
to IL-5 by regulated expression of the IL-5Rα isoforms. However, this regulated expression 
may change during eosinophil differentiation, maturation and localization. On CD34+ 
progenitor cells, it has been demonstrated that IL-5 induces a switch from predominantly SOL 
isoform to TM-IL-5Rα mRNA expression at the splicing level 13. In mature blood 
eosinophils, IL-5, IL-3 and GM-CSF down-regulate IL-5Rα mRNA in a dose dependent 
manner at the promoter level 14. Liu and coworkers showed that IL-5 receptor expression on 
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airway eosinophils is down-modulated in vivo after inhaled allergen challenge and that this 
may be due to cleavage by membrane-associated metalloproteinases15;16. In addition, Gregory 
and coworkers have demonstrated that exposure of blood eosinophils to IL-3, IL-5, or 
granulocyte-macrophage colony-stimulating factor in vitro leads to sustained down regulation 
of surface IL-5Rα expression and reduced responsiveness to IL-5, but without sustained 
changes in CCR3 expression17. We have previously demonstrated that the TM-IL-5Rα is 
down-regulated on eosinophils in peritoneal dialysis fluid, as compared to blood eosinophils, 
from patients with peritoneal fluid eosinophilia18, whereas SOL-IL-5Rα concentrations were 
up-regulated (unpublished data). This indicates that IL-5Rα isoforms on mature eosinophils 
can be dynamically regulated at the extra-vascular site. However, all data are based on tissue-
dwelt eosinophils (BAL eosinophils and peritoneal fluid eosinophils) which may have 
different properties compared to resident tissue eosinophils. Recently, we demonstrated an 
up-regulation of SOL-IL-5Rα protein in serum and nasal polyp tissue19. We hypothesize that 
the expression of the IL-5Rα isoforms may be different depending on eosinophil activation 
state, maturation and localization. 
Taken these observations into account, we sought to study SOL and TM-IL-5Rα proteins and 
transcripts in blood and in tissue eosinophilia. Therefore a real-time PCR, FACS and ELISA 
were established to determine IL-5Rα isoform expression in peripheral blood and nasal tissue 
from control subjects and nasal polyp (NP) patients. Furthermore, we aimed to investigate 
whether in vitro stimulation of peripheral blood eosinophils with IL-5 could regulate the IL-
5Rα isoform expression similar to the expression found in tissue eosinophils and its relation 
to membrane type-1 matrix metalloproteinases (MT1-MMP or MMP-14). Finally, the 
biological activity of SOL-IL-5Rα in an hIL-5-driven proliferation assay was to be tested.  
 
RESULTS 
SOL and TM-IL-5Rα protein expression in blood and tissue  
We found increased median (IQR) concentrations of SOL-IL-5Rα in serum from 17 NP 
patients with concomitant asthma (778 pg/ml; 501-1191) compared to 16 controls (285 pg/ml; 
226-465; p = 0.009) and 17 NP patients without asthma (328 pg/ml; 272-448; p < 0.001). 
Whereas SOL-IL-5Rα could be measured in all serum samples, IL-5 protein concentrations 
were only measurable in four subjects (all with concomitant asthma). In controls the median 
percentage of blood eosinophils was 1.2% (0.5-2.5), whereas increased percentages were 
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found in NP (3.6%; 2.5-5.9; p = 0.02) and NP with asthma (9.7%; 6.9-19.5; p < 0.001), with a 
significant difference between the NP groups (p < 0.001).   
In supernatants prepared from nasal tissue homogenates median (IQR), concentrations of 
SOL-IL-5Rα were significantly higher in NP (1504 pg/ml; 1037-3757; p = 0.04) and NP with 
concomitant asthma (21069 pg/ml; 13177-29784; p < 0.001) compared to control nasal tissue 
(919 pg/ml; 735-1416). Whereas IL-5 was not detectable in control nasal tissue, increased IL-
5 concentrations were found in NP tissue of patients without (56 pg/ml; 43-197; p=0.03) and 
with concomitant asthma (244 pg/ml; 107-367; p=0.002). Within the NP group, there was a 
significant further increase of SOL-IL-5Rα (p < 0.001) and IL-5 (p = 0.01) in patients with 
concomitant asthma compared to patients without asthma. Increased eosinophil percentages 
were found in NP tissue with (11.3%; 8.1-25.7; p < 0.001) and without concomitant asthma 
(2.4%; 1.2-5.8; p = 0.006) compared to control tissue (0.2%; 0.1-0.5). Moreover, in NP tissue, 
SOL-IL-5Rα significantly correlated with concentrations of IL-5 (r = 0.500; p = 0.02), and 
percentage of eosinophils (r = 0.589; p = 0.003). 
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Figure 1: TM-IL-5Rα and 
CD69 (eosinophil activation
marker) expression was
evaluated by FACS analysis in
blood and in tissue of twelve
NP patients. The results are
presented as the proportion of
TM-IL-5Rα (filled symbols)
and CD69 (open symbols)
positive eosinophils. Statistical
analyses were performed using
the Wilcoxon test. 
 
When peripheral blood and polyp tissue cells were analyzed by flow cytometry the proportion 
of TM-IL-5Rα positive eosinophils was significantly (p=0.003) lower in polyp tissue 
eosinophils, 6.1 % (1.3-10.4) when compared to peripheral blood eosinophils, 72.6 % (60.6-
86.4) (n=11). The proportion of CD69 positive eosinophils was significantly (p=0.018) up 
regulated on polyp tissue eosinophils, 63.9 % (63.0-78.4), as compared to peripheral blood 
eosinophils, 2.7 % (1.9-3.6) (Figure 1). 
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SOL and TM-IL-5Rα mRNA expression in blood and tissue 
Analysis of peripheral blood and nasal tissue samples with quantitative real-time PCR 
revealed that relative amounts of SOL and TM-IL-5Rα isoforms (copies of mRNA/µl) were 
significantly higher in samples of patients with NP compared to controls. Within the NP 
group, SOL and TM-IL-5Rα mRNA levels were increased in peripheral blood of patients 
with concomitant asthma compared to patients without asthma (Figure 2a). In NP tissue of 
patients with asthma the SOL-IL-5Rα mRNA was significantly increased whereas the TM-
IL-5Rα mRNA was significantly decreased when compared to NP patients without asthma 
(Figure 2b). The median SOL/TM ratio in blood was 1.6 (1.3-1.8) with no significant 
differences between groups. In control and NP tissue of non-asthmatics, the median SOL/TM 
ratio was 0.32 (0.21-0.44) and 0.33 (0.23-0.43) respectively, which was significantly lower 
(both p < 0.001) than the SOL/TM ratio’s in NP tissue of patients with asthma 1.12 (0.89-
1.63). There were no differences in relative expression of MMP-14 mRNA (β-actin corrected) 
in peripheral blood (8.3x10-6; 5.7x10-6 - 10.3x10-6) and nasal tissue samples (2.0x10-3; 1.5x10-
3 - 2.9x10-3) of controls and NP patients. In peripheral blood samples of NP patients, relative 
amounts of SOL and TM-IL-5Rα mRNA were significantly correlated to eosinophil 
percentages (Figure 2a). In polyp tissue, protein concentrations of IL-5, SOL-IL-5Rα, and 
eosinophil percentages correlated positively to SOL-IL-5Rα, but inversely to TM-IL-5Rα 
mRNA expression (Figure 2b).  
SOL and TM-IL-5Rα protein expression after in vitro stimulation with rh IL-5 
Purified eosinophils from seven healthy blood donors were incubated with rh IL-5 for 2 and 
24 hours. Flow cytometric analysis showed that rh IL-5 induced a significant (p=0.018 for all) 
down-regulation in the proportion of TM-IL-5Rα positive eosinophils at 2 hours, 37.5 % 
(27.4-61.8) and 24 hours, 13.9 % (8.8-22.0) as compared to the RPMI controls, 78.3 % (68.1-
86.0) and 55.0 % (46.9-62.3), respectively (Figure 3a). The SOL-IL-5Rα concentrations in 
the supernatants were significantly higher after incubation with rh IL-5 compared to RPMI 
controls at 2 hours (p=0.002) and 24 hours (p=0.03) (Figure 3b). SOL and TM-IL-5Rα 
protein expression correlated negatively at 24 hours (r= -0.612; p=0.03). 
SOL and TM-IL-5Rα mRNA expression after in vitro stimulation with rh IL-5 
Stimulation of blood eosinophils with rh IL-5 resulted in a significant decrease in TM-IL-5Rα 
mRNA expression after 2 and 24 hours compared to baseline, which is at both time points 
significantly lower when compared to the RPMI controls (Figure 3c). SOL-IL-5Rα mRNA 
expression decreased significantly after 2 and 24 hours, without difference between rh IL-5 
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incubation and RPMI controls (Figure 3d). Since IL-5Rα cleavage by membrane-associated 
metalloproteinases was suggested, we investigated the relation to MMP-14 expression. There 
was no difference in relative MMP-14 mRNA expression (β-actin corrected) between 
different time points or between stimulation with rh IL-5 and RPMI controls. MMP-14 
expression was positively correlated with SOL-IL-5Rα (protein & mRNA) (r=0.354; p>0.05 
& r=0.786; p=0.005) and TM-IL-5Rα mRNA expression (r=0.638; p=0.02), whereas a 
negative correlation was shown with TM-IL-5Rα surface expression (r= -0.750; p=0.007).  
Biological activity analysis of SOL-IL-5Rα on FDC-P1-CA1 cells 
The biological role of SOL-IL-5Rα is still uncertain, therefore we analyzed the behavior of 
SOL-IL-5Rα in the hIL-5-driven FDC-P1-CA1 proliferation assay20;21. At physiologic 
concentrations of hIL-5 (here 10 pg/ml), SOL-IL-5Rα was able to neutralize the hIL-5 
induced growth of FDC-P1-CA1 cells only at high concentrations (> 500 ng/ml) (Figure 4). 
This implicates that at least 18500 times more SOL-IL-5Rα than IL-5 is needed to block its 
activity in this assay system.  
 
DISCUSSION 
Our results demonstrate differential expression of IL-5Rα isoforms in blood and tissue 
eosinophils. In blood, SOL and TM-IL-5Rα mRNA and protein expression is up regulated in 
NP versus controls and correlated to eosinophil percentages, whereas in polyp tissue TM-IL-
5Rα levels showed an inverse relation to eosinophilia and SOL-IL-5Rα expression. Blood 
eosinophils express high levels of surface-anchored TM-IL-5Rα and are not activated as 
judged by a low CD69 expression. In contrast, tissue eosinophils are activated and 
demonstrate a low level of surface receptors to IL-5. These results extend studies in mice 
showing that tissue eosinophils have a low or undetectable expression of TM-IL-5Rα 22, and 
recent studies on human peritoneal fluid 18 and BAL fluid eosinophils 16 that indirectly 
suggest a low expression of TM-IL-5Rα in tissue versus blood eosinophils.  
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Figure 2: Relative amounts of SOL and TM hIL-5Rα / β-actin (copies mRNA/µL) were determined by a isoform 
specific real-time PCR in peripheral blood (A) and in nasal tissue (B) of 16 controls (C), 17 nasal polyps (NP) 
and 17 nasal polyp patients with concomitant asthma (NP+Asth). The Box-and-whisker plot represents the 
median, the lower to upper quartile, and the minimum to the maximum value, excluding "far out" values. 
Statistical analyses were performed using the Mann Whitney U-test (ns = not significant). Spearman rank 
correlation coefficient (r) was used to assess the relationships between the parameters.   
Regulated interleukin 5 receptor α isoform expression in blood and tissue eosinophils. 
142
Chapter 8 
 
 
SOL and TM IL-5Rα /β-actin (copies mRNA) in nasal tissue 
C          NP       NP+Ast                C          NP       NP+Ast 
       SOL IL-5Rα                                   TM IL-5Rα  
C
op
ie
s 
m
R
N
A
 / 
β-
ac
tin
 
0,005
0,004
0,003
0,002
0,001
0
p < 0,001  
p <  0,001  p =  0,002  
ns  
p <  0,001  p <  0,001  
(B) 
 
 
 
 
0 0,0001 0,001 0,01
SOL IL-5Rα / β-actin (copies mRNA) 
100 
10 
1 
0,1 
0,01 
Ti
ss
ue
 e
os
in
op
hi
ls
 (%
) 
0,0001 0,001 0,01
TM IL-5Rα / β-actin (copies mRNA) 
100
10
1
0,1
0,01
Ti
ss
ue
 e
os
in
op
hi
ls
 (%
) 
r = 0,634 
p = 0,002 
 
r = - 0,521 
p = 0,008 
 
 
 
Figure 2 (Continued) Relative amounts of SOL and TM hIL-5Rα / β-actin (copies mRNA/µL) were determined 
by a isoform specific real-time PCR in in nasal tissue (B). 
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Also, Liu et al. demonstrated that following airway antigen challenge of atopic subjects, BAL 
fluid eosinophils showed a markedly reduced TM-IL-5Rα and βc-chain mRNA and did not 
release EDN when exposed ex vivo to IL-5 compared with circulating eosinophils16.  
Nasal polyposis is an excellent model for eosinophil-associated diseases, since 80 to 90% of 
bilateral nasal polyps are characterized by abundant eosinophilic infiltration. Nasal polyps are 
swellings of the lamina propria mucosa, a pathology that is frequently associated with asthma. 
Especially in nasal polyp patients with concomitant asthma the highest levels of IL-5 and 
eosinophil counts are reported 23;24. In this report we show that the SOL-IL-5Rα expression is 
increased whereas the TM-IL-5Rα mRNA expression is decreased in NP tissue of patients 
with asthma compared to those without asthma. Furthermore, TM-IL-5Rα mRNA is inversely 
correlated to protein levels of IL-5, SOL-IL-5Rα and the proportion of eosinophils. This 
suggests TM-IL-5Rα mRNA tissue expression is down regulated independently of eosinophil 
counts and this further supports the finding that tissue eosinophils have a low IL-5Rα surface 
expression. Hence, in tissue with the highest levels of IL-5 and eosinophils, a regulatory 
mechanism must operate to control the ongoing eosinophilic inflammation by up-regulation 
of SOL-IL-5Rα and down-regulation of TM-IL-5Rα. Taken together, our results suggest that 
the expression of the IL-5Rα isoforms differs according to the eosinophil activation state, 
maturation and localization in the body. 
It has been shown that differential splicing of the IL-5Rα gene can generate different mRNA 
isoforms: a signaling competent membrane-anchored TM-IL-5Rα isoform, and at least one 
secreted variant (SOL-IL-5Rα) 9;12. The expression of the latter depends on the utilization of a 
specific exon, leading to the loss of the membrane anchor. In human umbilical cord blood 
derived CD34 cells, a transient switch at the alternative splicing level from predominantly 
soluble isoform to TM-IL-5Rα messenger RNA (mRNA) expression was found during IL-5-
driven eosinophil development 13. This was accompanied by surface expression of IL-5Rα 
and acquisition of functional responses to IL-5. These data provide an explanation for the 
selective requirement of IL-5 for expansion of the eosinophil lineage within the bone marrow.  
In contrast, in mature human blood eosinophils Wang et al. demonstrated that IL-5, IL-3 and 
GM-CSF down-regulate IL-5Rα mRNA while up-regulating IL-3Rα, GM-CSFRα, and β-
chain mRNA. This cytokine-induced inhibition of IL-5Rα mRNA accumulation occurs at the 
IL-5Rα promoter level 14.  
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Figure 3: Purified eosinophils from seven healthy blood donors were incubated with 10ng/ml rh IL-5 for 2 and 
24 hours (RPMI+IL-5; full line). As control, eosinophils were incubated in RPMI alone (RPMI; dotted line). 
TM-IL-5Rα positive eosinophils (%) determined by FACS analysis (A); SOL-IL-5Rα(pg/ml) concentrations in 
supernatants determined by ELISA (B); TM-IL-5Rα/β-actin (C) and SOL-IL-5Rα/β-actin (copies mRNA) 
expression detremined by real-time PCR (D). The lines represent the median and the lower to upper quartile (*, 
p < 0.05). 
 
Recently, Hellman et al. demonstrated that surface TM-IL-5Rα was strongly down-regulated 
by recombinant IL-5, intermediately with both IL-5 and GM-CSF, and weakly with only GM-
CSF, suggesting that GM-CSF binding partially inhibits the surface IL-5 receptor to be down 
modulated25. Furthermore, the proportion of CD69 positive eosinophils was significantly up-
regulated to the same level by IL-5, GM-CSF as well as by the combination of both cytokines, 
which indicate that activation ofeosinophils, judged by CD69 up-regulation, is not mandatory 
linked to TM-IL-5Rα down-regulation. In the present study we show that freshly isolated 
mature human blood eosinophils express more SOL than TM-IL-5Rα mRNA expression. In 
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vitro exposure of mature human blood eosinophils with rh IL-5 for 2 and 24 hours induces an 
extensive down-regulation of IL-5Rα TM protein and mRNA, whereas SOL-IL-5Rα was 
only significantly up-regulated at the protein level. In contrast to Liu et al. 15 we demonstrated 
a significant down-regulation of the TM-IL-5Rα specific transcripts probably because of the 
higher statistical power (seven experiments versus three). Furthermore, they demonstrated 
that the down-modulation of TM-IL-5Rα from the cell surface and the increased release of 
SOL-IL-5Rα into culture supernatant fluid were partially inhibited by the MMP-specific 
inhibitor BB-94 15. These data suggest that exposure of peripheral blood eosinophils to IL-5 
results in a rapid, sustained loss of TM-IL-5Rα that is, at least in part, dependent on MMP 
activity. Furthermore, we recently demonstrated increased levels of MMP-7, MMP-9 and 
TIMP-1 in nasal polyp tissue compared to controls26. However, since TIMP-3, but neither 
TIMP-1 nor TIMP-2, inhibited the action of the proteinase activity on IL-5 receptor 
modulation, it is suggested that the responsible enzyme may be a membrane-associated 
metalloproteinase15. Although the expression membrane type-1 MMP (MT1-MMP or MMP-
14) is not different in polyps and controls and is not influenced by IL-5 stimulation of 
eosinophils, we found a significant inverse correlation between MMP-14 and IL-5Rα surface 
expression, which suggests a role in proteolytic cleavage of the receptor. Taken all 
observations into account we suggest that an IL-5 driven inflammation generates an 
eosinophil tissue phenotype that is characterized by a low TM but high SOL-IL-5Rα 
expression and that this process is partially the result of proteolytic receptor modulation and 
down-regulation of TM-IL-5Rα gene transcription.  
Undoubtedly, a primary role of IL-5 in eosinophil hemopoiesis and recruitment from the bone 
marrow is widely accepted, however its local role in inflamed tissue is much less clear. 
Eosinophils leave the bone marrow with a so-called “non-primed” phenotype that is refractory 
to activation. Upon interaction with IL-5 and other cytokines / chemokines these cells become 
prone for activation by physiologically relevant activators. Virtually all eosinophil responses 
are under control of this priming mechanism which acts as a safety lock preventing specific 
activation of this highly cytotoxic cell. The local tissue environment typically shows the 
highest levels of IL-5, providing sufficient levels of IL-5 into the bone marrow for selective 
expansion of the eosinophil lineage. Therefore it is not surprising to find an IL-5-dependent 
differential expression of the IL-5Rα isoforms according to the eosinophil activation state, 
maturation and localization in the body. Despite drastic reduction of TM-IL-5Rα expression, 
tissue eosinophils are activated and have a prolonged survival, suggesting that only a limited 
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number of receptors are sufficient for an IL-5 response. Furthermore, our data on the 
biological activity of SOL-IL-5Rα in a hIL-5-driven FDC-P1-CA1 proliferation assay suggest 
that only an excess of SOL-IL-5Rα (18500 times) compared to IL-5 can block its activity, 
whereas only limited amounts (0.3 times) of a humanized anti-IL-5 monoclonal antibody 
(SCH55700) are necessary to antagonize IL-5 activity (own data).  Indeed, the median 
concentration of SOL-IL-5Rα in nasal polyp tissue is 21069 pg/ml and can be up to 1200 
times higher than local IL-5 concentrations. Cameron and coworkers demonstrated that 
recombinant SOL-IL-5Rα in high concentrations of 5 µg/ml had antagonistic properties in 
nasal tissue explants since it almost completely attenuated the ragweed-induced decrease in 
eosinophil precursors and increase in MBP-immunoreactive cell numbers3. Although SOL-IL-
5Rα protein has antagonistic properties in vitro, it is important to note that the endogenous 
concentrations might be insufficient to block IL-5 activity in vivo. Furthermore, secreted 
receptors may bind their ligands in circulation, protecting them from proteolytic inactivation 
and prolonging their serum half-life or facilitating ligand-mediated signaling. Hence, SOL-IL-
5Rα may be involved in the fine-tuning of eosinophil homeostasis not only as an antagonist, 
but possibly also as a carrier.  
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Figure 4: SOL-IL-5Rα was tested for the ability to inhibit the effect of hIL-5 on FDC-P1-CA1 cells. 
Proliferation was measured by monitoring ³[H]thymidine incorporation. The full line represent proliferation of 
FDC-P1-CA1 cells in the presence of hIL-5 (10 pg/ml) and a dilution of SOL-IL-5Rα. The dashed line indicates 
proliferation in the presence of hIL-5 (10 pg/ml) alone. The experiment was performed in triplicate samples and 
similar results were obtained in several independent assays. 
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CONCLUSIONS:  
This report demonstrates differential expression of SOL and TM-IL-5Rα in blood and tissue 
eosinophils. Interestingly, in polyp tissue SOL-IL-5Rα expression is increased and correlated 
to disease severity and eosinophil percentages, whereas TM-IL-5Rα levels decreased and 
were inversely correlated to eosinophils and SOL-IL-5Rα expression. In vitro exposure of 
blood eosinophils to IL-5 reduces the expression of TM-IL-5Rα, but induces SOL-IL-5Rα 
protein release. SOL-IL-5Rα protein has antagonistic properties in vitro, however, 
endogenous concentrations might be insufficient to block IL-5 activity and thereby act as an 
IL-5 carrier in vivo. The expression of the IL-5Rα isoforms differs according to the 
eosinophil activation state, maturation and localization in the body and may therefore be 
involved in the fine-tuning of the eosinophil homeostasis. 
 
MATERIALS AND METHODS 
Patients 
Thirty-four subjects with bilateral nasal polyps and 16 controls were recruited at the 
Departments of Otorhinolaryngology at the Ghent University Hospital, Belgium and the 
Karolinska Hospital in Stockholm, Sweden. Peripheral blood and nasal polyp samples were 
collected in 34 NP subjects (mean age 51.4 years, range from 22-79 years; twelve females/ 
twenty-two males) during routine endoscopic sinus surgery and immediately processed for 
ELISA and PCR measurements, whereas flow cytometry was performed on blood and tissue 
samples of eleven NP subjects. Bilateral nasal polyposis was diagnosed based on history, 
clinical examination, nasal endoscopy and sinus CT-scan. A history of asthma was reported in 
seventeen nasal polyp patients, with seven subjects additionally demonstrating a history of 
aspirin hypersensitivity. Patients treated with oral corticoids within the last 4 weeks prior to 
surgery were excluded.  
Blood and nasal tissue (inferior turbinates) from healthy controls were obtained during routine 
corrective nasal surgery. All controls (mean age 34.5 years, range from 18-71 years; seven 
females/ nine males) were skin prick test negative, in generally good health, and none had a 
history of nasal or sinus disease, allergic disease (asthma, rhinitis or dermatitis), upper 
respiratory tract infection in the previous month, use of any intranasal medications, 
decongestants, antihistamines or oral steroids. The ethical committees of both universities 
approved this study and a written informed consent was obtained from all subjects before 
inclusion in the study.  
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Preparation of nasal tissue  
Removed polyps were transferred to +4°C HEPES (10mM)-buffered RPMI 1640 medium 
(Gibco, Paisley, UK). The polyp tissue was either homogenized or prepared to single cell 
suspension. To obtain tissue homogenates, nasal tissue specimens were weighed, and 1 ml of 
0.9% NaCl solution was added for every 0.1 g of tissue and then homogenized with a 
mechanical homogenizer (B. Braun Melsungen, Germany) as described previously 23.   
For single cell suspensions, the tissue was cut into small pieces, passed through a fine wire 
mesh by a syringe stamper and rinsed with RPMI. The cell suspension was centrifuged at 
200g for <1 minute at +4°C and remaining tissue elements were sedimented. The cell 
supernatant was further centrifuged at 300g for 12 minutes at +4°C. Twenty up to fifty million 
cells were obtained in a single cell suspension of nasal polyps and the cells were separated 
(per one million cells). One part was lysed and stored at –80°C until RNA purification. The 
other part was resuspended in 5 ml PBS and used for FACS analysis.  
Preparation of blood and serum 
Peripheral blood was collected in tubes containing EDTA (Vacutainer, 5 ml, with 50 µl of 
21% EDTA) (Terumo, Leuven, Belgium). Leukocytes were isolated by hemolysing 150 µl 
portions of blood in 3 ml +4°C isotonic NH4Cl-EDTA lysing solution (154 mM NH4Cl, 10 
mM KHCO3, 0.1 mM EDTA, pH 7.2) for 5 minutes at +15ºC. Cell suspensions were then 
centrifuged at 300g for 6 minutes at +4ºC and washed in PBS. The cells were used for RNA 
preparations and FACS analysis. Serum was collected tubes with no additives, was allowed to 
coagulate for 30 minutes and centrifuged at 1500g for 15 minutes at +4ºC.  
Preparation of purified peripheral blood eosinophils 
Peripheral blood eosinophils from healthy blood donors (age 18-64 years) were purified by 
the magnetic cell separation system MidiMacs (Miltenyi, Biotec, Bergisch Gladbach, 
Germany) 27. Briefly, blood was layered onto Percoll solution (Pharmacia-Upjohn, Uppsala, 
Sweden) and centrifuged (30 minutes, 1000g, 20°C). The mononuclear cell layer was 
removed and the remaining cell suspension was hemolysed in isotonic lysing solution (154 
mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.2). Eosinophils and neutrophils were 
washed in PBS and anti-CD16 magnetic beads were added for 20 minutes at +4°C. The 
eosinophils were obtained by negative selection using a separation column in a magnetic field 
where magnetically labeled cells (CD16+ neutrophils) were trapped and unlabelled cells 
(eosinophils) were collected. 
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In vitro incubation of purified eosinophils with recombinant human IL-5,  
Purified eosinophils (1.0x106/ml) were incubated with recombinant human (rh) IL-5 (10 
ng/ml) (Immunokontact, Frankfurt, Germany) diluted in HEPES (10mM)-buffered RPMI 
1640 medium (Gibco, Paisley, UK) supplemented with 10% heat-inactivated fetal calf serum 
(RPMI). As control, eosinophils were incubated in RPMI alone. The cell suspensions were 
incubated in 24-well plates for 2 or 24 hours at +37°C in 5% CO2. Supernatants were 
collected and stored at –30°C until ELISA measurements. The cells were washed twice in 
PBS (300g for 5 minutes at +4°C) and used for FACS.  
Immunofluorescence staining of eosinophils and flow cytometry 
Polyp tissue cells (0.5-1.0 ×106), isolated blood leukocytes or purified eosinophils (0.1×106) 
were incubated with non-conjugated mAb to IL-5Rα (10 µg/ml, Clone: α16, non-
neutralizing; gift by Prof J Tavernier). Secondary immunostaining was performed with 
fluoroscein isothiocyanate (FITC)-conjugated Rabbit Anti Mouse immunoglobulin, F(ab´)2 
(50 µg/ml, Code: F313) (DAKO A/S). Polyp tissue cells and blood leukocytes were double 
stained with phycoerythrin (PE)-conjugated mAb to CD16 (Immunotech) or stained with 
FITC-conjugated mAb to CD69 (5µg/ml, Clone: L78) (Becton Dickinson, Meylan-Cedex, 
France) together with mAb to CD16 (Immunotech). Cells and antibodies were incubated for 
30 minutes at +4°C, and then washed in PBS. Non-specific binding was determined with 
isotype-matched control antibodies in corresponding concentrations. Cells were finally diluted 
in 0.5 ml PBS and a minimum of 1000 eosinophils was analyzed in an EPICS XL-MCL 
(Beckman Coulter Inc., Fullerton, CA, USA) flow cytometer. Polyp tissue and peripheral 
blood eosinophils were detected and analyzed as a separate CD16 negative population by 
using depolarized light 28. The flow cytometer was calibrated daily with Flow Check and 
Flow Set (Beckman Coulter). 
Measurement of IL-5 and SOL IL-5 Rα protein concentrations  
A SOL-IL-5Rα specific sandwich ELISA was developed by combining two monoclonal 
antibodies (Innogenetics, Gent, Belgium). A detailed description and characterization of this 
ELISA was previously published19. Serum, tissue homogenates and eosinophil supernatants 
were assayed by a research ELISA for SOL-IL-5Rα (Innogenetics, Gent, Belgium) and IL-5 
(R&D Systems, Minneapolis, USA).  
SOL and TM IL-5 Rα Real time PCR 
As a standard we used PCR products generated from plasmids containing the cDNA 
sequences for SOL and TM hIL-5Rα. The cDNA sequences of the SOL and TM isoforms 
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were amplified using a forward primer complementary to a common sequence of hIL-5Rα 
5’GTGTCTGCTTTTCCAATCCATTGC 3’ and reverse specific primers: TM hIL-5Rα 
reverse primer: 5’ TTTTGGTGCTGGAATTGGTGG 3’ and SOL hIL-5Rα reverse primer: 5’ 
TCAGATACGGTGTGGGGCAG 3’. All primers were designed using the Primer Express 2.0 
Software (Applied Biosystems, Foster City, US) and purchased from Invitrogen. The PCR 
resulted in a unique band that was purified by using the PCR Gel extraction QIAquick 
(Qiagen, Hilden, Germany) spin columns. The purified fragments were quantified using 
PicoGreen reagent (Molecular Probes, Leiden, The Netherlands). Equimolar 10 fold dilutions 
of both PCR products were used to generate standard curves for each spliced variant.  
RNA was isolated from snap frozen blood leukocytes and nasal tissue cells of 16 controls and 
34 NP patients using the Rneasy Kit (Qiagen, Hilden, Germany), whereas RNA from 
eosinophil cell pellets was extracted using the TriReagent method (Sigma, Bornem, Belgium). 
Total RNA was quantified using RiboGreen Kit (Molecular Probes) and 0.5 µg was reverse 
transcribed using Superscript II Reverse Transcriptase (Invitrogen), oligo dT and random 
hexamers (Amersham Pharmacia Biotech, Buckinghamshire, UK) according to the 
manufacture’s protocol. cDNA equivalent to 25 ng total RNA was used to perform the Real 
Time PCR. The Real Time amplifications were performed using the 1X SYBR Green I 
Mastermix (Qiagen, Hilden, Germany) and a set of primers including a common forward 
primer 5’-GCAGCAGTGAGCTCCATGTG-3’  (nts 1177 to 1196, Genbank accession 
number M96652) and specific reverse primers for SOL hIL-5Rα 5’-
TGGATGTTATCTCCTTTATCTTGAGAAC-3’   (nts 1248 to 1272) and TM hIL-5Rα 
isoforms 5’-AGGGCTTGTGTTCATCATTTCC-3’  (nts1245 to1264). All the PCRs were 
performed in a 5700 SDS Thermal Cycler (Applied Biosystems, Foster City, US). Each 
sample was tested in duplicate. The quantity of each amplicon was calculated from the values 
of each standard curve and normalized by the quantities obtained for β-actin transcripts 29.   
MMP-14 RT-PCR was done with Assay-on-Demand Gene Expression products (Applied  
Biosystems, Fosteer City, CA). PCR was performed in a 25 µl reaction mixture  
composed of cDNA (equivalent to 25 ng total RNA), primers and FAM-labeled  
probes and TaqMan Universal PCR Master mix (Applied Biosystems, Foster City, US). 
Reactions were incubated for 10 min at 95°C, followed by 40 cycles of a two-step 
amplification procedure composed of denaturation for 15 seconds at 95°C and 
annealing/extension at 60°C for 1 minute. A standard curve of pooled cDNA from  
tonsils was used for calculation of relative quantities. 
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Biological activity analysis of SOL-IL-5Rα on FDC-P1-CA1 cells 
FDC-P1-CA1 cells are derived from murine, early myeloid FDC-P1 cell-line. hIL-5 
responsiveness was obtained by stable transfection of a chimeric IL-5Rα-chain, consisting of 
the human extracellular part fused to the transmembrane and intracellular parts from the 
mouse IL-5Rα-chain (mIL-5Rα)20;21. Cells were cultured in RPMI 1640 medium containing 
10% FBS and 1 ng/ml hIL-5. Baculo virus expressed human SOL-IL-5Rα was purified 
(Innogenetics, Ghent, Belgium) and tested for the ability to inhibit the effect of hIL-5 on 
FDC-P1-CA1 cells. hIL-5 (10 pg/ml) was pre-incubated with or without indicated dilutions of 
SOL-IL-5Rα for 6h. Cells were washed to remove hIL-5 and resuspended in medium depleted 
of growth factors for 3h. Then, FDC-P1-CA1 cells were added to the hIL-5/SOL-IL-5Rα 
mixture. After four days, growth was measured by monitoring ³[H]thymidine incorporation 
(0,5µCi per well; 4-6h; 37°C). The experiment was performed in triplicate samples and 
similar results were obtained in three independent assays. 
 
Statistical analysis 
Data are expressed as median and interquartile range (IQR). When comparisons were made 
between groups, significant between-group variability was first established using Kruskal-
Wallis test. The Mann Whitney U-test was then used for between-group (unpaired) 
comparison. Differences between the paired data were calculated by using the Wilcoxon test. 
Spearman rank correlation coefficient (r) was used to assess the relationships between the 
parameters.   
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ABSTRACT  
Background: Antagonizing the effect of Interleukin-5 (IL-5) is a potential new treatment 
strategy in nasal polyposis (NP), as polyp tissue is characterized by an eosinophilic 
inflammation and high IL-5 levels.  
Methods: In a double-blind, placebo controlled, randomized, two-center, safety, and 
pharmacokinetic study, 24 subjects with bilateral NP were randomized to receive a single 
intravenous infusion of Reslizumab, a humanized anti-human IL-5 monoclonal antibody, at 3 
mg/kg or 1 mg/kg, or placebo. We evaluated safety and pharmacokinetics of reslizumab, 
whereas biological activity was assessed by nasal peak inspiratory flow, symptoms, 
endoscopic evaluation of NP size, peripheral eosinophil counts, peripheral and local IL-5, 
soluble IL-5 receptor and ECP levels. 
Results: We demonstrated that a single injection of Reslizumab up to 3mg/kg is safe and well 
tolerated. Blood eosinophil numbers and concentrations of ECP and SOL-IL-5Rα were 
reduced up to eight weeks after treatment in serum and nasal secretions. Individual nasal 
polyp scores improved only in half of the treated NP patients for four weeks. Responders had 
increased IL-5 concentrations in nasal secretions at baseline compared to non-responders, and 
logistic regression analysis revealed that increased nasal IL-5 levels (> 40 pg/ml) predict the 
response to anti IL-5 treatment. Only responders had a decrease in nasal IL-5 levels after 
treatment, which sustained for two weeks. 
Conclusion: A single dose of anti IL-5 treatment reduces the size of nasal polyps in half of the 
patients up to four weeks after intravenous injection, and nasal IL-5 levels predict the 
response to anti IL-5 treatment. 
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INTRODUCTION 
Bilateral nasal polyps (NP) are characterized by an abundance of eosinophils in more than 80 
% of cases and are frequently associated with asthma1;2. The role of eosinophils in this disease 
is not clear, and its clarification awaited the availability of a specific drug approach that 
would not, like topical or systemic glucocorticosteroids, affect a wide range of cells and 
mediators. Interleukin (IL)-5 is essential for terminal differentiation of the committed 
eosinophil precursor, but also activates and prolongs survival of the mature cell in the tissues, 
and represents such a specific therapeutic target3;4. IL-5 was found to be significantly 
increased in NP, compared to healthy controls and other forms of sinusitis, independent of the 
atopic status of the patient5;6. The highest concentrations of IL-5 were found in NP tissue of 
subjects with non-allergic asthma and aspirin sensitivity, conditions linked to severe tissue 
eosinophilia. The key role of IL-5 was supported by the finding that treatment of eosinophil-
infiltrated polyp tissue with neutralizing anti-IL-5 monoclonal antibody (mAB), but not anti-
IL-3 or anti-GM-CSF mAbs, resulted in eosinophil apoptosis and decreased tissue 
eosinophilia in-vitro7.  However, as in asthma, only antagonizing the effect of IL-5 in nasal 
polyposis in vivo would be the ultimate test of the IL-5 / eosinophil hypothesis8. 
Several clinical trials with humanized monoclonal antibodies against IL-5 in mild to severe 
asthmatics demonstrated depletion from blood and sputum eosinophils, but no effect on 
airway hyperresponsiveness or the late asthmatic reaction to inhaled allergen challenge9-11. 
Kips et al. described a dose rising study with a humanized monoclonal anti-IL5 antibody 
(Reslizumab; SCH55700) in steroid-treated patients with severe persistent asthma12. A single 
administration of Reslizumab at a maximum dose of 1mg/kg seems to be safe and well 
tolerated, but despite the profound long-lasting reduction in blood eosinophil counts, the 
significant increase in FEV1 was short lived and only persisted as a trend at subsequent time 
points. This rapid but short improvement in FEV1 may have been due to a direct blockade of 
the actions of IL-5 on airway smooth muscle, which in turn improved airway caliber12.  
At the local tissue level, strategies to antagonize IL-5 may have to face unexpected difficulties 
since it was demonstrated that in BAL derived eosinophils from asthmatics 13;14and in nasal 
polyp tissue, the membrane-anchored (TM) IL-5Rα isoform is down-regulated whereas the 
secreted (SOL) IL-5Rα variant (antagonistic) is up-regulated compared to peripheral blood6. 
As a target tissue for measuring the effect of anti-IL5 treatment on eosinophilic inflammation, 
nasal polyps have the advantage of being easily visualized by nasal endoscopy and are 
accessible for the measurement of IL-5, SOL IL-5Rα and ECP levels.  Furthermore, it is 
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possible to determine if anti-IL5 treatment affects tissue eosinophilic inflammation without 
the confounding effects of systemic corticosteroids required by most subjects with persistent 
asthma.   
The primary objective of this study was to determine the safety and pharmacokinetics of 
Reslizumab (SCH55700) given as a single intravenous dose of 3 mg/kg to subjects with 
severe nasal polyposis. In addition, the activity of Reslizumab on the clinical course of severe 
nasal polyps, on peripheral and nasal eosinophilic inflammation was evaluated. 
 
METHODS 
Patients 
24 subjects with massive bilateral nasal polyps (Grade 3 or 4, Table 1) or recurrent nasal 
polyps after surgery were included. The baseline characteristics were comparable between 
treatment groups (Table 2), with exception of sex, where males outnumbered females. The 
exclusion criteria specified that the use of systemic corticosteroids was not allowed during the 
last month prior to treatment, whereas subjects were not permitted to use systemic and nasal 
corticosteroids, nasal antihistamines, nasal atropine, nasal cromolyn, nasal saline, and 
antibiotic treatment up to two months after dosing. The study was conducted at the 
Departments of Otorhinolaryngology of the University Hospitals in Ghent, Belgium and in 
Graz, Austria. The local ethics committees approved the study and all volunteers gave a 
written informed consent before participation in the study. 
Table1: Baseline characteristics 
  Reslizumab (SCH55700) 
 Placebo (n=8) 1mg/kg (n=8) 3mg/kg (n=8) 
Age, yr (range) 48 (21-59) 43.6 (22-63) 48.5 (18-57) 
Female/male 2/6 2/6 4/4 
Asthma in history 6 7 5 
Nasal surgery in history 4 2 6 
Total nasal polyp score (range) 6.00 (2-8) 5.75 (2-8) 4.25 (2-6) 
BLOOD/SERUM (mean±SEM)    
Blood eosinophils (10³/ml) 0.21 ± 0.03 0.31 ± 0.09 0.32 ± 0.06 
ECP (µg/l) 20.6 ± 8.4 26.6 ± 9.4  20.7 ± 5.9 
SOL IL-5Rα (pg/ml)  606.6 ± 112.9 521.6 ± 80.6 1306.7 ± 488.3 
NASAL SECRETION (mean±SEM)    
ECP (µg/l) 567.5 ± 244.6 876.6 ± 451.9 512.2 ± 153.1 
IL-5 (pg/ml)  74.4 ± 26.2 126.9 ± 52.0 55.7 ± 17.7 
SOL IL-5Rα (pg/ml)  2122.3 ± 730.2 3758.9 ± 1375.9 4104.8 ± 1764.2 
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Study Design  
This is a Phase I, single dose, randomized, double-blind, placebo controlled, three-arm, 
parallel group, two-center, safety, and pharmacokinetic study of Reslizumab in patients with 
nasal polyps. Following a 1-2 week run-in period, subjects were randomized to receive 
treatment with Reslizumab (Schering-Plough Research Institute, Kenilworth, NJ, US) at 3 
mg/kg or 1 mg/kg or placebo. A single dose was given as an intravenous infusion over 30 
minutes in a double-blind fashion.  Subjects were confined to the study site for 24 hours after 
dosing for safety evaluations and collection of samples for pharmacokinetic analyses. Follow 
up visits were scheduled 48 hours after dosing and 1, 2, 4, 8, 12, 16, 20, 24, 28, 32, and 36 
weeks after dosing. 
Outcome measures 
Safety was assessed by adverse event reporting, vital signs, symptom check, physical 
examination, ECG, blood and urine analysis. The key efficacy variable was the nasal polyp 
score evaluated for each nostril by nasal endoscopy. Polyps were graded from 0 to 4, based on 
polyp size: 0 = no polyps; 1 = small polyps in the middle meatus not reaching below the 
inferior border of the middle concha; 2 = polyps reaching below the lower border of the 
middle turbinate; 3 = large polyps reaching the lower border of the inferior turbinate or polyps 
medial to the middle concha; 4 = large polyps causing complete congestion/obstruction of the 
inferior meatus. Throughout the manuscript, the total nasal polyp score is used, which is the 
sum of the right and left nostril scores. Furthermore, daily nasal peak inspiratory flow (nPIF) 
measurements and symptoms (anterior rhinorrhea, nasal obstruction, postnasal drip, and loss 
of sense of smell) were recorded daily on subjects’ diary cards. Biological activity was 
evaluated by peripheral blood eosinophil counts, peripheral blood and nasal secretion (local) 
IL-5, SOL IL-5Rα and ECP levels.  
Blood eosinophil counts were automated on a 2ml heparinized blood sample. Nasal secretions 
were obtained by placing sinus packs (IVALON® 4000 plus) in both nasal cavities for exactly 
5 minutes. All freshly obtained nasal secretion and serum samples were immediately 
processed, separated and stored in aliquots at – 20°C until analysis as previously described6. 
Serum and nasal secretions were assayed by ELISA for SOL IL-5Rα (Innogenetics, Ghent, 
Belgium) and IL-5 (R&D Systems, Minneapolis, USA)6. ECP concentrations were measured 
by the Uni-CAP system (Pharmacia & Upjohn, Upsala, Sweden).  
Nasal Interleukin-5 levels determine the response to anti-interleukin-5 treatment in nasal polyp patients. 
159
Chapter 9 
Statistical analysis 
Analysis of safety and efficacy were based on the data collected from all subjects randomized 
in the study (intention-to-treat population). Statistical analysis of efficacy was based on all 
randomized subjects. However, two subjects, both in the placebo group, had undergone sinus 
surgery due to unbearable symptoms, and their polyps removed during the treatment period. 
Therefore, additional analysis, excluding post nasal surgery data, was performed where 
applicable. Missing observations were replaced by the last non-missing observation carried 
forward. Results are expressed as means ± SEM. Baseline variables were analyzed by an 
unpaired T-test. Pair-wise treatment comparisons were obtained from a two-way ANOVA 
model with treatment and site effects. Changes in clinical and biological parameters were 
evaluated by repeated measure analysis of variance. We performed logistic regression 
analysis to identify independent predictors of rebound and response after anti-IL-5 treatment. 
Differences were regarded as statistically significant if p < 0.05.  
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RESULTS 
Safety and adverse events 
Twenty-three of the 24 subjects (95.8%) reported at least one adverse event. The one subject 
who did not report an adverse event was in the 3.0 mg/kg treatment group. In two subjects, 
both in the placebo group, nasal surgery with removal of the nasal polyps was indicated 
during the treatment period. The most common adverse event was upper respiratory tract 
infection, reported by a total of 14 subjects (58.3%): 5 in each of the treatment groups and 4 
in the placebo group. Examination of other adverse events did not reveal any major difference 
between treatment groups. Administration of a single dose of Reslizumab was well tolerated 
and no clinically meaningful changes were observed in laboratory parameters, vital signs or 
physical examinations in any of the treatment groups. 
Table 2: Clinical course of nasal polyps 
 
  Reslizumab (SCH55700) 
 Placebo (n=8) 1mg/kg (n=8) 3mg/kg (n=8) 
total NP score 
compared to 
baseline score is 
worse no change better worse 
no 
change better worse 
no 
change better 
Week 1 3 4 1 1 4 3 0 5 3 
Week 2 3* 4 1 0 5 3 0 4 4 
Week 4  3 3 2 0 4 4 0 5 3 
Week 8 3* 4 1 1 2 5 3 4 1 
Week 12 3 2 3 1 2 5 4 3 1 
Number of subjects who developed a better, an unchanged or a worse total nasal polyp 
score compared to individual baseline score. * nasal surgery with removal of the nasal 
polyps was indicated in two subjects 
Clinical efficacy analysis 
At no individual time point, there was a significant difference in the total nasal polyp score, in 
the symptom scores or in the nPIF in both treatment groups compared to placebo (Figure 1). 
However, this study was not designed and not powered to detect treatment differences in 
efficacy variables. Therefore, the individual clinical course was evaluated and expressed as 
the number of subjects who had a better, an unchanged or a worse total nasal polyp score 
compared to the individual baseline score (Table 2). Treatment with 1mg/kg Reslizumab 
improved the NP scores up to twelve weeks in 5 out of 8 subjects. In the 3mg/kg treatment 
group, 4 out of 8 patients had a better NP score up to 4 weeks after treatment, however, with a 
deterioration of the NP score in 4 subjects after 12 weeks after receiving Reslizumab. In the 
placebo group, three patients had worse nasal polyp scores of whom two patients needed 
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nasal surgery at 2 and 11 weeks, whereas one patient had a better NP score. Systemic and 
nasal corticosteroids were permitted after 8 weeks, and were used in 7 and 20 out of 24 
patients, respectively, with an equal distribution over the three groups and follow-up visits 
(from 12 to 36 weeks). To avoid bias by concomitant treatment, further analysis was mainly 
focused on the first 12 weeks after dosing.  
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Figure 1:  Change from mean baseline total nasal polyps score (Panel A) and blood eosinophil counts (Panel B) 
after intravenous administration of placebo (n = 8; open circle), or a single dose of reslizumab, an antihuman 
IL-5 antibody, at 1 mg/kg (n = 8; solid square) or 3 mg/kg (n = 8; solid triangle). The changes from baseline 
were significantly different in the 1 mg/kg group (*) and in the 3 mg/kg group (**) compared to placebo (p < 
0.05). 
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Figure 2:Panel A shows the effect of a single dose of reslizumab, at 1 mg/kg (n = 8; solid square) or 3 mg/kg (n 
= 8; solid triangle) versus placebo (n = 8; open circle), on blood eosinophil counts, concentrations of ECP and 
SOL IL-5Rα in serum.  
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Figure 2 (continued): Panel B shows the effect on the concentrations of ECP, IL-5 and SOL IL-5Rα in nasal 
secretions. The mean changes from baseline were significantly different in the 1 mg/kg group (*) and in the 3 
mg/kg group (**) compared to placebo (p < 0.05). 
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Biological activity analysis 
Reslizumab induced a significant decrease in blood eosinophils in both treatment groups 
compared to placebo as early as 12 hours post dose, which sustained through week 8 after 
dosing (Figure 1). Blood eosinophils returned to baseline levels at week 12. However, a 
significant rebound eosinophilia was noted at week 24 and week 32 after 1mg/kg and 3mg/kg 
treatment, respectively (Figure 1). Rebound eosinophilia with a more than 100% increase of 
baseline eosinophil numbers was present in 6 and 4 patients of the 1mg/kg and 3mg/kg 
treatment group, respectively. Serum ECP and SOL IL-5Rα levels decreased significantly in 
both treatment groups compared to placebo and paralleled the blood eosinophil counts, but 
did not show a significant rebound at later time points (Figure 2a).    
Nasal secretion levels of ECP and SOL IL-5Rα decreased in both groups receiving 
Reslizumab compared to placebo and sustained through week 8 (Figure 2b). Nasal IL-5 
concentrations were only significantly suppressed at day 2 in both treatment groups versus 
placebo. In the 1mg/kg group, nasal IL-5 levels exceeded baseline levels at 4 weeks, and 
reached its maximal level at 16 weeks post dose, without statistical significance. The 
evolution of the nasal IL-5 levels in the 3mg/kg was similar but less pronounced than in the 
1mg/kg treatment group.   
Responders versus Non-responders 
Based on the individual course of the total nasal polyp score (all treated patients with an 
improvement of one unit within 4 weeks post dosing), were sorted in responders (n=8) and 
non-responders (n=8). The total nasal polyp score was significantly decreased in responders 
compared to non-responders from 1 to 4 weeks post treatment (Figure 2). At baseline, the 
nasal scores and biological markers were comparable between both groups, with the 
exception the IL-5 levels in nasal secretion, which were significantly higher in the responders 
than in the non-responders (p = 0.03; Table 3). Logistic regression analysis revealed that 
increased nasal IL-5 levels (> 40 pg/ml) predict the response to anti IL-5 treatment (odds ratio 
= 21.0; 95% confidence interval = 1.5 to 293.3; p = 0.009), whereas no other variables could 
be retained in the model. Nasal IL-5 concentrations decreased significantly within 2 days post 
dose and sustained through week 2 after dosing in the responders (Figure 2), whereas it 
increased in the non-responders with reaching significance within 12 to 20 weeks after active 
treatment. The decrease in nasal ECP levels was only significant for 1 week and was more 
pronounced in responders compared to non-responders. There was a significant decrease in 
blood eosinophil counts and SOL IL-5Rα concentrations in serum and nasal secretions in 
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both treated groups compared to placebo (similar as in Figure 1), without significant 
difference between responders and non-responders (data not shown).  
 
Table 3:  Comparison of baseline characteristics responders versus non-responders.  
Based on the individual course of the total nasal polyp score all treated patients (with an 
improvement of one unit within 4 weeks post dosing) were sorted in responders and non-
responders. 
 Reslizumab (SCH55700) at 1mg/kg or 3mg/kg 
 Non-responders (n=8)  Responders (n=8) 
Age (years) 48 (33-63) ns 42 (18-57) 
Sex (female/male) 4/4 ns 2/6 
Asthma in history 6 ns 6 
Sinus Surgery in history  5 ns 3 
Total nasal polyp score (max. 8) 4.12 (2-8) ns 5.87 (2-8) 
SERUM    
Blood eosinophils (10³/ml) 0.38 ± 0.09 ns 0.24 ± 0.03 
ECP (µg/l) 30.3 ± 9.1  ns 17.1 ± 5.6 
SOL IL-5Rα (pg/ml)  870.4 ± 80.6 ns 957.9 ± 461.9 
NASAL SECRETION    
ECP (µg/l) 876.6 ± 451.9 ns 512.2 ± 153.1 
IL-5 (pg/ml)  32.8 ± 4.4 p = 0.03 149.9 ± 48.8 
SOL IL-5Rα (pg/ml)  4123.7 ± 1802.8 ns 3740.0 ± 1324.2 
 
 
DISCUSSION 
This study demonstrates that administration of a single dose of Reslizumab, a humanized anti-
human IL-5 monoclonal antibody, at 3mg/kg is safe and well tolerated in subjects with nasal 
polyposis. Individual nasal polyp scores improved only in half of the verum-treated patients 
for up to four weeks. When carefully analysing responders and non-responders, only those 
nasal polyps with increased levels of IL-5 (> 40pg/ml) in nasal secretions before treatment 
seemed to benefit from anti-IL5 treatment. Furthermore, nasal IL-5 decreased only in the 
responders, whereas it increased in the non-responders. The decrease in circulating blood 
eosinophils was as pronounced in responders as in non-responders and sustained for 8 weeks, 
whereas the decrease in nasal ECP was stronger in responders, but lasted for one week only. 
These data show that at least in 50% of the nasal polyps, IL-5 and eosinophils play a key role 
(IL-5-dependent) in sustaining polyp size, whereas in the other group, eosinophilia may be 
dependent on other factors such as eotaxin (IL-5-independent)15.  
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Figure 3: Based on the individual course of the total nasal polyp score all treated patients with an improvement 
of one unit within 4 weeks post dosing, were sorted in responders (n = 8; solid triangle) and non-responders (n 
= 8; solid square). The total nasal polyp score and concentrations of IL-5 in nasal secretions were significantly 
decreased in responders (***) compared to non-responders. The mean changes from baseline in blood 
eosinophil counts were significantly different in the non-responders (*) and in the responders (**) compared to 
placebo (p < 0.05). 
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Analysis of anti-IL-5 studies in animal models of allergic disease shows that, although it has 
been observed that eosinophil trafficking to the allergic mucosa is markedly attenuated in IL-
5-/- mice or those treated with anti-IL-5 antibodies in comparison with wild-type responses, a 
marked residual tissue eosinophilia can persist in these mice after allergen inhalation16-19. 
Indeed, in a clinical trial, Flood-Page et al. observed a significant differential effect of IL-5 
blockade on eosinophil counts in various body compartments.9;10 After multiple dosing with 
mepolizumab, another anti-IL-5 mab, the authors found 100% reduction in blood eosinophils, 
but only 52% reduction in the bone marrow and a 55% decrease in the bronchial mucosa10. A 
possible reason for a different effect of anti-IL-5 in one compartment as opposed to another 
may be due to poor penetration of anti-IL-5 into the tissues or a varying IL-5 sensitivity due 
to a different expression of the IL-5Rα isoforms according to activation state, maturation and 
localization in the body. Liu et al. showed that IL-5 receptor expression on airway eosinophils 
was down-regulated in vivo after inhaled allergen challenge, associated with a loss of IL-5 
responsiveness13;14. In addition, Gregory et al. have demonstrated that exposure of blood 
eosinophils to IL-3, IL-5, or granulocyte-macrophage colony-stimulating factor in vitro leads 
to sustained down-regulation of SOL IL-5Rα expression and reduced responsiveness to IL-5, 
but no sustained changes in CCR3 expression20. Analysis of nasal tissue samples revealed that 
SOL IL-5Rα protein and mRNA levels were significantly increased in polyp versus control 
tissue, whereas the TM IL-5Rα was down-regulated in polyp tissue with severe eosinophilia6. 
Here we demonstrate that anti-IL-5 treatment of NP patients reduced SOL IL-5Rα levels for 
several weeks, especially in nasal secretions. Since SOL IL-5Rα shows antagonistic activity 
in vitro21-24, it could theoretically be expected that assessment of endogenous SOL IL-5Rα 
levels may distinguish responders from non-responders, or help in the titration of anti-IL-5 
mAb therapy6. However, SOL IL-5Rα levels did not show any relation to the individual 
response in this safety study in NP patients. In contrast, local IL-5 concentrations predicted 
the response: only NP patients with increased nasal IL-5 showed a reduction of nasal polyp 
scores after a single dose of reslizumab.  
Recently, Foster et al. have shown that local chemokine networks in the allergic lung 
regulate eosinophil accumulation independently of IL-5, and that this mechanism plays an 
important role in disease processes15. In the absence of IL-5 and eotaxin, tissue eosinophilia is 
abolished in BALB/c mice and so is AHR16;17. Furthermore, inhibition of eotaxin alone does 
not abolish eosinophilia and AHR, thus targeting both pathways is required17. These studies 
indicate that pathways operated by local chemokine systems (in particular those which 
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involve CCR3, the eotaxin receptor) play an important role in regulating the recruitment of 
eosinophils into tissues independently of IL-5, and that this mechanism is linked to the 
induction of disease. Importantly, this mechanism also operates in the absence of blood 
eosinophilia15. 
A heterogeneous group of disorders characterized by the presence of unexplained 
blood eosinophilia is hypereosinophilic syndrome (HES). Two reports showed successful 
treatment of patients with mepolizumab and reslizumab 25;26. Anti-IL5 therapy effectively 
controlled eosinophilic dermatitis with a drop in eosinophil counts, IL-5, eotaxin and ECP 
levels in serum26. However, one report described an exacerbation of symptoms and a rebound 
eosinophilia as drug levels waned25. Reinstitution of monthly anti-IL-5 treatment led to 
decreased eosinophilia and symptomatic improvement25. Here we describe a rebound 
eosinophilia in 10 out of 16 NP patients after anti-IL-5 treatment, but without major 
exacerbation of symptoms. In the 3mg/kg treatment group, the rebound was less dramatic and 
later than in the 1mg/kg, suggesting that higher concentrations and/or repeated dosing of anti-
IL-5 mabs might overcome rebound effects. Currently, none of the present studies in asthma, 
HES or nasal polyps were large enough to detect different subgroups and to differentiate 
between patients with IL-5 dependent disease from those mainly dependent on other 
mediators. Long-term studies in well characterized patients are therefore needed and should 
include analysis of local IL-5 and other cytokines or chemokines such as eotaxin. 
 
In summary, we here show that anti-IL-5 treatment results in a decrease in volume of 
nasal polyps only in patients with increased nasal IL-5 levels. It is therefore suggested to 
select appropriate patients before conducting further clinical trials with IL-5 antagonists. 
Furthermore, a combination therapy with anti-IL-5 and a CCR3 antagonist may be another 
successful approach, as this would have the advantage of inhibiting both bone marrow 
maturation (primarily IL-5 dependent) and tissue accumulation (mainly a CCR3-dependent 
effect). 
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DISCUSSION - PERSPECTIVES 
 
In view of the prominence of eosinophilic inflammation associated with the vast majority of 
nasal polyps and the well recognised potential of eosinophils in eliciting tissue damage and 
subsequent re-modelling, it is likely that a better understanding of the mechanisms underlying 
the migration, activation and maintenance of eosinophils in nasal polyp tissue will be key to 
understanding the aetiology and pathogenesis of nasal polyps. Especially the regulation of 
interleukin-5 and the interleukin-5 receptor α isoforms were studied with emphasis on future 
therapeutic strategies in NP. 
 
NASAL POLYPOSIS: AN EOSINOPHIL MEDIATED DISEASE? 
In chapter 4 we aimed to identify the most important factors in polyp growth. How 
eosinophilic inflammation leads to polyp formation remains largely unclear. 
Histomorphologic characterisation of two early stage manifestations of NP showed the 
presence of eosinophils, forming a subepithelial cap over a pseudocyst area, which was filled 
with albumin. In mature NP, a large pseudocyst area containing albumin was surrounded by 
subepithelial eosinophilia. The stroma of mature polyps is mainly characterised by its 
oedematous nature and consists of supporting fibroblasts and infiltrating inflammatory cells, 
localized around “empty” pseudocyst formations. These observations suggest a central 
deposition of plasma proteins (albumin), regulated by the subepithelial, mainly eosinophilic 
inflammation, as pathogenetic principle of polyp formation and growth. The extravasated 
plasma - for reasons of distance, binding force, or by extracellular matrix abnormality – may 
not find its way to the airway surface. Furthermore, the subepithelial accumulation of 
eosinophils points to the epithelium as probable location of a stimulating factor (such as 
antigens or an infection) for polyp etiogenesis. 
Second, in an approach to quantify and to study possible relations between eosinophilic 
inflammation and changes in the concentrations of extracellular tissue components, we 
measured IL-5, eotaxin, ECP, LTC4/D4/E4, TGF-β1, fibronectin, hyaluronic acid and 
albumin in nasal tissue homogenates of control and NP patients. The comparison between the 
untreated polyp group and controls showed significantly higher concentrations of IL-5, 
eotaxin, ECP and albumin in polyp supernatants, whereas TGF-β1 was significantly lower. 
Thus, the overproduction of IL-5 and the lack of TGF- β1 would favor eosinophil survival and 
facilitate degradation of tissue matrix, both characteristics of polyp formation.  
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Third, in oral GCS treated polyps, IL-5, ECP and albumin were significantly reduced 
compared to untreated nasal polyps, whereas TGF-β1 was increased. These data indicate that 
GCS affect nasal polyps by reducing eosinophil inflammation and albumin retention, leading 
to the shrinkage of NP (Figure 5). The major drawback is that it is a retrospective, descriptive 
finding in a limited number of subjects. On the other hand, it is surprising that little evidence 
or studies are present on treatment with oral corticosteroids of nasal polyps, although these 
treatment courses are daily practice in the ENT clinic.  
Perspectives 
- We are currently performing the first double-blind, placebo controlled, multi-centre study 
with oral administration of methylprednisolone or placebo in nasal polyp patients. The 
above studied markers and mediators will be measured in serum and nasal secretion.      
- A paper on the evolution and impact of eosinophilic inflammation after sinus surgery is in 
preparation (in cooperation with Dr. JB. Watelet).  
- In this thesis we focused exclusively on bilateral nasal polyposis, however currently we 
are comparing these findings with other chronic sinus diseases such as chronic rhino-
sinusitis and nasal polyps in cystic fibrosis (in cooperation with Dr. S. Claeys).  
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Figure 1: Eosinophils in the pathophyiology of nasal polyposis and the impact of oral corticosteroid 
treatment (GCS) 
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EOSINOPHILIC INFLAMMATION AND IGE FORMATION IN NASAL POLYPS 
Another hallmark of bilateral nasal polyposis are the elevated total IgE levels in polyp fluid 
that accompanies tissue eosinophilia. Therefore, an allergic aetiology of nasal polyps has been 
presumed, but never firmly demonstrated. In chapter 5 we could demonstrate that skin prick 
tests do not predict total IgE levels in polyp homogenates. In 10 out of 20 non-polyp and in 13 
out of 20 NP patients, the skin prick test was positive for at least one allergen. As expected, 
increased total IgE and specific IgE in the nasal tissue of subjects allergic rhinitis was found 
in correspondence with the skin prick test results. In marked contrast, atopy based on positive 
skin prick tests to inhalant allergens was not related to IgE concentrations or IgE antibodies in 
NP tissue. Furthermore, within the NP group no impact was found on the levels of IgE, IL-5, 
IL-4, eotaxin, LTC4/D4/E4, sCD23, ECP and number of tissue eosinophils, questioning the 
role of common allergens in nasal polyp pathophysiology. Strikingly, IL-5, eotaxin, ECP and 
number of eosinophils in NP tissue were significantly correlated with tissue total IgE.  
In chapter 6 we demonstrated the organisation of secondary lymphoid tissue in nasal polyp 
tissue and a polyclonal hyper-immunoglobulinemia E associated with the presence of IgE 
specific to S. aureus enterotoxins (SAEs), colonization with S. aureus, and increased 
eosinophilic inflammation in a relevant subgroup of nasal polyp patients. Furthermore, the 
dissociation in IgE levels and IgE antibodies between nasal polyp tissue and serum suggests 
that IgE in NP are mainly due to a local production. Detailed analysis of IgE expression in 
serum and tissue of NP patients reveals two patterns: “the allergic type” and “the polyclonal 
type” that can be found either isolated or combined. The “allergic” type of IgE expression is 
characterized by increased concentrations of total IgE and IgE antibody specificities in nasal 
tissue that correspond to those in serum and to the skin prick test results. In contrast, the 
“polyclonal” IgE expression is a local process and IgE antibodies found in polyp tissue are 
only partially reflected in serum of the same patients and are independent of the skin prick 
results. Notably, this polyclonal expression is associated with a hyper-immunoglobulinemia 
and only a small fraction of the total can be explained by IgE antibodies. Polyclonal 
expression was described in 16/24 NP tissues and was associated with IgE antibodies to SAEs 
in 12 cases, indicating that other than the classic enterotoxins might have acted as 
superantigens. Additionally we found a higher incidence of S. aureus colonisation (17/24) and 
IgE antibodies to SAEs in NP tissue (12/24) compared to controls (resp. 3/12 and 0/12). 
An augmented local synthesis of IgE may, under appropriate circumstances, increase allergic 
reactivity, but when it is excessive, it could suppress specific reactivity by saturation of Fcε 
receptors on mast cells through polyclonal IgE and/or an inhibition of specific antibody 
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synthesis to envorimental allergens by the polyclonal response. These mechanisms could 
explain why nasal symptoms and markers of nasal mucosal inflammation did not increase in 
relation to natural seasonal allergen exposure in highly ragweed-allergic patients with polyps 
and why nasal provocation in nasal polyps is largely unsuccessful although elevated IgE 
levels are present. However, the backside of this local polyclonal IgE production may be the 
permanent triggering of the IgE-mast cell-FcεRI cascade that maintains polyp growth.  
We illustrated binding of biotinylated SAE to follicular structures and in lymphoid 
accumulations in NP tissue. The follicular structures were mainly characterized by an 
accumulation of B-cells and T cells, whereas lymphoid accumulations showed diffuse plasma 
cell infiltration. These data suggest an organization of secondary lymphoid tissue with 
polyclonal B-cell activation in nasal polyps due to chronic microbial colonization and release 
of enterotoxins. In this context staphylococcal toxins can act as both superantigens and 
“conventional” allergens and therefore play a role in modulating chronic inflammatory airway 
disease, via both non-IgE and IgE-mediated mechanisms.  
Relevance to other diseases 
Studies of patients predominantly suffering from atopic dermatitis have increasingly 
demonstrated associations between incidence of disease and colonisation with S. aureus or 
presence of staphylococcal superantigens, thus proposing a putative causative role for S. 
aureus in the pathogenesis of atopic dermatitis. Recently, we demonstrated that IgE 
antibodies to SAE were more often found in serum from patients with severe asthma than in 
those with mild asthma 1. These antibodies were linked to the severity of inflammation, 
concentrations of IgE antibodies, and corticosteroid dependence. Similarly to severe asthma, 
we found significantly elevated IgE to SAE in COPD patients 2.  
Finally, these findings on local IgE formation in NP that is independent of skin prick tests or 
serum RAST data are of particular interest in the understanding of other so called non atopic 
diseases such as intrinsic asthma or NARES (nonallergic rhinitis with eosinophilia syndrome). 
Perspectives 
- The evidence for the role of S. aureus superantigens in airways disease is preliminary and, 
at best, circumstantial. Eradication of S. aureus may provide insights leading novel 
therapeutic strategies for these disorders. Currently, we are performing a double-blind, 
placebo controlled, multi-centre trial comparing oral doxycyline to placebo in NP patients.  
- Considering the marked local production of IgE-antibodies in nasal polyps and its relation 
to severity of disease, strategies to antagonize IgE antibodies could be of relevance (an 
application with the FWO is submitted to study the effect of anti-IgE-treatment on NP). 
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INTERLEUKIN-5 RECEPTOR α ISOFORM EXPRESSION IN NASAL POLYPOSIS 
Given the key role of interleukin-5 in processes leading to differentiation, recruitment and 
activation of eosinophils, we investigated IL-5Rα expression in human nasal polyposis. 
Regulated alternative splicing of the IL-5Rα-subunit leads to the generation of either a 
signaling, membrane-anchored (TM) isoform, or a soluble (SOL) variant with antagonistic 
properties in vitro. It is suggested that eosinophils are able to control their responsiveness to 
IL-5 by regulated expression of these IL-5Rα isoforms. Therefore, a better understanding of 
the biology of IL-5 and the regulation of its receptors seems to be mandatory to understand 
the effect of anti-IL-5 treatment in eosinophil-associated diseases.  
In chapter 7 we described a sensitive, specific and reliable ELISA that enables 
determination of SOL-IL-5Rα concentrations in various human body fluids such as serum, 
nasal secretion and nasal tissue homogenates. In nasal secretion, SOL-IL-5 Rα 
concentrations were well detectable and there was a strong correlation to the SOL-IL-5 Rα 
concentrations in nasal tissue confirming that collection of nasal secretion is a valuable 
alternative for biopsies. Furthermore, we demonstrated an abundant SOL-IL-5Rα expression 
in NP with concomitant asthma often dramatically exceeding the IL-5 concentrations. 
Indeed, in nasal tissue SOL-IL-5Rα levels up to 1200 times higher than IL-5 concentrations 
can be found. This finding questions the physiologic role of SOL-IL-5Rα. On one hand it 
could be that SOL-IL-5Rα is up-regulated to antagonise the massive eosinophilic 
inflammation. However, our data in a hIL-5-driven proliferation assay show that only an 
excess of SOL-IL-5Rα (18500 times) compared to IL-5 can block its activity. Although 
SOL-IL-5Rα protein has antagonistic properties in vitro, it is important to note that the 
endogenous concentrations might be insufficient to block IL-5 activity in vivo. Moreover, 
secreted receptors may bind their ligands in circulation, protecting them from proteolytic 
inactivation and prolonging their serum half-life or facilitating ligand-mediated signaling. 
Hence, SOL-IL-5Rα may be involved in the fine-tuning of eosinophil homeostasis not only 
as an antagonist, but possibly also as a carrier.  
In chapter 8 we examined SOL and TM-IL-5Rα expression and regulation at both protein 
and transcript level in vitro and in vivo by FACS, ELISA and real-time PCR. In blood, SOL 
and TM-IL-5Rα mRNA and protein expression was up-regulated in NP versus controls and 
correlated to eosinophil percentages, whereas in polyp tissue, TM-IL-5Rα levels showed an 
inverse relation to eosinophilia and SOL-IL-5Rα expression. Blood eosinophils express high 
levels of surface-anchored TM-IL-5Rα and are not activated as judged by a low CD69 
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expression. In contrast, tissue eosinophils are activated and demonstrate a low level of surface 
receptors to IL-5. Hence, in tissue with the highest levels of IL-5 and eosinophils, a regulatory 
mechanism must operate to control the ongoing eosinophilic inflammation by up-regulation 
of SOL-IL-5Rα and down-regulation of TM-IL-5Rα.  
In vitro exposure of mature human blood eosinophils with rh IL-5 for 2 and 24 hours induces 
an extensive down-regulation of IL-5Rα TM protein and mRNA, whereas SOL-IL-5Rα was 
only significantly up-regulated at the protein level. It is suggested that the down-modulation 
of TM-IL-5Rα from the cell surface and the increased release of SOL-IL-5Rα into culture 
supernatant fluid dependent on MMP activity. Although the expression membrane type-1 
MMP (MT1-MMP or MMP-14) is not different in polyps and controls and is not influenced 
by IL-5 stimulation of eosinophils, we found a significant inverse correlation between MMP-
14 and IL-5Rα surface expression. In addition, Gregory (in cooperation with us) have 
demonstrated that exposure of blood eosinophils to IL-3, IL-5, or granulocyte-macrophage 
colony-stimulating factor in vitro leads to sustained down regulation of surface IL-5Rα 
expression and reduced responsiveness to IL-5, but without sustained changes in CCR3 
expression 3.  
Taken all observations into account we suggest that an IL-5 driven inflammation generates an 
eosinophil tissue phenotype that is characterized by a low TM but high SOL-IL-5Rα 
expression and that this process is partially the result of proteolytic receptor modulation and 
down-regulation of TM-IL-5Rα gene transcription. Furthermore, the expression of the IL-
5Rα isoforms differs according to the eosinophil activation state, maturation and localization 
in the body and may therefore be involved in the fine-tuning of the eosinophil homeostasis. 
Since IL-5Rα surface expression is down-regulated in NP tissue, which probably causes IL-5 
responsiveness, our findings indicate that strategies to antagonize IL-5 may have to face 
unexpected difficulties. 
Relevance to other diseases 
In serum of asthmatics we found increased SOL IL-5Rα levels compared to controls, whereas 
within the asthma group, SOL IL-5Rα levels were significantly higher in severe versus mild 
asthma (in cooperation with P Howarth, Southampton, UK). Remarkably, serum levels of 
SOL IL5Rα are increased in chronic obstructive pulmonary disease (COPD) with the highest 
levels in virus-associated exacerbations of COPD (in cooperation with G. Rohde, Bochum, 
Germany) 4 . 
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In atopic dermatitis patients serum levels of SOL IL-5Rα are increased compared to healthy 
controls and correlated with the SCORAD, which represents severity of disease (in 
cooperation with A Kapp, Hannover, Germany). 
Perspectives 
In human serum, we demonstrate that SOL IL-5 Rα concentrations are detectable in all serum 
samples and with a median concentration of 210 pg/ml in healthy controls. Despite absent to 
low eosinophil counts in controls, a baseline expression of SOL IL-5Rα is found in all 
samples (serum, tissue, nasal secretion) without any relation to eosinophil numbers. Certainly, 
this finding needs further investigation, especially because it points again to other cellular 
sources of IL-5 Rα next to eosinophils. With reliable methods now in place to determine SOL 
IL-5Rα protein and mRNA expression, detailed studies can be performed to detect other cell 
populations expressing IL-5Rα.   
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ANTAGONISING THE IL-5 FUNCTION IN NASAL POLYPS 
The key role of eosinophils in the pathogenesis of nasal polyposis is strongly suggested by the 
previous studies, however never firmly proven since the findings are observational. Indeed, 
the increased concentrations of IL-5 and severe tissue eosinophilia were found in NP tissue 
and treatment with oral corticosteroids affect nasal polyps by reducing eosinophil numbers, 
IL-5 levels, and albumin retention, leading to the shrinkage of NP. Systemic 
glucocorticosteroids affect a wide range of cells and mediators and therefore, these finding 
only may be circumstantial. Given the key-role of IL-5 in the eosinophil biology, treatment 
strategies antagonizing IL-5 offers the ultimate opportunity to test the IL-5 / eosinophil 
hypothesis in nasal polyposis. 
In chapter 9 we described a double-blind, placebo controlled, randomized, two-center, 
safety, and pharmacokinetic study, 24 subjects with bilateral NP were randomized to receive a 
single intravenous infusion of Reslizumab, a humanized anti-human IL-5 monoclonal 
antibody, at 3 mg/kg or 1 mg/kg, or placebo. It is important to note that the primary objective 
of this study was to determine the safety and pharmacokinetics of Reslizumab (SCH55700) 
and that it was not designed and not powered to detect treatment differences in efficacy 
variables. Nevertheless, we assessed biological activity by nasal peak inspiratory flow, 
symptoms, endoscopic evaluation of NP size, peripheral eosinophil counts, peripheral and 
local IL-5, soluble IL-5 receptor and ECP levels.  
Administration of a single dose of Reslizumab, a humanized anti-human IL-5 monoclonal 
antibody, at 3 mg/kg is safe and well tolerated in subjects with nasal polyposis. Individual 
nasal polyp scores improved only in half of the verum-treated patients for up to four weeks. 
When carefully analysing responders and non-responders, only those nasal polyps with 
increased levels of IL-5 (> 40pg/ml) in nasal secretions before treatment seemed to benefit 
from anti-IL-5 treatment. Furthermore, nasal IL-5 decreased only in the responders, whereas it 
increased in the non-responders. Remarkably, blood eosinophil numbers and ECP levels in 
serum and nasal secretion were not different at baseline between responders and non-
responders. The decrease in circulating blood eosinophils after anti-IL-5 treatment was as 
pronounced in responders as in non-responders and sustained for 8 weeks, whereas the 
decrease in nasal ECP was stronger in responders, but lasted for one week only. Anti-IL-5 
treatment reduced SOL IL-5Rα levels for several weeks, especially in nasal secretions. As 
regulatory properties (antagonist/carrier) of SOL IL-5Rα were proposed, it could theoretically 
be expected that assessment of endogenous SOL IL-5Rα levels may distinguish responders 
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from non-responders, or help in the titration of anti-IL-5 mAb therapy. In contrast to local IL-
5, concentrations of SOL IL-5Rα did not show any relation to the individual response. 
Although a single injection of anti-IL-5 treatment resulted in shrinkage of NP in half of the 
patients, nasal polyps never disappeared completely. Furthermore, it is clear from this and 
other studies that anti-IL-5 treatment failed to completely inhibit eosinophilia at the tissue 
level. Completely blocking IL-5 activity in vivo therefore appears to be much more difficult 
than in vitro. A possible reason may be the poor penetration of anti-IL-5 into the tissues or a 
varying IL-5 sensitivity due to a different expression of the IL-5Rα isoforms according to 
activation state, maturation and localization in the body. Nevertheless, the ultimate judgement 
on the role of eosinophils in nasal polyps cannot be made based on the current therapeutic 
anti-IL-5 approach. However, we may conclude that at least in 50% of the nasal polyps, IL-5 
and eosinophils play a key role (IL-5-dependent) in sustaining polyp size, whereas in the 
other group, eosinophilia may be dependent on other factors such as eotaxin (IL-5-
independent).  
Relevance to other diseases 
Asthma was, indeed, for long the main target of anti-IL-5 treatment. Currently, the first 
reflections on the disappointing clinical results are the subject of many debates. The role of 
IL-5 and eosinophils in asthma is even more complex than in nasal polyposis, since there exist 
many features of asthma, including airflow obstruction, bronchial hyperresponsiveness and 
airway remodelling, each likely to be regulated by distinct processes. In this respect 
comparison of the findings between asthma, nasal polyps or atopic dermatitis are of interest. 
A heterogeneous group of disorders characterized by the presence of unexplained blood 
eosinophilia is hypereosinophilic syndrome (HES). Two reports showed successful treatment 
of patients with mepolizumab and reslizumab. Anti-IL5 therapy effectively controlled 
eosinophilic dermatitis with a drop in eosinophil counts, IL-5, eotaxin and ECP levels in 
serum. 
Perspectives 
This study re-opens therapeutic perspectives in nasal polyposis based on eosinophil-selective 
targets. Since anti-IL-5 treatment resulted only in a decrease in volume of nasal polyps in 
patients with increased nasal IL-5 levels, further clinical trials with IL-5 antagonists should be 
conducted in appropriately selected patients. Furthermore, a combination therapy with anti-
IL-5 and a CCR3 antagonist may be another successful approach, as this would have the 
advantage of inhibiting both bone marrow maturation (primarily IL-5 dependent) and tissue 
accumulation (mainly a CCR3-dependent effect). 
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